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Abstract 
In breast cancer, 15-20% of cases are reported with overexpression of human epidermal growth factor 
receptor 2 (HER2) that causes rapid cancer progression and poor prognosis. Fortunately, HER2-targeted 
therapy using specific antibodies such as Trastuzumab is effective for treating these cases. In situ 
hybridization (ISH) is a standard technique used for HER2 assessment. This technique locates the HER2 
gene by using complementary DNA probes. Two main ISH methods are fluorescence in situ hybridization 
(FISH) and chromogenic in situ hybridization (CISH). However, both FISH and CISH are expensive and 
laborious. Moreover, they can only be assessed in a small area of the tissue and thus are prone to errors in 
case of HER2 intra-tumoral heterogeneity (ITH). This thesis aims to improve HER2 assessment in breast 
cancer through various techniques related to microfluidics. The main component of our technology is a 
microfluidic tissue processor. This micro-fabricated chip is clamped to a microscope slide carrying a human 
tissue slice, creating a chamber that accommodates the tissue and delivering reagents to stain it. Five 
applications of this microfluidic technology to breast cancer diagnostics are presented in the three chapters of 
this thesis. In chapter 1, we present a microfluidic FISH protocol for HER2 gene assessment using a standard 
FISH probe and demonstrate that, when applying an oscillatory flow within the chip, hybridization efficiency 
is increased thanks to molecular replenishment. This back-and-forth motion of the diluted FISH probe inside 
a thin chamber above the tissue slide is the principle of microfluidic-assistance for ISH. We thereby succeed 
in drastically reducing the experimental time from 2 days to 1, and the amount of the expensive probe used 
per test by a factor of 10. We highlight the performance and reliability of microfluidic-assistance FISH by 
comparing the FISH scores obtained by this method to standard FISH technique scores using several clinical 
tissue samples. The principle of microfluidic assistance in FISH is also applicable to other types of ISH 
probes, including fast FISH based on Ethylene Carbonate and CISH. In chapter 2, we describe a new 
microfluidic method allowing the quantification of HER2 expression levels from formalin-fixed breast 
cancer tissues.  After partial extraction of proteins from the tissue slide, the extract is routed to an antibody 
microarray for HER2 titration by fluorescence. HER2-negative and positive samples can be distinguished 
using this simple test, and the obtained results agree with the FISH scores. In chapter 3, we establish a 
method allowing high content, cell-by-cell analysis of both protein overexpression and gene amplification 
using successive microfluidic immunofluorescence (IF) and FISH staining combined with image processing. 
We demonstrate that by using high-content automatic analysis, the HER2 status of the sample can be 
precisely assessed using both a quantitative IF technique based on HER2 and cytokeratin protein 
quantification and automatic scoring of HER2 loci and centromere of chromosome 17 signals in a FISH 
image. Furthermore, this method characterizes HER2 ITH quantitatively. In particular, heterogeneous 
clusters and individual cells are visualized in a reconstructed map of the tissue. We conclude that high-
content IF/FISH analysis is a powerful tool that can assist clinical diagnostics in the future. 
Key words: Breast cancer, fluorescence in situ hybridization (FISH), chromogenic in situ hybridization 
(CISH), immunofluorescence (IF), human epidermal growth factor receptor - 2 (HER2), protein microarrays, 
microfluidics, tissue slides, protein extraction, tissue biomarkers, HER2 assessment, intratumoral 
heterogeneity, automatic analysis, high-content analysis. 
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Version abrégée 
15 à 20% des cas du cancer du sein sont associés à une surexpression du récepteur 2 pour les facteurs de 
croissance épidermiques humains (HER2) qui induit une progression rapide du cancer et un mauvais 
pronostic. Heureusement, la thérapie HER2-ciblée utilisant des anticorps spécifiques tels que le Trastuzumab 
est efficace pour traiter ces cas. L'hybridation in situ (ISH) est une technique conventionnelle utilisée pour 
l'évaluation de HER2. Cette technique localise le gène HER2 en utilisant des sondes d'ADN 
complémentaires. Les deux principales méthodes d’ISH sont l'hybridation in situ en fluorescence (FISH) et 
l'hybridation chromogénique in situ (CISH). Cependant, FISH et CISH sont des méthodes onéreuses et 
longues. De plus, elles ne peuvent être utilisées que sur une petite zone de l’échantillon et sont donc sujettes 
à des erreurs en cas d'hétérogénéité intra-tumorale (HIT). Cette thèse vise à améliorer l'évaluation de HER2 
dans le cancer du sein à travers différentes techniques basées sur la microfluidique. Nous utilisons une puce 
microfluidique de traitement du tissu qui est montée sur une lame de microscope portant une coupe de tissu 
humain pour créer une chambre qui contient l’échantillon et délivrer des réactifs pour le marquer. Dans le 
chapitre 1, nous présentons un protocole de FISH microfluidique pour l'évaluation du gène HER2 à l'aide 
d'une sonde de FISH conventionnelle et démontrons qu'en utilisant un flux oscillant créé par la puce, 
l'efficacité d'hybridation augmente grâce aux réapprovisionnements moléculaires. Nous avons ainsi réussi à 
réduire drastiquement le temps d'expérimentation de 2 jours à 1, et la quantité de la sonde utilisée par test 
d'un facteur de 10. Nous mettons en évidence la performance et la fiabilité du FISH microfluidique en le 
comparant avec le FISH conventionnel sur 17 échantillons de tissus humains. Ce principe d'assistance 
microfluidique est ensuite utilisé pour étudier une sonde HER2 FISH à réaction rapide basée sur des 
solutions tampons de carbonate d'éthylène et une sonde HER2 CISH. Dans le chapitre 2, nous mettons en 
œuvre une nouvelle méthode pour quantifier des protéines HER2 dans des lames de tissue. En appliquant une 
incubation à haute température sur le tissu dans une solution à base de détergent, nous extrayons les 
protéines solubles dans le tissu et les détectons sur puce de protéines HER2 en les acheminant dans une 
seconde puce dans laquelle sont placées des sondes d'anticorps immobilisées capturant des protéines HER2. 
Enfin, nous démontrons que des échantillons HER2 négatifs et positifs peuvent être distingués en utilisant ce 
simple test, et les résultats obtenus sont en accord avec des scores de FISH. Dans le chapitre 3, nous 
développons une analyse HER2 à haute densité pour caractériser à la fois la surexpression de la protéine 
HER2 et l'amplification du gène HER2 dans une lame entière. Nous démontrons le statut HER2 de 
l'échantillon peut être évalué avec précision en utilisant d’une part une technique immunofluorescence (IF) 
quantitative basée sur la quantification des protéines HER2 et de la cytokératine et d’autre part le comptage 
automatique des loci de HER2 et des centromères du chromosome 17 dans une image de FISH. De plus, 
cette méthode caractérise quantitativement l'HIT de HER2. En particulier, des clusters hétérogènes et des 
cellules individuelles sont visualisés par une image reconstruite du tissu en utilisant des indicateurs locaux 
d'association spatiale. 
Mots clés: Cancer du sein, hybridation in situ à fluorescence (FISH), hybridation chromogénique in situ 
(CISH), immunofluorescence (IF), récepteur du facteur de croissance épidermique humain 2 (HER2), 
biopuces à protéine, microfluidiques, lames tissulaires, extraction de protéines, cancer biomarqueurs 
tissulaires, évaluation HER2, hétérogénéité intratumorale, analyse automatique, analyse à haute densité. 
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(2 or 4 h), a volume of 4 ?l continuously oscillated at a flow rate of 0.01 ?l/s without quiescent flow periods 
inserted between each back-and-forth flows. _________________________________________________ 58 
Figure 2.6 - FISH signal presentation. (a) Evaluation of the MA-FISH signal is based on a set of 3?3 mosaic 
z-stack images (typically 21 layers, ?z= 0.2 ?m), recorded at different positions of the tumor area after the 
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staining process. The recorded images span a tissue volume of 400 ? 300 ? 4 ?m3. (b) The nine images of 
one layer of the z-stack. (c) Zoom on a region of interest of b, from which the FISH signal can be acquired. 
(d) Projected image of the 3-dimensional region of interest in a single plane, following deconvolution of all 
layers of the z-stack (HRM software, Scientific Volume Imaging B.V., Nertherlands) and three-dimensional 
reconstruction (IMARIS software, Bitplane, Switzerland) of the latter. This is a HER2-negative case (i.e. not 
amplified), which shows 1 to 2 copies of the HER2 gene (corresponding to the red signals) per nucleus in the 
cancerous cells (their large nuclei can be appreciated thanks to the blue DAPI counterstain), and an 
approximately equivalent number of copies of centromere 17 (CEP17, corresponding to the green signals). 
(e) Projected image of a HER2-positive case (i.e. amplified), in which the cancer cells have large nuclei 
containing >6 HER2 copies (red signals) per nucleus, while the number of CEP17 (green signals) is not 
increased, yielding a HER2/CEP17 ratio >2. (f) The same case as in e, but focusing on a region in the tissue 
of non-cancerous cells that have smaller nuclei and show no amplification of the HER2 gene (internal 
negative control). _______________________________________________________________________ 59 
Figure 2.7 - Image processing performed on one focal plane of the z-stack in the MA-FISH protocol. (ai) 
One tile of the 3?3 mosaic picture. (aii) Zoom in one region of interest (ROI) of the picture in ai. (bi-iii) 
DAPI, green and red channel, respectively, of the picture in ai. (ci) Nuclei were identified by thresholding 
the signal in bi. A DAPI mask was created for allowing only selection of signals that are inside a nucleus. 
(cii) CEP17 signals, identified by thresholding the intensity in bii. (ciii) HER2 signals, identified by 
thresholding the intensity in biii. (di) Overlay of the outline of the identified nuclei, of the CEP17 signals, 
and of the HER2 signals with the original image. (dii) A zoom in one ROI of the picture di. Scale bar: 10 
?m. _________________________________________________________________________________ 61 
Figure 2.8 - Example of four consecutive images in a z-stack. For scoring signals in a FFPE tissue that was 
stained using a MA-FISH protocol, a zoom on consecutive images within a z-stack reveals several red and 
green signals that are identifiable in different focal planes. (a-d) 4 successive focal plans. In this example, 4 
green CEP17 signals and 6 red HER2 signals are scored, as these are identifiable by the same signal pattern 
over the different images. To be counted as a signal, it should appear in at least two consecutive focal planes 
of the z-stack. _________________________________________________________________________ 63 
Figure 2.9 - Experimental parameter study of the MA-FISH protocol: Influence of probe dilution, 
hybridization time, and flow rate. (a) Optimization of the probe dilution. Four adjacent slides originating 
from the same tumor were incubated on-chip during 4 h with three different dilutions (5?, 10?, 20?) of a 
standard commercial probe solution, or off-chip using the standard protocol. The on-chip square-wave 
oscillatory flow was applied with an amplitude of 1 nl s-1 at a frequency of 10-4 Hz. The green bars were 
obtained by averaging the green signal diameter and contrast originating from the CEP17 and the red bars 
were obtained by averaging the red signal diameter and contrast originating from the HER2 probes from a 
mosaic image composed of 9 tiles. The last 2 bars correspond to standard off-chip overnight hybridization 
conditions with an undiluted solution. The different panels represent (ai) the average diameter of a signal, 
(aii) the average contrast of a signal (aiii) the average count of red signals (HER2) per nucleus of a cell 
(HER2/cell) for the three probe dilutions and the standard, obtained from 3 different positions for each slide 
(full line, left axis) and the HER2/CEP17 ratio (dashed line, right axis). (b) Optimization of the hybridization 
time. Four adjacent slides originating from the same tumor were incubated on-chip with a 10? diluted probe 
with a flow rate of 1 nl s-1 at a frequency of 10-4 Hz, using three different hybridization times (8, 4, and 2 h), 
respectively. The last 2 bars in each graph correspond to standard off-chip overnight hybridization 
conditions. (bi) The average diameter of a signal. (bii) The average contrast of a signal. (biii) HER2/cell 
number for the three hybridization times and the standard, obtained from 3 different positions for each slide 
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(full line, left axis) and the HER2/CEP17 ratio (dashed line, right axis). (c) Optimization of the flow rate. 
Five adjacent slides originating from the same tumor were incubated on-chip during 4 hours using a 10? 
diluted probe, using five different flow rates of the on-chip square-wave oscillatory flow (0, 1, 10, 100, and 
1000 nl s-1) corresponding to push-pull cycle frequency f = 0, 10-4, 10-3, 10-2, 10-1 Hz, respectively. (ci) The 
average diameter of a signal. (cii) The average contrast of a signal (ciii) HER2/cell number for the five flow 
rate conditions and the standard, obtained from 3 different positions for each slide (full line, left axis) and the 
HER2/CEP17 ratio (dashed line, right axis). __________________________________________________ 65 
Figure 2.10 - Effect of microfluidics on hybridization. Three adjacent sections originating from the same 
tumor were incubated with a 10?  diluted probe solution during 4 h under a coverslip (abbreviation in the 
graph: “off-chip”), with a 10? diluted probe solution during 4h according to the MA-FISH protocol (“MA-
FISH”) and with a standard probe concentration (1?) and long hybridization time (overnight) of probe under 
a coverslip (“standard”), respectively. The green bars were obtained by averaging the signal contrast and size 
originating from the CEP17 signals and the red bars were obtained by averaging the signal contrast and size 
originating from the HER2 probes, from a mosaic image composed of 9 tiles. (a) Average contrast of a 
signal. (b) Average diameter of a signal. (c) Average count of red signals (HER2) per nucleus of a cell 
(HER2/cell) (full line, left axis) and the HER2/CEP17 ratio (dashed line, right axis). The results were 
obtained from 3 different positions for each slide (20 cells evaluated for each position). In the “off-chip” 
results, images did not reveal any red signal, explaining the inexistent red signal contrast and diameter. The 
results were presented as mean ± standard deviation (SD). ______________________________________ 68 
Figure 2.11 - Average number of HER2/cell and HER2/CEP17 ratio results from MA-FISH tests, in the full 
domain (left image) and in the sub-domain of HER2/cell number ?6 and HER2/CEP17?2 (right image). The 
test results that were obtained from slides of the same patient are represented by the same symbol in the 
graph. The dotted lines represent the cut-off values for HER2 status classification according to 2013 
ASCO/CAP guidelines. In the right panel, some borderline cases, laying close to the dotted lines 
representing HER2/cell=4 and=6, are more likely to result in different clinical classifications, hence 
accounting largely for the assessment discrepancies discussed in the text. The total number of tissue slides 
analyzed here was N= 51 (17 tissues samples, analyzed in triplicates). _____________________________ 70 
Figure 2.12 - Comparison of the MA-FISH with the in-house standard FISH protocol. Comparison between 
the results obtained for the MA-FISH and standard technique for (a) HER2/cell number in the full domain 
(left image) and in the 0 to 6 sub-domain (right image) and (b) the HER2/CEP17 ratio in the full domain (left 
image) and in the 0 to 2 sub-domain (right image). The results shown here correspond to 17 independent 
cases. The data represented for each point were the mean scores of 3 MA-FISH adjacent sections versus the 
mean scores of an in-house standard FISH adjacent section, obtained from the same tissue block. The 
vertical error bars represent the SD, with respect to the average of each specific slide, defined as the square 
root of the average of the variances obtained for each slide of the triplicates. The horizontal error bars are the 
SD of the scores among 3 positions in standard FISH slides. The dotted lines represent the cut-off values for 
HER2 status assessment according to 2013 ASCO/CAP guidelines. The linear fits show a good correlation of 
the FISH results (HER2/cell number and HER2/CEP17 ratio) between the MA-FISH and the standard FISH 
(Pearson’s correlation coefficients were 0.98 and 0.95 respectively). ______________________________ 71 
Figure 2.13 - ESIMA-FISH optimization protocol using human tissue samples (a) Optimization of the 
contrast for HER2 (in red) and CEN17 (in green) signals. The plot shows the linear regression coefficients of 
the HER2 and CEN17 signal contrasts, corresponding to 7 experimental parameters, namely the absence or 
presence of a post-fixation step (P), the flow rate during hybridization (Q), the probe concentration (C), the 
denaturation temperature (T), the total volume of probe used (V), and the duration of the denaturation (td) and 
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hybridization steps (th). (b) Optimization of the diameter for HER2 (in red) and CEN17 (in green) signals. 
The plot shows linear regression coefficients of the HER2 and CEN17 signal diameter, corresponding to the 
same 7 parameters as (a). From our analysis, we find as optimal condition: post-fixation step present, 
discontinuous flow, 4× dilution, no denaturation (td = th = 45°C), 12 ?l probe volume and 35-minute 
hybridization. __________________________________________________________________________ 75 
Figure 2.14 - Comparison of ESIMA-FISH and standard IQ-FISH (a) Deconvoluted z-stack (0.2 ?m-step) 
from an ESIMA-FISH-treated tissue slide. (b) Deconvoluted z-stack (0.2 ?m-step) from a standard IQ-FISH-
treated tissue slide adjacent to that in (b). The HER2 signal obtained from ESIMA-FISH tends to have a 
weaker intensity than that of the standard IQ-FISH technique. The images were acquired using a 
fluorescence microscope with a 63? objective. Scale bars: 5 ?m. _________________________________ 76 
 Figure 2.15 - Comparison of standard IQ FISH, ESIMA-FISH and “off-chip” IQ FISH obtained from a cell 
line slide (SKBR3). Standard IQ FISH (non-diluted probe and 1h hybridization) and off-chip IQ FISH (8× 
diluted probe and 15 minute hybridization) were performed using the coverslip technique (see the standard 
IQ FISH protocol in section 2.2.4.2). ESIMA-FISH and off-chip IQ FISH were implemented using the same 
probe concentration (8×) and hybridization time (15 min). (a) Image of a single focal plane of: (ai) an off-
chip IQ FISH image stack (aii) an ESIMA-FISH image stack and (aiii) a standard IQ FISH image stack. 
Scale bar: 10 ?m. (b) Quantitative analysis of HER2 signal in standard IQ FISH, ESIMA-FISH and “off-
chip” IQ FISH images shown in (a): (bi) Contrast measurements (bii) Diameter measurements. The datasets 
were compared using an ANOVA test followed by a Tukey multiple comparison test:* for p<0.05, ** for 
p<0.01, *** for p<0.001. _________________________________________________________________ 77 
 Figure 2.16 - Comparison between ESIMA-FISH and standard IQ-FISH obtained from 2 adjacent tissue 
slides. Two adjacent slides from the same breast cancer sample were processed with ESIMA-FISH (4× 
diluted, 35 min incubation) and the standard IQ-FISH protocol, respectively, after which they were imaged 
using the same exposition conditions and then assessed using an automatic image processing routine. (a) 
Contrast of the red and green signal (dots) from two methods. (b) Diameter comparison of red and green 
signals from the two FISH methods. The red signal diameter of ESIMA-FISH is strongly decreased in 
comparison to the standard method. However, this did not affect the interpretation of the signal. The different 
datasets (ESIMA-FISH vs. standard IQ-FISH) were compared using a Student’s t-test: * for p <0.05; ** for p 
<0.01;*** for p <0.001. __________________________________________________________________ 78 
Figure 2.17 - Comparison between ESIMA-FISH and standard IQ-FISH on human tissue slides. (a) Plots of 
HER2 copies per cell (HER2/cell) obtained by ESIMA-FISH versus standard IQ-FISH in a set of clinical 
breast cancer samples with HER2/cell ranging (ai) from 0 to 15 and (aii) from 0 to 5. The dotted lines 
represent the threshold for negative, equivocal or positive HER2 classifications. (b) Plots of the 
HER2/CEN17 ratio (HER2/CEN17) obtained by ESIMA-FISH versus standard IQ-FISH in the same set of 
clinical samples than in (b) with HER2/CEN17 ranging (bi) from 0 to 5 and (bii) from 0 to 2. The data shown 
here are mean ± SD obtained from the scores measured in 3 different clusters of 20 cells in each slide. The 
dotted lines represent the threshold for negative/equivocal or positive HER2 classifications. ____________ 79 
Figure 2.18 - (a) Optimization of the hybridization step using FISH images of a series of cell lines. The plot 
shows linear regression coefficients of the two HER2 signal outputs (contrast and diameter), corresponding 
to 3 experimental parameters, namely the hybridization time, the probe dilution, and the type of flow regime 
used. The signal quality is assessed by measuring the diameter and contrast of the red and green fluorescence 
signals (dots). From our analysis (see section 2.5.1.1), we find as optimal conditions a 2 hours hybridization 
time, a 4 ? probe dilution and the application of discontinuous flow. (b) Result of an optimal microfluidic-
assisted FISH protocol applied on a cell line. The cell is marked with 3 colors corresponding to the 2 probes 
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(HER2 in red and CEN17 in green) and DAPI counterstaining for nucleus revelation (in blue). HER2 probe 
is labeled with Texas Red and the CEN17 probe is labeled with FITC. Scale bar: 5?m. ________________ 81 
Figure 2.19 - Results of optimized microfluidic-assisted FISH (MA-FISH) and MA-CISH protocol using a 
discontinuous flow regime. (a) MA-FISH image of a cell line slide (SKBR3). (b) Comparison of HER2 
signal output (diameter and contrast) in two SKBR3 cell line slides obtained by MA-FISH and standard 
FISH, respectively. The same dot diameter and a higher contrast are obtained by MA-FISH compared to 
standard FISH. The datasets (on chip vs. standard) were tested with a one-way ANOVA followed by a post-
hoc Tukey test: p-value: ***<0.001. (c) MA-CISH image of the cell line slide shown in (a) after performing 
the protocol shown in figure 2.2b. The slide is marked with 3 colors corresponding to 2 probes (HER2 in red 
and CEN17 in dark blue) and hematoxylin in violet for nucleus revelation. (d) CISH image obtained using a 
standard CISH protocol performed on an SKBR3 cell line slide. Scale bars: 20 ?m. __________________ 82 
Figure 2.20 - Comparison of (a) MA-CISH (on chip) and (b) off chip CISH (using the coverslip method) 
performed on 2 adjacent tissue slides using the same conditions (8?dilution, 2 h hybridization). MA-CISH 
was implemented using a discontinuous flow regime (figure 2.5a). MA-CISH still resulted in a recognizable 
HER2 signal (a black arrow points to one red dot) while an off chip CISH did not give any HER2 signal in 
these conditions. The slides are marked with 3 colors corresponding to 2 CISH probes (HER2 in red and 
CEN17 in dark blue) and hematoxylin in violet for nucleus revelation. _____________________________ 83 
Figure 2.21 - Correlation study between the optimized MA-CISH and the standard CISH protocols for 4 
tissue slides and one cell line. HER2 and CEN17 signals in a cluster of 20 cells are scored to obtain the 
average number of HER2 gene copies per cell (HER2/cell) and the ratio between the total number of HER2 
and CEN17 signals in 20 cells (HER2/CEN17 ratio). (a) Comparison between MA-CISH and standard CISH 
results. (ai) Correlation of HER2/cell number between MA-CISH and standard CISH performed on two 
slides generated from the same set of 4 clinical tissues and one cell line (SKBR3). (aii) Correlation of 
HER2/CEN17 ratio between MA-CISH and standard CISH performed using the same set of samples. (b) 
Correlation between automatic scoring and manual scoring using the MA-CISH images used in (a). (bi) 
Correlation of HER2/cell number (bii) Correlation of HER2/CEN17 ratio. Full lines show the fitting curves 
of a linear regression model. Dotted lines represent the threshold for negative, equivocal or positive HER2 
classification. __________________________________________________________________________ 84 
Figure 3.1 - Design of the protein extraction system. (a) Schematic view of the MTP/tissue slide stack. (b) 
Cross-section view of the setup during the experiment. The tissue section slide is incubated with 
tris(hydroxymethyl)aminomethane hydrochloride (Tris/HCl) buffer supplemented with sodium dodecyl 
sulfate (SDS) inside the microfluidic chamber. After incubation, the extract is either collected for standard 
proteomic analysis, such as a bicinchoninic acid (BCA) assay, sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE), liquid chromatography tandem-mass spectrometry (LC-MS/MS), or injected 
to the detection microfluidic chip (DMC). ___________________________________________________ 90 
Figure 3.2 - Design of the DMC system and principle of the FISH technique. (a) Design of the Ab 
microarray. The array was composed of 5 replicated columns. Each column consisted of 4 spots of 
fluorescently F555-labeled streptavidin at 4 different concentrations (4 ?g/mL, 2 ?g/mL, 1 ?g/mL, 0.5 
?g/mL) for fluorescence signal control calibration; 2 replicated spots of anti-urokinase Plasminogen 
Activator (uPA) capture Ab at 4.5?M for negative control; 3 replicated spots of anti-HER2 capture Ab at 4.5 
?M; and one spot of carbonate buffer for negative control. (b) Exploded view of the setup consisting of a 
microscope slide spotted with 2 Ab microarrays sandwiched by two DMCs. One DMC, named “assay”, 
received the protein extract and the other DMC, named “control”, received only the extraction buffer (free 
from proteins). Scale bar: 2 cm. Each DMC consisted of a serpentine microfluidic channel and an 
 15 
 
observation window. (c) The spotting design of one array placed inside the serpentine channel. (d) Schematic 
presentation of  HER2 detection steps on the Ab microarray: (1) immobilization of anti-HER2-capture Ab on 
an NHS-activated glass slide; (2) capture of HER2 protein from the tissue extract; (3) recognition with anti-
HER2 Ab (mouse anti-human HER2); (4) detection with goat anti-mouse Ab labeled with Cy3. (e) 
Schematic representation of uPA detection steps on the Ab microarray: (1) immobilization of anti-uPA-
capture Ab; (2) capture of uPA protein; (3) recognition with biotinylated anti-uPA Ab (mouse anti-human 
HER2); (4) detection with F647-labeled streptavidin. __________________________________________ 92 
Figure 3.3 - Flow regimes used during the DMC protocols. (a) Flow regime applied during incubation of 
protein extraction solution with Ab microarray (b) Flow regime applied during the detection steps on the Ab 
microarray. ___________________________________________________________________________ 93 
Figure 3.4 - SDS-PAGE for optimization and reproducibility analysis. (a) SDS-PAGE of protein extraction 
solutions obtained from different extraction protocols (S1 to S5) of the same breast cancer tissue patient (P1). 
M is the reference mass ladder. P1-S1 and P1-S5 are two replicates of the same protocol. (b) SDS-PAGE of 
protein extraction solutions obtained with protocol 4 from different breast cancer tissue patients (P2, P3, P4, 
P5, P6, P7). Protein extraction solutions obtained from adjacent sections of the same breast cancer tissue 
patient are number S1, S2, S3. Protein extraction solutions obtained from two successive extractions from 
the same breast cancer tissue section of the same patient are number E1 and E2, respectively. (i) Tissue 
slides P2-S1-E1, P2-S1-E2, P2-S2, P2-S3, P3-S1. (ii) Tissue slides P4-S1, P4-S2, P5-S1, P6-S1, P7-S1, P7-
S2. __________________________________________________________________________________ 97 
Figure 3.5 - Microarray and IF results. (a) Fluorescence image of the “assay” array of the Ab microarray 
after incubation of the protein extraction solution in the DMC. The positions of spots are the same as in 
figure 3.2a, c. In particular, positions of HER2 spots are indicated by white arrows. Fluorescence intensities 
from F555-streptavidin and HER2 were measured at 532-nm excitation wavelength (green channel), whereas 
those from uPA were measured at 635-nm excitation wavelength (red channel). The two fluorescence images 
were then merged into a single two-color image. (b) Fluorescence intensities (arbitrary unit, left axis) of 
HER2 detection signals from “control” (green bars) and “assay” (red bars) microarrays obtained from 5 
protein extraction samples. These samples were prepared from 5 tissue sections of 4 different breast cancer 
patients (P8-11), two of them (P9-S1 and P9-S2) being adjacent sections of the same breast cancer tissue 
patient (P9). Fluorescence intensities from replicate spots in figure a were averaged and the SD was 
calculated. The ratio between “assay” and “control” signals is plotted as the extraction-to-control ratio (ECR) 
(dots, right axis). The error bars are obtained from the assay and control SDs. ______________________ 100 
Figure 3.6 - Comparison of fluorescence intensities obtained from “assay” Ab microarray (blue bars) and 
“control” Ab microarray (red bars) after performing the incubation of protein extraction solution in the 
DMC. (a) Detection of HER2 and uPA biomarkers in protein extraction solution from breast cancer HER2-
negative patient (P9-S2). (b) Detection of HER2 and uPA biomarkers in protein extraction solution from 
breast cancer HER2-positive patient (P11-S1). HER2 status was classified by FISH. Fluorescence intensities 
from various F555-labelled Streptavidin concentrations (4 ?g/mL, 2 ?g/mL, 1 ?g/mL, 0.5 ?g/mL) 
demonstrated that the slide–to-slide variation for 532 nm excitation wavelength was not significant (ratios of 
SD to mean are in the range of 0.08 to 0.3). uPA fluorescence signals displayed the same level in the “assay” 
and ”control” microarrays while HER2 fluorescence signals were systematically higher in the “assay” 
microarray than in the “control” one. ______________________________________________________ 101 
Figure 3.7 - Correlation study of four mean ratios between extract and control signals (ECR) obtained from 
all microfluidic-microarray spots and the LC-MS/MS analysis spectral counts. Each point represents HER2 
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protein quantity in the protein extraction solutions obtained from two adjacent sections from the same breast 
cancer tissue patient, measured by the two methods (P8-S1, P9-S1, P9-S2, P11-S1 in table 3.3).________ 102 
Figure 4.1 - High-content analysis of microfluidic IF and FISH. (a) Sequential IF/FISH staining. i)  
Immunostaining of cell pellet or tissue biopsy via the MTP (microfluidic tissue processor, see chapter 1) 
clamped onto the tissue-carrying glass slide to deliver the reagents in a highly-controlled fashion. ii) In the IF 
protocol, HER2 protein is tagged with a rabbit anti-human HER2 Ab, and CK is tagged with a mouse anti-
human CK Ab. Fluorescent labeling is then achieved by using AF594-labeled goat anti-rabbit IgG Ab and 
AF647-labeled goat anti-mouse IgG Ab. Nuclei are marked with DAPI. The whole slide is scanned using a 
low magnification objective (20×). The image of a cluster of cells is presented. HER2, CK, DAPI signals are 
respectively displayed in red, green and blue. iii) In an elution step, staining agents are removed from the 
slide using proteolytic enzymes. iv) In the FISH protocol, the HER2 loci are labelled with fluorescent HER2 
probes, and centromeres of chromosome 17 are labelled with fluorescent CEP17, and nuclei are marked with 
DAPI. An image of the same cells as in ii is shown. HER2 loci, CEP17 centromeres and nuclei are 
respectively displayed in red, green and blue. (b) Image-processing of the IF and FISH images obtained after 
the protocol from A. IF and FISH images, aligned using the common DAPI channel, are sequentially 
processed. i) For IF analysis, clusters of cells are segmented into an individual cell or a smaller group of cells 
based on nuclear analysis from the DAPI and CK channels. The HER2 signal also defines the membrane 
area in which the mean HER2 and CK intensities for each cell are measured. ii) For FISH analysis, nuclei 
define the area where HER2 and CEP17 signals for each cell are scored. (c) Data analysis protocol.  The cell 
HER2 expression given by IF is merged with the cell HER2 amplification obtained from FISH, followed by 
a filtering step that selects the cells of interest. For each sample, scores for HER2 overexpression and 
amplification based on the analysis of all the cells are obtained. Then, intra-tumoral heterogeneity analysis 
using spatial association is performed. Scale bars: 10 ?m. ______________________________________ 109 
Figure 4.2 - Schematic presentation of a nucleus with several HER2 loci. Left: section of thickness t selects 
only some among all HER2 loci. Right: 2D presentation of the section and the nucleus. ______________ 113 
Figure 4.3 - Relation between the apparent radius ???and true radius ?. ? is the center of the cut relative to 
the center of the nucleus. The position of the two boundaries of the cut are ??, ??. __________________ 114 
Figure 4.4 - Simulated HER2 loci histogram of a truncation model. The cell section can contain different 
numbers of HER2 loci varying from 1 to N, where N is the theoretical number of HER2 loci which is 
identical for the 20000 truncated cells generated. The x axis represents the number HER2 loci in each cell. 
The y axis shows the number of cells having a given number of HER2 loci. Here the total number of TC M= 
20000, theoretical TC radius ? =7 ?m, thickness of the cut?? =4 ?m and N=25. _____________________ 116 
Figure 4.5 - HER2 positive- and negative- cell line characterization by both IF and FISH technique. On the 
horizontal axis: the mean HER2/cell number obtained from an automatic scoring of FISH signals. On the 
vertical axis, the mean HER2 intensity of an IF image. Triplicates of HER2-negative (HER2-) and HER2-
positive (HER2+) samples were performed. _________________________________________________ 117 
 Figure 4.6 - HER2 assessment of cell lines and tissues using automatic and quantitative IF-FISH analysis. (a)  
HER2 overexpression (given by the cell-by-cell ratio between the HER2 and the CK signals) versus HER2 
amplification (given by the cell-by-cell ratio between the number of HER2 loci and CEP17) for HER2 
positive (+) and HER2 negative (-) cell lines. Data are plotted as a mean ± SD. (b) Assessment of HER2 
overexpression and amplification with the same methodology as in A for HER2+ and HER2- tissues. The 
HER2 status is obtained from pathological assessment by a standard FISH technique. (c) IF image of a 
HER2-negative tissue. (d) Cell-by-cell representation of HER2/CK. and HER2/CEP17 signals. Cells are 
represented by dots. The contours of the dots (in yellow scale) denote the normalized HER2/CK ratio, while 
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the inside of the dots (in red scale) indicate the HER2/CEP17 ratio of the cells in C. Normalization of the 
HER2/CK ratio (yellow scale) is obtained by allocating the value 1 to the maximum HER2/CK ratio that was 
obtained from all tissues. The maximum of the red scale is chosen as 8 for easy distinction between positive 
and negative cells. (e) IF image of a HER2-positive tissue. F) Cell-by-cell representation of the tissue in E 
with the same methodology as in D. Colors in IF images: Blue=DAPI, Green=CK, Red=HER2.________ 119 
Figure 4.7 - The ratios of the mean HER2 and CEP17 signals versus the mean of HER2/CEP17 ratios for 
different tissue slides. Nearly perfect correlation is found (R2=0.98). _____________________________ 121 
Figure 4.8 - Validation of our quantitative and automatic IF-FISH scoring method by comparison with the 
standard HER2 assessment for tissue and cell line samples. (a) Correlation between HER2 overexpression 
(HER2/CK ratio obtained from the microfluidic staining protocol and automated IF image-processing) and 
HER2 amplification (HER2/CEP17 ratio obtained from standard FISH scoring). The threshold for positivity 
of HER2/CK obtained by IF (horizontal dotted line) is defined as the lower bound of the 95% confidence 
interval obtained from a t-test on the mean HER2/CK scores of three HER2-positve cell line slides. The 
threshold for positivity of HER2/CEP17 obtained by FISH (vertical dotted line) is obtained from the ASCO 
2013 guidelines. (b) Correlation between the HER2 loci number per cell obtained from our automated 
counting algorithm and from the standard FISH technique. Thresholds for positivity for the variable 
HER2/cell is taken as 6 (dotted lines), obtained from the ASCO 2013 guidelines. (c) Correlation between the 
HER2/CEP17 ratio obtained from our automated counting algorithm and from the standard FISH technique. 
In our automatic method, the HER2/CEP17 ratio is calculated as the mean of the HER2/CEP17 ratios in all 
CK-positive cells of a tissue, while in the standard method it is calculated as the ratio of mean HER2 and 
CEP17 signals in a cluster of 20-100 cells chosen by the pathologist. The threshold for positivity for the 
automatic HER2/CEP17 ratio (horizontal dotted line) is 2.4 (see text). The threshold for positivity of 
HER2/CEP17 obtained by FISH (vertical dotted line) is obtained from the ASCO 2013 guidelines. _____ 122 
Figure 4.9 - Correlation between HER2/cell number and HER2/CEP17 ratio obtained in all tissue and cell 
line slides tested. ______________________________________________________________________ 123 
Figure 4.10 - Analysis of a heterogeneous tissue using correlation of HER2 signals of neighboring cells. (a) 
IF image of a tissue with definition of two regions of interest c and d, in which we will analyze the genetic 
heterogeneity. The red and green colors respectively representing the HER2 and Cytokeratin markers are 
almost colocolized, making orange in the area where tumor cells are located. Blue color represents the 
nuclei, equivalent to hematoxylin staining in a bright-field image. (b) Model of the tissue in a using the same 
cell-by-cell representation as in figure 4.6d,f. (c) Heterogeneity analysis of a HER2 FISH-positive region of 
the tissue in a. i) IF image: blue=nuclei, red=HER2, green=CK. ii) Correlation status of the cells in i. Cells 
are classified based on their own HER2 IF-status (High or Low) and on the IF-status of their neighbors (High 
or Low), resulting in: High-High (HH), High-Low (HL), Low-High (LH), Low-Low (LL)-type cells. Cells 
and their neighbors are classified as High (respectively Low) if their HER2/CK ratio is higher (respectively 
lower) than a threshold of 0.25. This threshold is the lower boundary of the 95% confidence interval of a t-
test on the HER2 FISH-positive cell lines’ HER2/CK obtained from figure 4.6a. iii) FISH image of the 
region. Blue=nuclei, green=CEP17, red=HER2. iv) Automatic scoring of HER2 loci and CEP17 of the 
region in iii. v) Spatial association status of the cells in iv. Cells are classified as High (respectively Low) if 
their HER2 loci number is ?6 (respectively <4).They are non-classified (NC) in the intermediate interval of 
HER2 loci number from 4 to 6, where the FISH HER2 status is equivocal. (di-v) Heterogeneity analysis of a 
HER2 equivocal region of the region of interest d of the tissue in a, following the same procedure as in c. 
While the IF readout is similar, the FISH status is clearly distinct. (e) Spatial association analysis of the 
HER2 protein expression by IF for the whole tissue in a. (f) Spatial association analysis of HER2 
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amplification by FISH for the whole tissue in a, showing cluster heterogeneity, i.e. having clusters of HH 
cells that span in area more than 10% of the tissue. Scale bars: 10 ?m. ____________________________ 125 
Figure 4.11 - Interpretation of mosaic intratumoral heterogeneity (ITH) by comparison to a statistical 
truncation model. (a) The mosaic ITH is measured in all tissue samples and benchmarked with the readout of 
the two cell lines: it is defined as the ratio of the number of individual heterogeneous cells (i.e. cells with 
positive/negative FISH status in a cluster of cells of negative/positive FISH status), divided by the total 
number of cancer cells in a tissue. For a HER2 positive sample (mean HER2/cell?6 or HER2/CEP17?2), 
mosaic ITH cells correspond specifically to LH cells of a spatial association analysis, like the ones marked 
by the + symbol in figure 4.10f. For a HER2- negative and equivocal sample (mean HER2/cell<6 and 
HER2/CEP17<2), mosaic ITH cells correspond to HL cells of a spatial association analysis, like the ones 
marked by the × symbol in figure 4.10f. For each cell line and tissue, the apparent mosaic ITH of a 
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(d) HER2 overexpression versus HER2 amplification for all tissues with additional heterogeneity 
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cluster heterogeneity (data of figure 4.10f) among the 20 patients tested. Thresholds for positivity are defined 
as before and indicated by the dotted lines. __________________________________________________ 128 
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1. INTRODUCTION TO CANCER DIAGNOSIS AND MICROFLUIDICS 
1.1. Overview of breast cancer  
1.1.1. Epidemiology 
The World Health Organization reported about 14.1 million new breast cancer cases and 8.2 million deaths 
worldwide in 2012, making breast cancer one of the main causes of death in women [1]. Multiple factors are 
associated with the incidence risk of breast cancer. Unhealthy nutrition, consumption of alcohol, smoking, 
excess body weight, and lack of physical activity are associated with a high risk of breast cancer. In the mid-
1990s, the cancer mortality rate in some high-risk countries such as the United States was dramatically 
decreased due to modern screening and adjuvant horm onal treatments (figure 1.1) [2].   
Figure 1.1 - Women’s breast cancer mortality rate in selected countries [1]. In y axis: Rate per 100,000. 
Early diagnosis of breast cancer is essential if the disease is to be treated efficiently. Detection of all 
symptoms such as breast lumps, nipple abnormalities (discharge, retraction, distortion, or eczema) suggests a 
need for clinical examination, imaging techniques (mammography, ultrasound) and needle biopsy. In case of 
strong indications of breast cancer, the lump is removed by surgery and evaluated by pathologists. Breast 
cancer is classified by type, grade, stage and gene expression. The latter has recently been added to 
histopathological assessment routine as a part of modern personalized medicine. In particular, the treatment 
of each patient is based on the gene expression classification. In this chapter, histopathological techniques for 
gene expression classification and some current personalized treatments are presented. 
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1.1.2. Cancer classification  
Cancer is traditionally classified by the tissue from which it is originated. It can be either carcinoma or 
sarcoma. For carcinoma, cancer cells are generated from epithelial cells while for sarcoma, cancer originates 
from connective cells such as adipocytes. Breast carcinoma was the most common type of cancer in women 
worldwide in 2012 [1]. Breast carcinoma is further classified based on its location inside the breast and its 
aggressiveness. For example, a carcinoma can be classified as invasive ductal carcinoma, ductal carcinoma 
in situ (DCIS), and other rarer types such as inflammatory breast cancer [3]. For a DCIS case, tumor cells 
(TCs) are contained inside milk ducts, while for an invasive ductal carcinoma TCs invade adjacent tissues 
and often metastasize to distant sites. Invasive ductal carcinoma is the most common form of breast 
carcinoma [2]. 
 
Figure 1.2 - Molecular classification panels for breast cancer. In lines: hematoxylin & eosin (HE), estrogen 
receptor (ER), progesterone receptor (PR) and human epithelial growth factor receptor (HER2) staining of 
tissue slides, respectively. In columns: different subtypes of breast cancer. In all slides, nuclei are stained 
blue using hematoxylin. In the HE image, cytoplasm is stained pink with eosin. In the ER, PR, and HER2 
images, these biomarkers are tagged with a brown compound. This brown staining is stronger in positive (+, 
i.e. overexpressed of protein) than in negative (-) cases. Figure is adopted from [4]. 
Concerning the state of the disease, cancer is classified by grade and stage. Grade 1 to 3 are based on the 
appearance of TCs in a tissue biopsy (assessment of tubule/gland formation, nuclear pleomorphism, and 
mitotic counts). A high grade implies high metastatic activity. The stage of breast cancer (1 to 4) indicates 
the progression of the disease and is evaluated according to the size of the tumor and the invasion of TCs 
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from the tumor to near lymph nodes. The higher the stage, the smaller the survival rate and treatment 
efficiency.  
Breast cancer can also be classified according to its gene expression [5]. Based on some indicative molecules 
(biomarkers), breast carcinoma is divided into four groups: luminal A, luminal B, HER2 positive and triple 
negative (basal type). These groups are characterized by different expression levels of 3 proteins ER, PR and 
human epithelial growth factor receptor (HER2), see table 1.1 and figure 1.2. Because each group has a 
specific prognosis and clinical characteristics, treatments are tailored to each (see section 1.1.4). 
Table 1.1 - Subtypes of breast cancer based on molecular classifications [4]. 
 ER PR HER2 
Luminal A & B 
A: low grade 
B: high grade 
+ + - 
HER2 positive - or + - or + + 
Triple negative (Basal) - - - 
 
After being removed from a patient, the tumor is sliced into thin sections. To enhance the contrast of the 
tissue to observe its morphology, hematoxylin and eosin (HE) staining are performed (figure 1.2, the first 
row). Nuclei are stained blue with hematoxylin and cytoplasm is stained pink with eosin. By observing the 
morphology of the HE-stained tissue, assessment of tumor malignancy, type of cancer tissue and cancer 
grade can be performed by a pathologist. Therefore, HE staining is considered an essential step in current 
cancer diagnostic practice.  
Several treatments are recommended for breast cancer patients. Classical treatment such as surgery, 
radiotherapy, and chemotherapy are three principle methods applied for most cancer cases worldwide.  
However, cancer often relapses and patients suffer from the side effects of radio- and chemo-therapies. 
Personalized medicine such as adjuvant hormonal therapy and targeted therapy in breast cancer have had a 
considerable impact on cancer treatment, increasing the survival rate of cancer patients while triggering less-
important side-effects. Personalized treatments, based on gene expression characterization, carefully select 
patients eligible for a hormonal or targeted therapy. For example, hormone therapies such as Tamoxifen are 
used to treat Luminal A & B patients while HER2-positive patients are treated with Trastuzumab 
(HERCEPTIN®) [6]. Trastuzumab is a humanized monoclone antibody (Ab) that binds to the domain IV of 
the extracellular segment of the HER2 receptor, activating several pathways which leads to cell proliferation 
inhibition and immune destruction of TCs.  
More recently, immunotherapy has been approved by the United States Food and Drug Administration to 
treat certain types of cancer such as melanoma. Immunotherapy involves boosting the patients’ immune 
system using engineered T-cells and immune checkpoint blockade [7]. Contrary to classical methods, 
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immunotherapy can pursue TCs long after treatment, thus preventing cancer relapse. Clinical trials are 
currently being conducted to prove its efficiency to treat breast cancer [8].  
1.1.3. Intratumoral heterogeneity (ITH) 
Heterogeneity is an important feature of cancer. It is characterized by distinct morphologies, phenotypes or 
genes in different TCs, existing either in two different cancer patients (intertumoral heterogeneity) or in the 
same tumor (ITH). Intertumoral heterogeneity causes different responses to a given treatment for different 
patients having the same type of cancer. Recently, personalized medicine has improved patients’ survival 
rate by adjusting cancer treatments according to the genetic and phenotypic characteristics of each patient. 
However, current personalized treatment is less efficient for patients with ITH, which is characterized by 
genetic or phenotypic differences among different subclones in different regions of the tumor [9]. While the 
cause of ITH is still being debated, two models are widely accepted: the tumor stem cell model and the 
clonal evolution model. The former indicates that a cancer stem cell (CSC) can differentiate into different 
cancer phenotypes, suggesting a hierarchical development of the tumor. The latter represents different 
genetic and epigenetic changes during tumor development. In reality, both scenarios can take place in 
complex developments of the tumor [10]. Several factors influence CSC differentiation and clonal evolution, 
such as genetic instability, stochastic processes, cell and tissue plasticity, and, in particular, adaptation to the 
tumor microenvironment (TME). The TME mainly consists of blood vessels, extracellular matrix, stromal 
cells such as fibroblasts, adipocytes and immune cells and other signaling molecules that surround a tumor. 
During the development, TCs can acquire several new mutations. However, only some of these mutations 
can survive after undergoing selective pressures (e.g. hypoxia or immune attacks) generated by the TME, as 
the basis of Darwinian evolution. When the TME conditions change, some subclones might gain or lose 
survival and proliferation advantages. Continuous mutations and selections during cancer evolution are the 
sources of tumor heterogeneity. Furthermore, cancer treatments may enhance selective pressure that 
aggravates ITH [11]. Regarding the consequence of ITH, different subclones can have different phenotypes 
exhibiting varied proliferation rates, motility, and protein expression, thus contributing to cancer resistance 
to certain treatments, e.g. chemotherapy [12], targeted therapy [13] and immunotherapy [14]. As a result, 
developing a tool for intratumoral analysis is an urgent need for personalized cancer treatment. 
1.2. Molecular analysis methods for cancer prognostics 
Accurate biomarker assessment is essential for cancer diagnosis and treatment. Some biomarkers have a 
prognostic value indicating patient survival information and others can predict the likelihood that a patient 
will benefit from a specific cancer treatment. Validated techniques for protein biomarker analyses in breast 
cancer are enzyme-linked immunosorbent assay (ELISA) and immunohistochemistry (IHC). For gene 
biomarkers, ISH and gene (DNA and RNA) assays and arrays are approved for clinical diagnostics. All 
mentioned methods have a common working principle: the detection of target biomarkers (either protein or 
gene) using probe molecules that have an affinity to the targets. Fluorescence or chromogenic tags can be 
used to reveal the probe/target position. In the following, some techniques for histopathological assessment 
are presented.  
1.2.1. ELISA and microarrays 
ELISA is a popular tool that uses antibodies (Abs) and an enzymatic reaction to identify a substance, usually 
an antigen. Two ELISA configurations exist: either the target protein is immobilized on a glass surface and 
captures the probe mixed in a solution, or it is diluted in a solution from which is captured by a probe 
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immobilized on a surface. In both configurations, the probe-target structure is detected using a reporter Ab 
that is linked directly or indirectly to an enzyme, in most cases horseradish peroxidase (HRP) (figure 1.3ai, 
ii, iii). In the presence of an appropriate substrate, the enzymatic reaction by HRP creates a color change at 
the probe-target site, which can be visible in a bright-field microscope (figure 1.3aiv). In breast cancer, 
ELISA is used for the detection of a urokinase plasminogen activator (uPA) and plasminogen activator 
inhibitor 1 (PAI1) [15]. These are two new validated biomarkers predicting the recurrence likelihood in 
negative lymph node breast cancers [16]. These biomarkers are extracted from a tissue and quantified by 
ELISA.  
  
Figure 1.3 - Principle of enzyme-linked immunosorbent assay (ELISA) and microarrays. (a) ELISA. (i) 
Direct assay. The target antigen (Ag) is immobilized on a surface and recognized by an enzyme-linked 
Antibody (Ab). In the presence of an adaptive substrate, a color change caused by an enzymatic reaction 
reveals the position of the Ag-Ab structures. (ii) Indirect assay. The immobilized target Ag binds to a 
primary Ab that is linked to another secondary Ab. The secondary Ab has an enzyme label that creates color 
changes when a substrate is presented. (iii) “Sandwich” capture assay. The target Ag is first captured by an 
immobilized Ab, then is detected by primary and enzyme-linked secondary Abs. The revelation is performed 
by an enzymatic reaction of the substrate. (iv) Final image of an ELISA test taken from a bright-field 
camera. Images are taken from www.thermofisher.com and www.enzolifesciences.com. (b) Different protein 
microarrays. (i) Direct labeling. The target Ag is labeled before introducing to the microarrays, then binds to 
an antibody immobilized on a surface. (ii) Indirect assay. The target Ag is labeled with biotin or small 
haptens, then binds to immobilized Ab. The Ag is then detected with labeled avidin or hapten-specific Ab. 
(iii) Capture assay “Sandwich”. The target Ag is unmodified, first captured by an immobilized Ab, and is 
then detected by either tagged-primary Ab or via a primary Ab/tagged-secondary Ab. (iv) Final image of 
CHAPTER 1: INTRODUCTION TO CANCER DIAGNOSIS AND MICROFLUIDICS 
26 
 
microarrays recorded by fluorescence scanner. Figures are adapted from [17] and www.gesundheitsindustrie-
bw.de.  
Protein microarrays are also based on probe-target binding such as ELISA but use a fluorescence-tagged Ab 
for revelation instead of chromogenic labels (see figure 1.3b). Furthermore, protein microarrays use a smaller 
quantity of probe and target solution for each test (~100nl compared to ~100 ?l for ELISA). The positions in 
which proteins are immobilized (spots) are organized into arrays. Thus, the throughput of the tests is 
improved compared to ELISA. The detection of protein microarrays is performed using a fluorescence 
scanner. 
DNA microarrays are similar to protein microarrays. In a common configuration, DNA probe fragments are 
immobilized on a substrate surface and bind to DNA or RNA in a lysate solution [18]. The DNA probes are 
spotted on the surface by arrays. The DNA-RNA binding is revealed by fluorescent tags. DNA microarrays 
provide prognostic information for newly cancer-diagnosed patients. In breast cancer, DNA microarray tests 
such as MammaPrint help assess the recurrence risk and identify patients who might benefit chemotherapy 
[19]. 
1.2.2. Immunohistochemistry (IHC) and immunofluorescence (IF) 
Table 1.2 - Criteria for HER2 assessment by IHC [20]. 
Criteria Class 
No staining or incomplete staining that is faint or hardly distinguishable 
and within less than or equal to 10% of the invasive TCs 
0 
Incomplete membrane staining that is faint or hardly distinguishable and 
within more than 10% of the invasive TCs 
1+ 
Circumferential membrane staining that is incomplete and/or weak or 
moderate and within more than 10% of the invasive TCs 
Complete and circumferential membrane staining that is intense and 
within less than or equal to 10% of the invasive TCs 
2+ 
Strong and complete circumferential membrane staining 3+ 
IHC is the most popular method for histopathological assessment of biomarkers. While ELISA detects 
targeted Abs dissolved in a solution, IHC identifies proteins at their specific location inside a tissue. When 
Ab probes are applied to a tissue section, they can diffuse into the tissue and recognize the specific target 
proteins. Similar to the revelation step of ELISA, the IHC probe-target binding is revealed using a secondary 
Ab that binds to the primary Ab probe. The secondary Ab binds to an HRP molecule (figure 1.4a) or a 
polymer bone possessing several HRP molecules (see figure 1.4b) for enzymatic revelation. Using 3,3'-
diaminobenzidine (DAB), the enzymatically-reactive sites are revealed by a colored compound originating 
from oxidized DAB. Therefore, the locations of target Abs in the tissue are detected and assessed in a bright-
field microscope (figure 1.4c). In breast cancer, as part of the clinical practice, three main biomarkers ER, 
PR and HER2 are assessed using IHC. In addition, assessment of some other prognosis biomarkers, such as a 
marker of cell proliferation Ki-67 and a marker of differentiation Cytokeratin (CK) are also performed using 
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IHC [21]. Nevertheless, IHC is a semi-quantitative method that relies on subjective assessment of staining 
intensity and the number of positive cells (see table 1.2 and figure 1.4c). In particular, for HER2 assessment, 
a second test using in situ hybridization (ISH) is required if the IHC test results are equivocal (IHC 2+, see 
figure 1.4ciii). 
 
Figure 1.4 - The principle of immunohistochemistry (IHC) and immunofluorescence (IF). (a) Indirect 
IHC: detection of Ag using primary Ab and horseradish peroxidase (HRP)-tagged secondary Ab. Figures 
are obtained from [22]. (b) Indirect IHC with an additional amplification step using a polymer carrying 
several HRP labels that binds to secondary Ab/primary Ab/Ag structures [23]. (c) Image of cells with 
HER2 IHC staining having different classes: (i) 0 : negative (ii) 1+: negative (iii) 2+: equivocal (iv) 3+: 
positive. (d) Direct and (e) and indirect immunofluorescence staining. i. In a direct-IF configuration, an 
Ag in one cell is tagged by a fluorescent primary Ab. In an indirect-IF configuration, the Ag/primary Ab 
structure is labeled by fluorescent secondary Abs. f. A typical IF image. Images are adopted from 
www.abcam.com and www.cellsignal.com. 
Similar to IHC, IF uses a specific Ab to recognize the target Ab. However, the techniques differ in the 
revelation phase. While IHC uses enzymatic reaction to mark the protein locations, IF uses a fluorescence-
labeled secondary Ab and fluorescence microscope to detect the probe-target binding (figure 1.4d,e,f). IF has 
many applications in biology, such as living organism imaging and flow sorting. In breast cancer, recent 
studies have proved that IF signals are more quantitative than those of IHC [24], as they reflect better the 
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protein quantity in the probe-target binding sites. Although quantitative IF is not yet a validated method, it 
can be considered a promising alternative method of IHC. 
1.2.3. Fluorescence in situ hybridization FISH and chromogenic in situ hybridization (CISH) 
Figure 1.5 - Fluorescence in situ hybridization (FISH) images for HER2 assessment. (a) A HER2-negative 
case. (b) A HER2-positive case.  In blue: nuclei; red: HER2 gene; green: centromere of chromosome 17 
(CEN17). Chromogenic in situ hybridization (CISH) images for HER2 assessment. (c) A HER2-negative 
case. (d) A HER2-positive case.  In light blue: nuclei; black: HER2 gene; magenta: CEN17. Figures are 
obtained from [25]. 
FISH is a cytogenetic technique for detecting and locating a specific DNA sequence on a chromosome. A 
DNA probe, labeled with a fluorescent molecule, is applied to the cell and binds to the target-complementary 
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sequence of a specific chromosome within the nuclei. Both target and probe DNA segments are denatured at 
high temperature and recombined at lower temperature.  The position of the interested gene can be located 
when the chromosome is observed by a fluorescence microscope. This technique can therefore be used to 
build a genetic map for analysis of chromosomal aberrations and genetic abnormalities in various organisms 
such as animals and plants. In pathology, FISH is one of today’s most important diagnostic, prognostic tools 
for genetic alteration-related diseases, like cancer or detection of congenital disorders. In particular, in breast 
cancer FISH is used for detecting the HER2 gene amplification responsible for HER2 protein overexpression 
(figure 1.5a, b). In particular, as FISH is quantitative and accurate, it is used for reassessing cases with an 
HER2-equivocal status in an IHC test (classified as 2+ in table 1.2). Similar to FISH, CISH is designed to 
detect a chromosome aberration. The main difference is that CISH uses an enzymatic label leading to a 
chromatic signal visible in a bright-field microscope. CISH  is an alternative validated method for HER2 
amplification assessment in breast cancer (figure 1.5c, d). 
1.3. Introduction of microfluidics: technology and theory 
1.3.1. Overview of microfluidics 
Microfluidic systems, also known as lab-on-a-chip (LOC) systems, have attracted much research attention 
since the mid-1990s. The domain has a wide range of applications, but most importantly in analytic biology 
and chemistry. In particular, microfluidic systems use miniaturized fluidic channels to implement biological 
and chemical reactions. The main advantages of microfluidics are that, in these narrow channels, the surface-
to-volume ratio is very high and the diffusion time is shortened. Therefore, the kinetics of reaction that takes 
place on a surface can be increased thanks to fast-fluidic exchanges of molecules in the presence of flows. 
Besides, miniaturization lowers consumption of reagents, which is essential when dealing with biological 
samples. Moreover, integration of electronic and optical components allows precise monitoring of fluids, 
molecules, and particles. Finally, the possibility of multiplexing is also an advantage of microfluidic systems 
towards performing high-throughput analyses. Research advances in microfluidics resulted in several 
industrial applications. Several multinational companies and startups have commercialized microfluidic-
related products in different fields of technology. For example, Illuminia Inc. and Fluidigm Corp are leading 
companies in the gene sequencing domain, and Agilents and the Abbott Laboratory are key players in point-
of-care diagnostics. In 2013, the microfluidics market value was estimated at $1.6 billion and will be 
extended to reach $3.6-5.7 billion by 2018 [26]. 
In most applications presented in this thesis, hydrodynamic flows are used for increasing molecular 
exchanges, shortening reaction time and decreasing the reagents needed. Below, we explain the role of 
hydrodynamic flows in biological reactions by providing some microfluidic background and hypothesis. 
First, we study a model for a biosensor configuration (protein or DNA microarrays) and then generalize the 
principle for biological reactions in a tissue such as FISH or IHC. Biosensors are detection devices based on 
a biological interface that interacts with target molecules and characterizes them by a biochemical reaction. 
The literature shows that biosensors become more sensitive with down-scaling [27]. However, when the 
biosensors are too small, the target molecules have difficulty encountering with the sensor’s probe 
molecules, thus increasing the time needed for detection. Microfluidics help create an effective mass 
transport that facilitates the capture of target molecules on the surface of biosensors.  In addition, the high 
surface-to-volume ratio in microfluidics systems is inherently adapted for integration of biosensors, which 
requires a large solid-liquid interface area.  
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1.3.2. Convection, diffusion and reaction theory 
1.3.2.1.     Reaction-induced and diffusion-induced flows in a biosensor  
We consider a typical chamber used in microfluidics for biological detection, as described in figure 1.6, 
where ?? is the width of the channel, H the channel height, Q the flow rate, L the sensor length along the 
fluid and a ?? the width in the perpendicular direction to the fluid flow.  
 
Figure 1.6 - A typical reaction chamber for biosensor-based detection of molecules. Figure is adapted from 
[28]. 
A biosensor with immobilized probes on top (for example, Ab or DNA) is placed inside the chamber filled 
with fluids containing target molecules. During the biological assay, solutions containing the target 
molecules are injected into the chamber and flow above the biosensor surface. Some target molecules arrive 
at a location close enough to the probes and bind with them thanks to the probe-target affinity. As the target 
molecules are consumed in the vicinity of the biosensor, a depletion volume surrounding the biosensor 
appears, which enlarges with the reaction time. This volume is characterized by a depletion layer thickness 
(??). At the same time, a concentration gradient of the target molecules ???????, is created due to the 
presence of the depletion layer. ?  is the concentration of the target molecules inside the solution. The first 
Fick law suggests that when there is a concentration gradient, a diffusion flow ?? ? ????????? is present, 
where D is the diffusion coefficient, to counterbalance this gradient. ?? is a flow density, i.e. flow per surface 
unity. In a set up as presented in figure 1.6, we can assume that the surface of the biosensor is much larger 
compared to the size of a probe molecule. Therefore, the concentration is the same for all points having the 
same z. Therefore  ?? can be rewritten as: 
?? ? ????????? ? ??
??
?? (??1) 
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Furthermore, at the surface of the sensor we have ?? ? ??, where ?? is the reaction flow-density created by 
the biosensor by adsorbing molecules from the solution. To calculate ??, we use a Langmuir isotherm model, 
a classical model for the reaction of two species (here is probe P and target T) as follows: 
Given a reaction  
? ? ? ? ??  
Then the reaction rate ?? is presented as follows: 
?? ?
?????
?? ? ?
????
?? ? ?
????
?? ? ???????? ? ???????????????? 
????? 
where ??? is the concentration of the target in the solution at the vicinity of the biosensor, [P] is the density 
of the non-combined probe available on the sensor, ???? is the density of the combined probe-target on the 
sensor, ?? is the forward reaction coefficient representing the association of probe and target and ?? is the 
backward reaction coefficient representing the dissociation of probe and target. If the initial density of the 
biosensor is known as ??, ??? is presented as c, and [PT] is presented as b, the equation (1.1) is represented 
as follows.  
?? ?
??
?? ? ????? ? ??? ? ????????????? 
????? 
?
Combining equation (1.1) and (1.3), we obtain: 
?? ? ?? ?
???? ? ?? ??
?? ?
?????
?? ? ????? ? ???????? ? ?? ?? ? ?????????????? 
????? 
This equation is a reaction-diffusion differential equation containing two variables, c and b. Now we apply 
some assumptions to simplify this equation. 
In the case of molecular transportation to the surface being faster than the probe-target binding rate, the 
transport is ‘reaction limited’. In this case we can assume that ?? ? ??. Therefore, an analytic solution of 
equation (1.4) can be obtained: 
????
?? ?
????
?? ? ???? ?? ? ?
???????????? ????? 
The reaction rate is: 
?? ?
?????
?? ? ?
???????? ? ?????
?? ? ???? ?
??????????? 
????? 
We would normally require a forward reaction to occur. Therefore the coefficient related to the forward 
reaction ???? should be superior to that of the backward reaction ??: ???? ? ?????>0. This reaction rate 
then decreases with time and is independent to the diffusion. 
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To establish a threshold between the diffusion- and reaction-limited regime, we consider the diffusive and 
reactive flux at the beginning of the reaction. If we consider that all probes are still available at t=0, then 
??? ? ?? ? ?. The reactive flux is written as 
???? ? ?? ?
???? ? ??
?? ? ??????? ? ?? ? ? ????????? 
????? 
In the beginning, only a tiny depletion layer  ?? ? ? is formed, which means the gradient of c can be written 
as 
???? ? ?? ??
?? ?
??
?? ??????????? 
????? 
The diffusive flux is then given as 
???? ? ?? ? ??
??
?? ? ??
??
?? 
????? 
Thus,  
????? ? ?????? ? ????
??????
? ? ?? 
?????? 
Da is the Damkohler number, the ratio between reactive and diffusive flux. When Da>>1, the consumption 
of molecules by the reaction is higher than the number of molecules that the diffusion can supply. Therefore, 
the mass transport is rate-limiting. When Da<<1, the mass transport is reaction-limited. To switch from 
reaction-limited to diffusion-limited, the only parameter that can be changed is the depletion-layer thickness 
??. Therefore, we use microfluidics to create convective flows that enhance transportation by shrinking ?? 
(vide infra). 
1.3.2.2.    Diffusion-convection interplay 
In a diffusion-limited regime (Da>>1), we are interested in knowing how fast a molecule immigrate from the 
bulk to the surface of the biosensor to supply the molecular consumption. Imagine that a molecule is 
traveling above the detection area with a velocity u, it has only a time of ?? ? ?? , where L the length of the 
detection area along the flow, where molecules can diffuse to the surface of the biosensor, before being 
washed away. ?? is the convection time or the time-of-flight of the molecule. Therefore, during ??, a 
molecule at a depletion layer is created above the surface of the biosensor, with a thickness ?? ? ????. 
Thus, on the molecular level, the shorter the convection time, the smaller the depletion layer ??. Now we 
consider a chamber with an initial concentration ?? and a flow rate Q. From the conservation equation, we 
obtain the following equation:  
????? ??
?? ? ?? ?? ? ?? ?? ? ??
????? ??
?? ?? ?
?????? ??
??? ?????????? 
?????? 
Where the convective molecular flow ??=?? ???? ??, thus??? ?? ? ? ?????????  (we suppose that the concentration 
do not depend on x and y axis in this configuration). 
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In this equation, we see the two terms ‘convection’ and ‘diffusion’ interplay and create the variation on the 
concentration. To understand whether the system is diffusion or convection limited, we define a Peclet 
number,???, as the ratio between the convective and diffusive flows: 
  
??? ?
????? ??
? ????? ???? ?
 
?????? 
Using the following approximations: 
????? ??
?? ?
??
?  
?????? 
 
?? ????  
?????? 
we obtain  
??? ?
? ????? ????
? ?????? ????? ?
? ?????
?????? 
This ??? number considers only the dimension of the channel, not the sensor itself. It reflects the balance 
between the diffusive and convective-limit regime at the channel level. However, at the sensor level, we 
define a shear Peclet number, ???, which takes in account the length of the sensor and defines the balance 
between the diffusive and convective flow at the sensor. From the literature [28], we have 
??? ?
??
?? ??
? ? ???
???? 
?????? 
Where ? is the ratio between the length of the sensor and the chamber height 
? ? ?? 
?????? 
From ??? and ???, simulations allow calculation of the depletion layer inside a diffusive-
convective system (see figure 1.7) [28]. 
 
?? ? ????
? ??  ?????? 
 
From equation (1.9) and (1.18), the rate in a diffusion-limited system is written as 
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??????? ? ???????
? ?? ?????? ???
? ??  
From equation (1.16), (1.17) and (1.19), we obtain the reaction rate ?? in function of flowrate Q: 
???????? ? ?????? 
Where ????? is the constant representing the dimensions of the channel and sensor. 
????? ? ??????????????????????? 
?????? 
 
 
 
(1.20) 
We use equation (1.20) to show that in a diffusion-limited system, if we want to detect a low concentration 
of the target solution (??? and maintain the same rate ??, we need to increase the ???. An increase of flow Q 
is thus required. 
For tissue staining, the principle of convection-diffusion is similar to that used in biosensor applications. The 
difference is that the molecule in the solution is the probe and the target is immobilized inside the tissue. If 
we suppose that the tissue is thin enough to be considered as surface, the diffusion-convection-reaction 
theory can thus be applied to tissue staining. In this case, we use the equation (1.20) to explain that by 
applying microfluidic flows, we can reduce the concentration of the probe needed, while performing the 
same reaction rate. 
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Figure 1.7 - Modeling of the depletion layer ? for different channel geometries and flow conditions. (a) 
Phase diagram by the ratio of the sensor length relative to the channel height ? ? ?? and the channel Peclet 
number ???. Each green star corresponds to a flow profile represented in figure c-i. (b) Dependency of 
dimension less flux F and ??? in different channel geometry. The green stars indicate the same flow regime 
as in a. c-i) Different flow regimes corresponding to an increasing ??? and various values of ?. Figures are 
adopted from [28]. 
1.3.3. Microfabrication technology 
Microfluidics has benefited from the progress in microtechnologies, especially in the field of micro-electro-
mechanical systems. In particular, the manufacturing of structures on a micrometer scale and smaller allows 
the fabrication of fully-functional miniaturized devices. Microfluidic systems can be fabricated by several 
microfabrication techniques such as milling, hot embossing, stereolithography, injection molding, 3D-
printing and silicon-based microfabrication [29]. The latter is based on the same concept as the 
microelectronic fabrication, in which the major principles are microlithography, etching, thin films, bonding, 
and polishing. As our microfluidic chip is fabricated using a silicon technology-based process, here we focus 
only on this method.  
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1.3.3.1.  Materials choice 
Microfluidic chips require microstructured patterns on a supporting substrate. Silicon is widely used as a 
substrate in microelectronics thanks to its excellent thermal and electrical characteristics. In particular, 
silicon is inert to most common solvents and reagents used in biological assays, and is stable at high 
temperature (melting temperature is more than 1400°C). Such features make it a suitable material for our 
microfluidic applications, in which biological reagents and high temperature (up to 95°C, the denaturation 
temperature in ISH applications) are involved. Besides this, glass is also a material highly adapted to use in 
microfluidic applications thanks to its transparency and stability to temperature and solvents. Glass and 
silicon substrates are usually supplied in the form of a wafer for facilitating the handling during successive 
microfabrication steps.  
1.3.3.2.  Photolithography 
Photolithography is a technique which uses ultra-violet (UV) light to pattern a photoresist layer. A 
photoresist is a photosensitive polymer whose solubility in a particular solvent changes after being exposed 
to a UV light beam. In a standard photolithography protocol, there are three main steps: resist coating on the 
substrate, UV exposure and development. Two types of photoresist exist: positive and negative resists. After 
the development step, the exposed parts of a positive photoresist are dissolved in a solution while the 
exposed parts of a negative photoresist stay on the substrate wafer. Therefore, if light is exposed through a 
micro-structured mask, features of the photoresist layer can be formed on the substrate. Photolithography is 
one of the most important steps in microfabrication, involving mask fabrication and pattern transfer from a 
mask to a wafer.  
1.3.3.3.  Mask fabrication 
A mask is based on a thick glass plate (order of mm of thickness) on which thin layers (order of ?m) of 
Chromium (Cr) and Chromium oxide (Cr2O3) are deposited. To create a pattern for a mask, a layer of 
photoresist is deposited on the surface of the Cr2O3/Cr/glass structure. Design from a layout is transferred to 
the photoresist layer using a computer-controlled laser beam. Positions, where the Cr2O3 and Cr layers are 
not covered by the photoresist are then etched by potassium hydroxide (KOH). After the etching step, the 
photoresist is removed from the plate by a resist-stripping protocol using an adaptive solvent. 
1.3.3.4.  Patterns transfer to wafers 
Patterns of the mask can be transferred to wafers using photolithography. First, photoresists are deposited on 
the surface of the silicon wafers by spin-coating and then baked and annealed. The wafer makes then contact 
with the mask and receives the UV light through the mask. After development, the patterns from the mask 
are transferred to the wafer. Depending on the type of photoresist, either positive or negative, the patterns of 
the wafer are identical or complementary to those of the mask. The resolution of photolithography is limited 
by the wavelength of UV light used, around 400 nm for a typical mercury lamp. This resolution is sufficient 
for our application. If multiple layers of microstructures are needed, the relative position of the wafer 
compared to the mask is adjusted. This step is called alignment.  
1.3.3.5.  Etching 
Once the patterns are printed on the photoresist layer, microstructures on the surface of the wafers are 
created by removing materials at the specific positions defined by the photoresist layer. The etching can be 
done in a solution (wet etching) or in a plasma (dry etching).  For plasma etching, the materials are removed 
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anisotropically while the materials are removed isotropically for wet etching. Dry etching using high-energy 
plasma to create high-aspect ratio features, is called deep reactive-ion etching (DRIE). For DRIE processing, 
as high-energy plasma is used, the photoresist layer used as etching mask can be replaced by a “hard mask” 
originating from more stable materials such as metal or silicon dioxide.  
1.3.3.6.  Thin film deposition 
In some applications, a nanometric layer of materials can be deposited on the surface of wafers using 
chemical vapor deposition (CVD) or physical vapor deposition (PVD). For PVD, materials are transformed 
to a vapor phase, then condense on the surface of a wafer where they create a thin film. For CVD, with the 
presence of a volatile precursor in a chamber, a chemical reaction occurs and creates a layer of materials on 
the surface of the wafer. CVD and PVD techniques help create a heterogeneous stack of different materials 
on the wafer. In our protocol, PVD of Parylene-C polymer is used for making an intermediate adhesion layer 
for the bonding process (see section 1.3.3.7). 
1.3.3.7.  Bonding 
In microfluidics, a bonding process is mostly required to create fluidic channels. Bonding of two wafers can 
be performed using either direct adhesion of two pieces or an intermediate adhesion layer such as Parylene-C 
polymer. Temperature, pressure and reactive plasma can be used to create bonds between different layers 
[29]. 
1.4. Microfluidic tissue processor (MTP) 
1.4.1. Design and fabrication of the MTP  
Considerable research on how using microfluidics for diagnostic applications has been performed. Most 
research and commercial products in this field are related to genetic and proteomic screening, biomarker 
analysis, and gene sequencing [30]. Our applications focus on cancer diagnostics, especially tissue biomarker 
characterization. In particular, Ciftlik et al. performed IF staining of breast cancer tissue using a MTP, a 
device of ~1 mm thickness consisting of a micromachined silicon wafer bonded to a glass slide (see figure 
1.8a,b). The silicon side has “tree-like” channels on one face which are connected to the other face via “feed-
through” holes. When the MTP is clamped to a microscope slide, on which a tissue is mounted, together with 
a plastic o-ring, it creates a reaction chamber above the tissue. Using a high flow rate, the MTP flushes 
reagents uniformly, and thus produces a homogenous probe concentration above the tissue in a large reaction 
chamber of 16?16 mm2 [31].  
The MTP is fabricated by a low-temperature polymer/polymer interface?free Parylene–C bonding step 
(figure 1.8c 1-6). A MTP consists of 2 main wafers: a silicon wafer and a pyrex (borosilicate glass) wafer. 
The silicon wafer was micropatterned by performing multi-step deep reactive-ion etching (DRIE). The hard 
mask used for DRIE was obtained by etching silicon oxides with a resist mask made by photolithography. 
They are bonded via a thin Parylene?C layer. The Parylene?C layer is deposited on the glass wafer by using a 
layer of Parylene monomers. Afterwards, both silicon and glass wafers are exposed to an O2 plasma for 
surface activation of the Parylene?C layer before being bonded. Finally, the bonding is performed at 280°C 
during 40 min with a tool pressure of 1 bar [31, 32].  
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Figure 1.8 - (a), (b) Two faces of the silicon slide: (a) the face structured with microfluidic channels, bonded 
to a glass slide via a thin Parylene-C layer; (b) the face that has an o-ring notch in order to make a chamber 
with an opposite microscope slide (c) Microfabrication process of the microfluidic chip. (1) 550 ?m silicon 
(Si) wafer coated by 2 ?m wet silicon oxide on two sides. (2) Micropatterning of a SiO2 layer using deep 
reactive ion etching (DRIE) through photoresist masks on both two sides. (3) DRIE of Si substrate via a 
resist mask created by a photolithography step to structure fit-through holes and in/outlets. (4) Resist 
stripping, followed by DRIE of the Si substrate through SiO2 hard mask to create microchannels. (5) A 500 
?m pyrex glass substrate, with 2 ?m Parylene-C on the pyrex substrate, is bonded to the Si wafer. (6) 
Additional DRIE of the Si side of the bonded glass-Si stack to finalize the fit-through holes. (d) An assembly 
of the MTP and a microscope slide.  The microscope slide is clamped against the silicon slide using a sealing 
o-ring to form a chamber. Microfluidic channel networks were designed to distribute the bioreagents 
uniformly within the chamber. (e) Modeling of the reagent concentration in the chamber, showing the rapid 
concentration change of the fluid thanks to convection. Figures are adapted from [31]. 
1.4.2. Effect of flows to immunostaining 
The MTP was previously used to perform IHC staining. Multi???? steps of reagent injection? ????washing 
were applied to the sample via the microfluidic processor. The tissue slide is clamped against the MTP half-
chamber, together with a plastic o-ring to form a complete chamber (figure 1.8d). Ab probes were injected 
from the inlet, passed through the “tree like channels”, entered the chamber and evacuated via the exit 
channels and the outlet on the right. Thanks to the MTP, the tissue was exposed to Abs with a precise control 
of time and concentration. As the chamber is thin, molecular exchange in the chamber during the injection 
was fast and homogeneous (see figure 1.8e). After incubation time of fluorescent probes, the fluids were 
flushed away. A result of the immunostaining is reported in figure 1.9a. The immunostaining signal was then 
characterized in function of the incubation time. The signal and background intensity of the immunostaining 
were measured in the inverted image (dark field) of figure 1.9a, shown in figure 1.9b. It was demonstrated 
that, during immunostaining, both the IF HER2 signal and background intensity increased with time with 
different rate (figure 1.9c). The background intensity increased due to non-specific adsorption of fluorescent 
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molecules. Therefore, the signal to background ratio is a linear function of the time only at the beginning of 
the incubation (figure 1.9d). To avoid the non-specific adsorption causing non-linearity, the incubation time 
was fixed at 2 min for all microfluidic immunostaining. Thanks to fast fluidic exchange, the immunostaining 
signal obtained was accurate and had a high contrast thanks to the low presence of non-specific adsorption of 
fluorescent molecules. The fluorescent signal strength resulting from the test was shown to be proportional to 
HER2 biomarker concentration and helped reduce ambiguous diagnostic outcomes [31]. In my thesis, the 
MTP is mainly used for other applications, such as FISH and protein extraction.  
 
Figure 1.9 - Microfluidic immunostaining intensity in relation with time and assessment method. (a) IHC 
image of a slide obtained from microfluidic staining. (b) Inverted image of figure a. From figure b, the 
signals and background intensity were obtained using an image processing program. (c) The HER2 
biomarker signal intensity and the background intensity measured in the IF image. Both signal and 
background intensity increase during the incubation time with different rates. The background intensity 
increases due to non-specific adsorption of fluorescent molecules. (d) The ratio between HER2 signal and 
the background obtained by different assessment method. The signal-to-noise ratio is a linear function of the 
time at the beginning of the staining (t<2 min) [31]. 
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1.4.3. Reliability of the MTP 
As we will use the MTP for applications involving high-temperature incubation of different kinds of 
reactants, we would like to know its reliability during long-term exposure to thermal shocks and solvents. 
The fabrication and working principle of the MTP is therefore presented here for the understanding of some 
potential problems related to the reliability of the device.  
In an experiment, the chip can be in direct contact with different types of reagents: organic (alcohol, 
detergent), inorganic (acid, salt and phosphate etc.) and biological (DNA, proteins) substances. Could these 
factors influence the reliability of the chip? The selected materials are in fact chemically and biologically 
inert. Indeed, Si and glass are very stable materials, even in a low pH environment or at a high temperature; 
and Parylene-C is usually used as a barrier or encapsulation material. Some research shows that Parylene-C 
is stable for a long-term contact with the saline solution and no organic solution, acid or alkaline materials 
could attack it in any significant manner [33]. We do not expect reactions between reagents and 
microchannels. 
The contact between the chip and the tissue slide is made by a mechanical clamp, which is either a magnetic 
or a screw-nut system, which exerts a vertical force on the chip. The chip is relatively thin (order of mm). 
The stresses in the chip can be thus considered as planar. Therefore, in the case of human error, this force 
could not significantly affect the chip. If the chip is not well placed, however, it could be bent or broken. 
Due to the fabrication method, the chip could be subjected to some thermal stress. Indeed, the dilatation 
coefficients of the composed materials of the chip are quite different: Parlylene-C’s thermal expansion 
coefficient of 3.5 ? 10-5/K is ten times higher than the pyrex and silicon’s coefficient (around 3 ? 10?6/K). In 
the worst case, the stress could break the bond at the Parylene-Pyrex or Parylene-Silicon interface to relieve 
the stress after some thermal cycles and decrease the adhesion between them. Moreover, Pyrex has a 
constant thermal expansion coefficient, while Parylene-C has a variable one. Thus, the thermal stress in these 
layers should be studied as well. Moreover, compared to IHC, FISH requires a heating step. The temperature 
is  increased from room temperature (RT) to 75°C and then maintained at 37°C. The chip is then cooled 
down for the next use. Therefore, we would need an investigation into the reliability of the chip under these 
thermal cycles. We study the impact of the thermal stress by layer. To simplify the problem, because the 
thickness of Parylene-C is too small compared to that of silicon and glass, we consider that the stress in the 
silicon layer is due to the glass layer and conversely. In contrast, the stress in Parylene-C depends on both 
the silicon and glass layer. 
First, we study the stress in the glass and silicon layer. In fact, the fabrication process has already resolved a 
part of this issue which links to the thermal characteristic difference between glass and silicon. Indeed, the 
bonding temperature is about 280°C. The glass and silicon wafers were heated up from RT. This bonding 
temperature is interesting because when the temperature of the stack decreases to the RT, the thermal stress 
in both layers decreases to approximately zero. The linear thermal expansion coefficients of glass and silicon 
are presented in the graph below, which explains this phenomenon: 
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Figure 1.10 - Thermal expansion coefficient of Silicon and glass [34] 
Indeed, figure 1.10 shows the thermal expansion coefficient of silicon and Pyrex as a function of 
temperature. We notice that at about 125°C, the thermal expansion coefficients of silicon and glass are equal. 
Above this temperature, silicon dilates more than Pyrex and below, it dilates less than glass. This means that 
if the bonding temperature is about 280°C, when the structure cooled down to RT, the tensile stress that 
develops in the silicon at higher temperatures will be compensated by the compressive stress that develops at 
lower temperatures. Therefore there is almost no stress in both the silicon and glass layer at RT. At some 
extreme conditions, the chip can be cooled down to 0°C and heated to 95°C (protein extraction protocol, 
chapter 3). During a cycle, the silicon slide is always in compression and the Pyrex slide is always in tension. 
However, these stresses are in the working stress interval of Silicon and Pyrex. Indeed, the compressive yield 
strength of single crystal silicon has range of GPa [35], and the tensile strength of glass is between 27 Mpa 
and 62 MPa (obtained from the website http://www.roymech.co.uk/). These are very high compared to the 
stress developed in the Silicon and glass layer that is estimated in the range of 100kPa (calculation not 
shown). Thus, the glass and silicon layers can withstand thermal stress. 
Concerning the Parylene-C layer, when the whole system is cooled down from 280°C to RT, it first goes 
through the rubber-like state (T°C>110°C ) where no stress is generated. The thermal stress in the Parylene-
C layer appears when the temperature is decreased from the glass transition temperature of about 110°C to 
RT. We estimate that at the RT the Parylene-C layer undergoes tensile stress that is 5 times smaller than the 
yield strength of Parlene-C of 55 MPa and thus still in the elastic domain. On the other hand, during a FISH 
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procedure, when the temperature increases up to 95°C, the tensile stress in Parylene-C layer decreases. 
Therefore, the Parylene-C layer is expected stable when the temperature changes in the range of temperatures 
used in the FISH experiment. In the protein extraction protocol, we apply even more extreme temperature to 
the MTP (down to 0°C or up to 95°C). The experiment proved that the chip is still reliable in these 
temperatures. However, at a higher of temperature than 110°C, the Parylene-C can melt and cause chip 
destruction [31, 32]. To conclude, the temperature conditions used in our experiment do not influence the 
reliability of the MTP.  
To create a homogenous distribution of reagents on the tissue, the liquid need to be pumped with a high 
velocity into the chamber. As the channels are small, the hydrodynamic resistance is increased as is the 
pressure to reach the desired velocity. However, if the pressure is too high, the chip could collapse (figure 
1.11). Mechanical tests of the MTP indicated that the burst pressure, i.e. the pressure just before the 
occurrence of a sharp pressure decrease, had a mean value of 7.6 MPa and a standard deviation (SD) of 1.7 
MPa [32]. Compared to a bonding strength of 10±3 MPa, the burst pressure is slightly lower but still in the 
same range. This burst pressure could occur due to the geometry of the chip, where stress was concentrated 
in some areas. Finally, the working pressure typically used for injecting IHC reagents to create a high flow 
rate of 10-100 ?L/s is only in the range of 10 kPa [31]. This pressure is 100 times less than the range of 
bonding strength and burst pressure (MPa) [32]. It ensures the reliability of the chip for long-term use. If we 
want to study further the effect of both the hydraulic pressure and thermal cycle on the chip, we need to 
study further by modeling them with a computational tool. 
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Figure 1.11- Diagram of (a) the burst pressure measurement setup, where the Pyrex part of the device is 
neither clamped nor assembled by any force other than that due to the Parylene–SiO2 bonding process. 
(b) Diagram showing of possible burst pressure failure events. The image is adopted from [32]. 
This study shows that the bonding strength, the burst pressure and failure mode are important criteria for 
studying the reliability of this system. After examining different reliability factors, we can conclude that 
MTP is totally adapted for experiments that require high-temperature heating, up to 100°C, such as FISH 
and protein extraction (vide infra). It is chemically stable, resistant to high hydraulic pressure and is not 
affected by thermal stress during the experiment. 
1.5. Statistical background for intratumoral heterogeneity study 
In the following section, I will present the basis for spatial autocorrelation analysis that is used in chapter 4.  
In many fields, scientists need to define a relationship between locations and values of selected variables at 
these locations. For example, in biology a number of species like cells, plants or human in adjacent and 
distant sites can interact. If there is a correlation between distances of samples and properties of samples, this 
reveals that spatial locations can affect the distribution of properties at these locations. This phenomenon is 
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called spatial auto-association, in which there are two tendencies. First, similar values of a property tend to 
be situated close to each other. In this case, the site property has a positive autocorrelation with its neighbors. 
Second, different values can be located next to each other, meaning this site property has a negative 
autocorrelation with its neighbors. To quantify these events, we use global and local Moran’s indicator 
(Moran’s I). Global Moran’s I (or Moran’s I in short)was developed by Patrick Alfred Pierce Moran [36]. It 
is calculated as follow 
? ? ? ??? ? ??????????  
where  
?: number of spatial units indexed from i to j 
? ??????
??
 
???= weight matrix which defines neighborhood. ??? ? ? if i and j are not neighbors of each other. ??? ? ? 
if i and j are neighbors of each other. The unit j is the neighbor of each unit i when distance between i and j is 
lower than a threshold distance 
?= variable value at the considered location 
??= mean of x 
?????????????????????? ? ???? ? ??
?
?  
??: variance  
?? ?
?? ? ??
?  
?? ?
?? ? ??
?  
Moran’s I has a value between -1 and 1. A positive Moran’s I hints that samples with high-value property is 
clustered together. A negative Moran’s I suggests that data is more scattered and high- and low- value 
samples are mixed. 
Local Moran’s I is one of local indicators of spatial association proposed by Luc Anselin [37]. It is in fact the 
indicator of Moran’s I computed at each unit i with its neighbor j. Moran’s I aims to test whether the data in 
the whole study area is more clustered or scattered, while local Moran’s I intends to identify elements within 
a homogeneous and heterogeneous cluster (local level). Without a specification, Moran’s I means global 
Moran’s I. The local Moran’s I is calculated at each sample position as follows: 
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?? ? ? ?? ???????
?
 
Local’s Moran I provides a classification of the sample of interest with 5 types of clusters, which are ”high-
high” (high value of unit i next to high value of neighbor j ??>0 and ? ?????? >0), “low-low”(low value of 
unit i next to low value of neighbor j, ??<0 and ? ?????? <0), “low-high” (low value of unit i next to high 
value of neighbor j, ??<0 and ? ?????? >0), “high-low” (high value of unit i next to low value of neighbor j, 
??>0 and ? ?????? <0), and “no significance” where there is no spatial association. If ??>0 the sample has a 
positive spatial autocorrelation and If ??<0 the point has a negative spatial autocorrelation. 
Here is an example of using five-cluster classification to locate low and high risk of Japanese Encephalitis 
(JE) incidence in Nepal (figure 1.12) [38]. 
 
Figure 1.12 - The map of five local Moran’I clusters for Japanese Encephalitis incidence from 2004 to 2008. 
The 5-cluster classification was obtained from local indication of spatial association (LISA) analysis. In all 
years, there is a local association of homogeneously low (low-low) and homogeneously high (high-high) 
clusters that are marked in blue and red respectively. In some years, heterogeneously low (low-high) clusters 
are observed (light blue). Figure is adopted from [38]. 
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From the local Moran’s I map of JE incidence in Nepal from 2004 to 2008, we found different clusters of 
regions: the red regions represent locations where there are high values of JE incidence, while the blue ones 
display low values of JE incidence. Light red areas (not shown) are sites with high values of JE incidence 
and located nearby low-JE-incidence regions. Reversely, for light blue regions, low-JE-incidence areas are 
close to areas with high values of JE incidence. Finally, in grey areas, it is not significant to define a 
relationship between locations and values of JE incidence at these locations. In Nepal, JE virus concentrated 
in the Far-west and Mid-west regions in 2004-2005 (red clusters in the map). In 2006, it transmitted to the 
Far-east and then to the center in 2007-2008. Besides, it is found that values of JE incidence are often low in 
the North-west and North-east locations, shown by blue area. Further explanations for global and local 
Moran’s I as well as their relation are described in Appendix A. 
My research interest is to identify cancer heterogeneity where tumor areas have different HER2 protein 
expression or gene amplification classifications. Therefore, the local Moran’s I is used as an indicator to 
pinpoint these tumor areas.  
1.6. Thesis motivation   
We have seen several state-of-the-art techniques for cancer classifications and treatments. Nowadays, cancer 
can be cured if the right treatment is applied at the right time. However, everything comes at a cost. The 
price for cancer diagnostics and treatments are increasing every year, provoking a rise in health insurance 
fees and financial burden for cancer patients. Personally, the author believes that cancer should not be a 
disease of the “rich”. Instead, medicine should become affordable for every person who needs it. In this 
thesis, several applications for cancer diagnostics are presented. The motivation is all about making the 
current cancer screening methods cheaper and faster, while maintaining good quality in the tests. To achieve 
this aim, biological detections of biomarkers in tissue such as FISH or CISH are performed using the MTP. 
Thanks to efficient mass transport hydrodynamic flow, the reagent and time requirements for the tests can be 
decreased, thus lowering costs (see chapter 2). A proof-of-concept for protein biomarker quantification by 
combining microfluidic extraction and microarray detection is presented in chapter 3. Finally, a high-content 
analysis of quantitative IF and automatic FISH scoring techniques for accurate cancer heterogeneity 
detection is presented in chapter 4. We hope that this research can advance the field of cancer diagnostics. 
We also anticipate that in the future, personalized medicine will become more precise and affordable for 
cancer patients worldwide. 
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2. MICROFLUIDIC-ASSISTED IN SITU HYBRIDIZATION 
FISH and CISH are well-recognized techniques for evaluating the human epidermal growth factor receptor 2 
(HER2) gene status in breast cancer, despite their traditionally long and costly experimental procedure. Here 
we develop microfluidic-assisted principle for ISH, in which hybridization of the FISH probes with their 
target DNA strands is obtained by applying oscillatory flows of diluted probe solutions in a thin microfluidic 
chamber of 5 ?l volume. We found that microfluidics helps reducing the experimental duration and 
decreasing the consumption of the expensive probe solution by improving the mass transport of the reactants. 
The study was done in 3 phases.  
First, microfluidic-assisted FISH (MA-FISH) decreased the consumption of a standard HER2 FISH probe 
(Pathvysion®) by a factor 10 with respect to the standard technique, and reduced the hybridization time to 4 
hours, which is 4 times faster than in the standard protocol, at the expense of a weaker HER2 gene signal. To 
validate the method, we blindly conducted HER2 MA-FISH on 51 formalin-fixed paraffin-embedded (FFPE) 
tissue slides of 17 breast cancer samples, and compared the results with standard HER2 FISH testing. HER2 
status classification was determined according to published guidelines, based on average number of HER2 
copies per cell and average HER2/CEP17 ratio (CEP17: Chromosome Enumeration Probe 17). Excellent 
agreement was observed between the two methods, supporting the validity of MA-FISH and further 
promoting its short hybridization time and reduced reagent consumption.  
While microfluidics was found to help improving the mass transport of the reactants, the hybridization time 
of a standard FISH probe could not be decreased further because the use of formamide, serving as a double-
helix destabilizing agent, slowed down the hybridization. Therefore, we combined a different, highly reactive 
probe solution containing ethylene carbonate buffer for fast double-helix destabilization (HER2 IQ-FISH 
pharmDxTM probe), with a microfluidic system for improved reactant delivery. As this fast FISH probe is 
radically different from the ones used in any previous microfluidic FISH studies, a complete redesign of the 
protocol is required. Therefore, we used a fractional factorial design of experiments to optimize the 
microfluidic, ethylene carbonate buffer-based FISH protocol. After optimization, the incubation time 
required for performing FISH can be as short as 15 min for a cell line sample and 30 min for a human tissue 
slide, corresponding respectively to a fourth and a half of the duration of the corresponding step in the 
classical IQ-FISH protocol. Extra-short incubation microfluidic-assisted FISH (ESIMA-FISH) is overall the 
fastest and most economic microfluidic FISH technique for tissue analysis at the moment. The main 
drawback of ESIMA-FISH is that its HER2 signal is weaker than the one from the classical IQ-FISH 
technique. However, this limitation does not affect the scoring of the FISH signals, as the HER2 assessments 
of adjacent slides of human breast cancer tissue by ESIMA-FISH and standard IQ-FISH were similar.  
Last, the microfluidic-assistance principle was applied to a CISH probe. The CISH probe used is diluted in a 
formamide–based hybridization solution and composed of a fluorescence that binds to enzymatic-labelled 
Ab. In this study, we achieve two aims: first we optimized MA-FISH using discontinuous-flow regime 
during hybridization step and apply the optimized MA-FISH parameter to perform Microfluidic-assisted 
CISH (MA-CISH). Hybridization time of MA-FISH and MA-CISH was then decreased from overnight 
down to 2 hours and 70% less probe solution is required for both tests, while achieving even a better signal 
quality than the corresponding standard techniques. Optimized MA-CISH was successfully tested for 6 
breast cancer tissue samples and two cell lines, showing a good correlation with standard CISH results as 
CHAPTER 2: MICROFLUIDIC-ASSISTED IN SITU HYBRIDIZATION 
48 
 
evaluated on adjacent slides. Finally, automatic scoring software was developed to facilitate CISH signal 
evaluation, and showed good agreement with the traditional counting protocol. 
2.1. Introduction 
FISH is a cytogenetic technique that targets a specific DNA or RNA location on a chromosome with a 
fluorophore-labeled oligonucleotide probe that is complementary to the target nucleic acid sequence [39]. In 
diagnostic and research laboratories, interphase FISH is widely used on FFPE tissue sections of cancer 
samples, to detect numerical and structural chromosomal alterations such as aneuploidies, amplifications, 
deletions and translocations [40]. However, its dissemination is impeded, among other factors such as its 
technical and analytical complexity, by the high cost of the probe and the long protocol times. Therefore, 
many studies focused on reducing the duration and reagent consumption of FISH tests through different 
approaches, including custom hybridization probes [41, 42], electric field mixing [43] and modification of 
the hybridization buffer composition [44]. In particular, microfluidic devices, where pl to ?l volumes of fluid 
are manipulated, were used for implementing on-chip FISH on cells. Pioneering work was reported by 
Sieben et al. [45], who demonstrated that, by using recirculating hydrodynamic flow or electrokinetic 
transport, it was possible to decrease by ~90% the reagent volume and to reduce the hybridization time to 
few hours for FISH staining on adherent cells. The same group also reported a fully automatic cell-based 
microfluidic FISH, which consumed ~5% of the standard used probe volume [46], Recently, for 
implementing rapid, economical and multiplexed FISH for cell analysis, Huber et al. proposed scanning a 
vertically oriented capillary that creates a hydrodynamic flow of FISH probe on a small area (~0.096 mm2) 
of the cell slide surface [47]. However, this technique can work only with fast hybridization centromere 
probes and has a small footprint due to the limited size of the capillary. While on-chip FISH analysis for 
immobilized cells is well-documented [47-54]. few examples of on-chip FISH analysis of FFPE tissue have 
appeared in the literature, partially because of the difficulty of miniaturizing the setup while preserving a 
large staining area.  
About 15-20% of breast cancer patients have amplified and/or overexpressed human epidermal growth factor 
receptor 2 (HER2, also referred to as ERBB2) gene, which is associated with poor prognosis but predicts 
tumor response to HER2-targeted therapies, such as trastuzumab and other agents, which improve the 
patients’ survival [55-58]. Reliable assessment of HER2 status is therefore of paramount importance and 
should be accomplished according to published guidelines [59, 60]. In a clinical perspective, immuno-
histochemistry (IHC) can be used for HER2 detection, is cheaper (~100-300 $/test) and faster (2 h/test) than 
FISH (~300-800 $/test, 2 days/test with an overnight incubation) [56-58]. However, standard IHC is largely 
This chapter is adapted from the following publications: 
H.T. Nguyen, R. Trouillon, S. Matsuoka, M. Fiche, L. de Leval, B. Bisig, M.A.M. Gijs, Microfluidics-
assisted fluorescence in situ hybridization for advantageous human epidermal growth factor receptor 2 
assessment in breast cancer, Lab. Invest. 97 (2017). 
H.T. Nguyen, L.S. Bernier, A.M. Jean, R. Trouillon, M.A.M. Gijs, Microfluidic-assisted chromogenic 
in situ hybridization (MA-CISH) for fast and accurate breast cancer diagnosis, Microelectron. Eng. 
183-184(Supplement C) (2017) 52-57. 
H.T. Nguyen, L.N. Dupont, E.A. Cuttaz, A.M. Jean, R. Trouillon, M.A.M. Gijs, Breast cancer HER2 
analysis by extra-short incubation microfluidics-assisted fluorescence in situ hybridization (ESIMA 
FISH), Microelectron. Eng. 189 (2018) 33-38. 
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qualitative, which may result in diagnostic ambiguities, whereas FISH is quantitative. In practice, in most 
pathology laboratories, HER2 status of a newly diagnosed breast cancer is first assessed by IHC, equivocal 
IHC cases are then elucidated by FISH [59, 60]. In this context, on-chip FISH for analysis of clinical tissue 
slides was recently reported for detecting HER2 amplification [61]. In this design, a removable 
polydimethylsiloxane (PDMS) chip was clamped against a glass slide containing a tissue or immobilized 
cells to create a chamber. This chip could automatize the FISH process and consumed only 2 ?l of probe 
solution, which is 1/5th of the classical probe volume per test, for a 5?5 mm2 tissue surface. Also, no 
improvement of the hybridization time was reported. Nevertheless, and despite the high economic impact, 
FISH-on-a-chip for either cells or tissue was never clearly established in a pre-clinical study and its potential 
for routine diagnostic use not unambiguously demonstrated.  
To address these challenges, in the first phase, we developed microfluidic-assisted FISH (MA-FISH), in 
which hybridization of the FISH probes with their target DNA strands is obtained by applying oscillatory 
flows of diluted probe solutions in a thin 16?16 mm2 microfluidic chamber of 5 ?l volume. The microfluidic 
system is based on a previously reported microfluidic chip used for the accurate IHC staining of breast 
carcinomas [31, 62]. The study consisted in two steps: optimization of MA-FISH experimental conditions, 
followed by validation of the optimized parameters by comparing MA-FISH with the standard FISH 
technique. Using the optimization parameter set, we show that MA-FISH can be performed on a tissue 
surface as large as 16?16 mm2 and uses only 1 ?l of the standard probe solution Locus Specific Identifier 
(LSI) HER2/CEP17 (PathVysion Kit, ABBOTT, IL, USA), which can be diluted, thus further decreasing the 
consumption of the expensive hybridization probe solution and the total duration of a test. In the validation 
step, we conducted HER2 MA-FISH on 51 FFPE tissue slides of 17 breast cancer samples, and compared the 
results with those obtained from standard HER2 FISH testing.  
So far, despite fast fluidic exchanges, the incubation time was still relatively long (2 h to overnight), owing 
to the intrinsically slow probe-target hybridization kinetics, because of the presence of the formamide 
component in the probe solution [44]. Therefore, in the second phase of the study, we developed a new fast 
FISH technique, namely ESIMA-FISH to overcome the limitations of MA-FISH. This technique combines 
the confinement capability and fast mass transport of microfluidics with the highly reactive IQ-FISH probes. 
The unique reaction kinetics of the ethylene carbonate buffer-based probe called for a novel study aimed at 
designing a new, specific protocol. This approach reduces both the incubation time and the probe 
consumption. The staining protocol was optimized with a fractional factorial design of experiments 
combined to a multivariate linear regression analysis. The HER2 classification results obtained by ESIMA-
FISH are compared to the standard IQ-FISH results using a series of tests ran on human breast cancer tissue 
samples. 
In the third phase, the microfluidic-assistance principle was applied for improving Chromogenic ISH 
(CISH). CISH is emerging as a cheaper alternative to FISH, the latter requiring an expensive fluorescence 
microscope setup. Still, CISH usually require a high amount of the expensive probe solutions as well as long 
experimental times. No study has demonstrated a microfluidic CISH signal that is comparable to a standard 
ISH technique, while significantly reducing both the experimental time and the probe consumption. 
Therefore, we developed a microfluidic-assisted chromogenic in situ hybridization (MA-CISH) technique. 
The signal can be revealed either by directly observing the fluorescence image using MA-FISH as a control, 
or by bright-field microscopy (MA-CISH), after performing some additional immunohistochemical steps. 
Optimization of the protocol was carried out with an HER2-positive breast cancer cell line (SKBR3) by 
CHAPTER 2: MICROFLUIDIC-ASSISTED IN SITU HYBRIDIZATION 
50 
 
analyzing different experimental conditions according to a fractional factorial design of experiments. The 
clinical performance of the optimized MA-CISH test was validated by comparing the results obtained from 
MA-CISH and standard CISH images originating from adjacent slides of 4 tissue samples and two SKBR3 
cell line slides. Furthermore, an image processing software was developed to automatically score the HER2 
and CEP17 signals, thus helping to reduce the analysis time. This study further improved microfluidic FISH 
and introduced MA-CISH as a promising tool for HER2 diagnostics.  
2.2. Materials and methods 
2.2.1. Chemicals and Materials 
All the reactants were purchased from Sigma, unless stated otherwise. All the solutions in this work were 
made using 18 M?.cm water obtained from a Millipore purification system. All fluidic connectors, tubes, 
and fittings were purchased from ThermoFisher Scientific (MA, USA).  
For the MA-FISH staining, the PathVysion HER-2 DNA Probe Kit (Abbott Molecular, IL, USA) was used 
and consisted of 2 differentially labeled probes focused at 2 different targets. The HER2 gene locus 
(17q11.2-q12) is targeted by a 190 kb SpectrumOrange-labeled probe, which comprises several 
complementary DNA segments of the specific gene, and in our analysis was assigned a red color. The 
centromeric regions of chromosome 17 (CEN17) (17p11.1-q11.1) are localized by the 5.4kb SpectrumGreen-
labeled CEP17 DNA probe, which comprises complementary DNA segments of the alpha-satellite region 
located at the CEN17, and in our analysis was assigned a green color. HER2 probe and CEP17 are diluted in 
a formamide-based hybridization buffer.  
ESIMA-FISH was performed using the reagents from the HER2 instance quality FISH (IQ-FISH) 
pharmDxTM kit (Agilent Technologies Schweiz AG, Basel, Switzerland) and MA-CISH reagents were from 
the HER2 Chromogenic in situ hybridization (CISH) pharmDXTM kit (Agilent Technologies Schweiz AG, 
Basel, Switzerland). HER2 IQ-FISH pharmDxTM probe solution contains Texas Red-labeled DNA probes 
target the human epidermal growth factor receptor 2 (HER2) gene and fluorescein isothiocyanate (FITC)-
labeled DNA probes target the CEN17. The probes are diluted in an ethylene carbonate-based hybridization 
buffer. HER2 CISH pharmDXTM kit is also consisted of Texas Red, and FITC-label reveal the position of 
HER2 gene and CEN17, but diluted a classical formamide-based hybridization buffer. Texas Red and FITC 
labels are respectively bound to alkaline phosphatase (AP)- and HRP- conjugated secondary Abs to develop 
colored compounds for visualization. 
2.2.2. Tissues and cell lines 
FFPE invasive breast carcinoma samples, diagnosed between 2012 and 2015, were retrieved from the 
archives of the Institute of Pathology from the Vaud University Hospital (CHUV, Lausanne, Switzerland), 
selected in order to span a wide range of HER2 status. For each sample, 4 ?m-thick tissue sections were cut 
from a representative FFPE block and mounted on Super Frost Plus slides (Menzel-Glaser, Germany). The 
invasive component of the carcinoma was located by a pathologist on adjacent hematoxylin and eosin (HE) 
stained slides. As part of an ethical convention (BB514/2012) with the Ethical Commission of Clinical 
Research of the state of Vaud, all tissues used in this study have been anonymized, codified and all patients 
have not expressed any objection to the use of their tissue. FFPE breast cancer cell lines (SKBR3) were 
produced by AMS Biotechnology (Europe) Limited, UK. 
CHAPTER 2: MICROFLUIDIC-ASSISTED IN SITU HYBRIDIZATION 
51 
 
2.2.3. Microfluidic chip and setup 
 
Figure 2.1 - Design of the microfluidic system. (a) The microfluidic chip consists of a bonded Pyrex-Si 
stack: (ai) view on the Pyrex side of the stack showing ‘tree’-like channels on Si layer allowing a 
homogenous distribution of the liquid for uniform staining of the tissue; the flow is channelized via 
feedthrough holes, for example the array encircled in white, to (aii) the Si chip face that later will form the 
microfluidic chamber, together with the spacer strips, Polydimethylsiloxane (PDMS) o-ring and the tissue 
slide. (b) Exploded view of the setup. A microscope slide carrying a tissue section is mechanically clamped 
against a microfluidic chip and thereby forms the bottom of a thin 16×16 mm2 size chamber. Two strips of 
Al foil serve as spacers controlling the chamber height to 20 ?m, while a PDMS o-ring hermetically seals the 
chamber and the fluidic circuit that are placed in a thermostatic copper holder. (c) View of the upside-down 
assembly of the setup of (b) on a hot plate, which itself is to be positioned in a thermally insulating 
polystyrene chamber afterwards. (d) Three-dimensional representation of the channels and the 5 ?l 
microfluidic chamber, in which square-wave oscillatory flow cycles are applied during the incubation step of 
a microfluidic-assisted in situ hybridization protocol. (di) and (dii) show the extreme situations of a cycle; 
the total staining solution volume (indicated in blue) is only 10-12 ?l and is flanked by perfluorinated oil that 
fills the rest of the channels. 
The microfluidic chip (see figure 2.1a) was micro-fabricated using the protocol illustrated in figure 1.8c in 
Chapter 1. The microfabrication process flow was adapted from reference [31]. Briefly, the chip consisted of 
a bonded Pyrex-Si stack: the Pyrex side showed ‘tree’-like channels (figure 2.1ai) allowing a homogenous 
distribution of liquid for uniform staining of the tissue; the liquid was channelized via feedthrough holes 
(figure 2.1aii) to the Si side of the stack (figure 2.1aiii) that later formed, using mechanical clamping via 
screws, the microfluidic chamber together with the spacer strips, PDMS o-ring and the tissue slide (see 
figure 2.1b). A controlled screwing force during assembly was provided by a dynamometric screw driver 
(TorqueVario-S, Wiha Werkzeuge GmbH, Germany) for reproducibility. Two 20 ?m thick aluminum strips 
served as spacers for fixing the chamber height at 20 ?m, while a 350 ?m thick PDMS o-ring (Shielding 
Solutions Ltd, Essex, UK) was inserted in a 275 ?m deep notch to hermetically seal the chamber. A rubber 
o-ring distributed the clamping force homogeneously, and also contributed to a better thermal insulation of 
the chamber. If a cell line slide was inserted, two additional plastic film spacers of 10 ?m-thickness were 
inserted inside the chamber in order to focus the flow stream on the pre-wetted surface of the cell pellet (Ø4 
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mm, not presented). The assembly of these elements was placed in a copper holder (figure 2.1b, c), the 
temperature of which was controlled by placing it on a hotplate (Scilogex MS-H280-Pro, Thomas Scientific, 
NJ, USA). Note that the assembly of figure 2.1b was presented upside-down for better visualization. Thermal 
stabilization was realized via read-out of an external thermometer probe (Fluke 54ii, Fluke, WA, USA) that 
was in contact with the microscope slide. During operation, the copper holder was also covered by a 
polystyrene foam-based thermal insulation chamber. Finally the copper holder was interfaced via 
commercial microfluidic fittings (see figure 2.1c) to 2 automated syringe pumps (Low Pressure Syringe 
Pump neMESYS V2 modules and base, code: A3921000102 and A3921000114, Cetoni GmbH, Germany). 
During the DNA hybridization step of the microfluidic FISH protocol, the pumps generated back-and-forth 
movements of the probe solution in the chamber (figure 2.1di-ii). 
2.2.4. Standard FISH and CISH protocols 
2.2.4.1. Standard HER2 Pathvysion FISH 
 
 
Figure 2.2 - Standard FISH and CISH technique illustration. (a) Schematic presentation of FISH method. 
After applying the probe solution via the microfluidic chip, probe-tissue incubation is performed under a 
hydrodynamic flow. The probe solution contains DNA probes that target the human epidermal growth factor 
receptor 2 (HER2) and the centromere of chromosome 17 (CEN17). During incubation, the DNA probes 
diffuse into the tissue where they combine with the denaturated single-stranded target DNA, revealing the 
different positions of HER2 oncogene copies and CEN17 inside a nucleus. After FISH, counting the HER2 
(in red) and CEN17 (in green) signals allows for HER2 scoring and classification. (b) Principle of DNA 
detection and chromogenic revelation in CISH. (bi) On-chip DNA hybridization between the two fluorescent 
probes and HER2 gene and CEN17, respectively. HER2 probe is labeled with Texas Red (in red) and the 
CEN17 probe (CEP17) is labeled with fluorescein isothiocyanate (FITC) (in green). (bii) Off-chip binding of 
the Texas Red molecule to an alkaline phosphatase (AP)-conjugated secondary Ab and of the FITC molecule 
to a horseradish peroxidase (HRP)-conjugated secondary Ab, respectively. (biii) Off-chip development of the 
chromogenic HER2 signal by AP-induced precipitation of a red colored compound from a substrate and of 
the chromogenic CEN17 signal by HRP-induced precipitation of a dark blue colored compound from a 
substrate. 
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The standard Pathvysion FISH protocol was adopted from the standard practice used at the Institute of 
Pathology. For dehydration, a FFPE tissue section was first heated to 65°C during 5 min on a hot plate, and 
subsequently cooled down during 1 minute before being immersed 3 times in a Histoclear II (National 
Diagnostics, GA, USA) deparaffinization solution for 5 min. Next, the slide was rehydrated in a six-step 
protocol, using 100%, 100%, 95%, 70%, 40% ethanol, and Tris/HCl buffer (DAKO, Denmark) solutions, 
respectively, each step taking 2 min. The slide was then dipped into a Coplin jar containing MES (2-[N-
morpholino] ethanesulphonic acid) 1? buffer (DAKO, Denmark) for 10 min at 95C, and was then allowed 
to cool down in the same solution for 15 min. The slide was subsequently rinsed twice in Tris/HCl and 
treated by pepsin for 10 min at 37°C to remove any residual proteins from the tissue. After being washed 
twice in Tris/HCl, the slide was exposed to phosphate buffered saline (PBS, pH= 7.4) supplemented with 1% 
formaldehyde (Merck Millipore, Germany), 0.021 M MgCl2 for 10 min and then rinsed in pure PBS. The 
slide was successively dehydrated in 40%, 70%, 95%, 100% ethanol using 2 minute sequences. The sample 
was retrieved from the ethanol bath and dried. After the complete ethanol evaporation, 10 ?l of dual-labeled 
PathVysion DNA probe (HER2 and centromere of chromogene 17 probe) was applied on the tissue slide 
(figure 2.2a). The probe was spread evenly over the sample by depositing a 22 × 22 mm2 coverslip on the 
slide and this stack was sealed by a thermoplastic rubber Coverslip Sealant (DAKO, Denmark). The sample 
was then exposed to 73°C for 5 min, on a hot plate, to denaturate the DNA and placed overnight (16 hours) 
in an oven at 37°C for hybridization. Upon completion of the hybridization step, the tissue slide was dipped 
in a stringent wash solution composed of 2? sodium-saline citrate (SSC), 0.3% Tween 20 (Bio Rad, CA, 
USA) at 73°C, followed by successive washing steps at room temperature in 2? SSC, 0.1% Tween 20 for 2 
min, then in 2? SSC for 2 min, and finally in de-ionized (DI) water for 10 s. The sample was then 
successively rehydrated in 100%, 85%, 70% and 40% ethanol before being mounted with mounting solution 
containing 4',6-diamidino-2-phenylindole (DAPI) and anti-fading agent (Fluorescence Mounting Medium, 
DAKO), coverslipped and sealed with nail polish before imaging. A typical example of standard HER2 
Pathvysion FISH image is detailed in figure 2.3. 
 
Figure 2.3 - Example of a fluorescence image obtained using the in-house standard FISH protocol. The 
image was acquired using a fluorescence microscope with high resolution objective (63?, NA=1.4, oil 
immersion). (a) Three-channel (blue, green and red) fluorescence microscopy image of a cluster of cells 
in a tissue. (b) Blue channel, locating the nuclei stained by DAPI. (c) Green channel, showing the 
centromere enumeration probe in chromosome 17 (CEP17). (d) Red channel, showing HER2 probe-
labeled signals locating the HER2 gene. Scale bar: 2 ?m. 
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2.2.4.2. Standard HER2 IQ-FISH 
For standard IQ-FISH, all pretreatment steps until the probe application step were similar as in standard 
Pathvysion FISH. During the probe application step, 10 ?l of probe mix HER2 IQ-FISH FISH pharmDxTM 
was applied on the tissue surface and the slide was subsequently covered with a glass coverslip and closed 
with rubber sealant. For standard IQ-FISH, the covered slide was put on a hot plate for denaturation at 66°C 
for 10 min (for IQ-FISH) and then incubated at 45°C for 1.2 hour on the hot plate (Scilogex MS-H280-Pro, 
Thomas Scientific, NJ, USA). For CISH, slides were then heated up to 73 °C for 5 min, then placed in a 
humid chamber (glass Petri dish, with humidified tissue, sealed with a plastic paraffin film) in the oven for 
overnight hybridization (45 °C). Once the hybridization step was completed, the rubber and coverslip were 
removed at room temperature. The slide was then processed with a stringent wash step, in which it was 
immersed in 1× stringent wash buffer (saline-sodium citrate (SSC) with Tween 20 detergent, respectively 
obtained from the standard IQ-FISH or CISH kit) at 63-65°C for 10 min, after which the specimens were 
washed twice with washing buffer for 3 min and dehydrated in a series of 70%, 85%, and 100% ethanol 
baths for 2 min each. For standard IQ-FISH, the slide was counterstained with DAPI (Agilent Technologies, 
CA, USA), covered with a glass coverslip and sealed with nail polish before imaging.  
2.2.4.3. Standard CISH 
All standard CISH pretreatment steps were similar to these of the standard FISH. 10 ?l of the CISH 
pharmDXTM probe is applied to the surface of the slide. 10 ?l of dual-labeled PathVysion DNA probe was 
applied on the tissue slide. The slide is then coverslipped and sealed by the Coverslip Sealant thermoplastic 
rubber. The sample was then exposed to 73-82°C for 5 min, on a hot plate, to denaturate the DNA and placed 
overnight (16 hours) in an oven at 45°C for hybridization. Following overnight hybridization, the slide was 
washed in the same hot stringent wash bath (65?2 °C, 10 min), followed by 2 washing steps in 
tris(hydroxymethyl)aminomethane hydrochloride (Tris/HCl) from the kit for 3 min each. After 2 washing 
steps in Tris/HCl, named “1st  wash buffer” for 3 min each, and after washing in Tris-buffered saline solution 
with 0.05% Tween 20, named “2nd wash buffer”, for 3 min, tissues were covered with Peroxidase block for a 
5?1 min incubation at room temperature (RT). After two 2nd wash buffer steps of 3 min each, tissues were 
covered with the CISH Ab mix (mix of HRP-conjugated Ab to FITC and AP-conjugated Ab to Texas Red, in 
50 mmol/L Tris buffer with stabilizer, pH 7.5) and put in a humid chamber for incubation during 30?1 min at 
RT (figure 2.2bii). After two 2nd wash buffer steps of 3 min each, tissues were covered with the red 
chromogen solution for incubation in a humid chamber (10 min) (figure 2.2biii). After two 2nd wash buffer 
steps of 3 min each, tissues were covered with the blue chromogen solution for incubation (10 min) (figure 
2.2biii). A 1:5 diluted hematoxylin solution was prepared, and put on the tissues after two 2nd wash steps 
using (3 min each) for counterstaining (5 min). Finally, tissues were rinsed with 2nd wash buffer, and left in it 
for 5 min, rinsed with distilled water and left to dry at 37 °C for approximately 30 min. After they had cooled 
down, slides were coverslipped with CISH-mounting medium, which was left to harden before inspection. 
Slides were then stored at RT.  
2.2.5. MA-FISH protocol 
The de-paraffinization, pre-treatment, protein digestion, post-fixation and washing steps were identical to 
that of the standard protocol and were done off-chip. However, the denaturation and hybridization steps were 
performed differently from the standard FISH protocol. In contrast with the standard FISH method, the 
PathVysion DNA probe solution was diluted with a solution consisting of 70% locus-specific identifier (LSI) 
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hybridization buffer (Abbott) and 30% DI water. Typically, the probe was diluted 10-fold, but other dilutions 
(5? and 20?) were also investigated. To run a MA-FISH protocol, a pre-treated and dehydrated tissue section 
was placed in the microfluidic system, which was then assembled (figure 2.1b). The spacer fixed the 
chamber height at h= 20 ?m. Afterwards, two empty 100 ?l syringes were partially loaded with ~30 ?l 
perfluorinated oil (FC-40, Sigma-Aldrich Chemie GmbH, Buchs, Switzerland), degassed in a vacuum 
chamber and placed in an automatic syringe pump system (Nemesys, Cetoni GmbH, Germany). Each syringe 
was fitted with polyether ether ketone (PEEK) tubings (160 ?m inner diameter, UpChurch Scientific, WA, 
USA). The probe was loaded in the system by aspirating a volume V= 10 ?l of diluted probe in the tubing 
system attached to one of the syringes. The chamber was filled with the probe at 0.1 ?l s-1 via fluidic 
connectors (UpChurch Scientific, WA, USA) until 5 ?l of probe had been injected or until it reached the 
outlet, as presented in figure2.1di. The chamber has to be filled slowly to avoid bubble formation. After 
filling, the second syringe was connected to the outlet to close the microfluidic system. Great attention was 
given to avoid trapping of any bubble during the assembly. The denaturation was initiated by placing the 
microfluidic chip on a hotplate at Td = 73°C for 5 min. The chip was then transferred to another hotplate, the 
temperature of which was fixed at Th = 37°C. When the temperature was stabilized, the whole platform was 
thermally insulated by covering it with a polystyrene chamber, and a periodic flow was applied to the probe 
solution. The syringe pumps were programed to set a push-pull injection pattern, with one syringe injecting 5 
?l of probe, and the other one aspirating the same volume, at the same flow rate. Once 5 ?l of solution had 
been displaced (figure 2.1dii), the direction of the flow was reversed, thus allowing for repeated, cyclic 
flushes of 5 ?l of probe over the sample. The flow rate Q was typically 1 nl s-1, but other flow rates (0, 10, 
100, 1000 nl s-1) were also investigated. Each flow rate Q= 0, 1, 10, 100, 1000 nl s-1 has a corresponding 
push-pull cycle frequency f = 0, 10-4, 10-3, 10-2, 10-1 Hz, respectively to keep exactly 5 ?l of probe solution 
moving on the tissue surface. The cyclic square wave flow was applied inside the chamber for typically 4 h 
(but other hybrization time (2h and 8h) were also investigated), while the system was still maintained at 
37C, to allow for hybridization. Hereafter, the slide was removed from the microfluidic setup, washed and 
prepared for imaging in the same manner as for the standard protocol. After being imaged, slides were stored 
at -25°C. The setup with the chip could be re-used after washing that was performed using a dummy slide, by 
injecting 2? SSC supplemented with 0.1 % Tween for ~2 min, rinsing it with 70 % ethanol, before drying the 
different components with compressed air. The MA-FISH protocol was optimized by comparing the 
fluorescence signal obtained from adjacent slides that were processed with series of different values of 
different experimental conditions (vide infra). The tissues that were used for the optimization process are 
different than the ones used in the validation phase.  
2.2.6. ESIMA-FISH protocol 
The ESIMA-FISH protocol was partially similar to the standard IQ-FISH protocol (vide supra), but the steps 
from the post-fixation to the end of the hybridization step were different. Here, several parameters can be 
adjusted, namely the absence or presence of a post-fixation step (P), the flow rate during hybridization (Q), 
the probe concentration (C), the denaturation temperature (T), the total volume of probe used (V), and the 
duration of the denaturation (td) and hybridization steps (th). We used a fractional factorial design of 
experiments to optimize these parameters, as described below in the optimization section. In our fractional 
factorial design, the post-fixation step could be present (P=1) or absent (P=-1). After the post-fixation step, a 
phosphate buffer saline (PBS) wash and a second dehydration in a series of 70%, 85%, and 100% ethanol, 
the denaturation and hybridization steps of ESIMA-FISH were implemented using the microfluidic setup. A 
syringe filled with FC-40 oil  and 12 ?l (V =-1) or 20 ?l (V =1) of the diluted probe mix is mounted on a 
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pump and connected to the inlet of the microfluidic setup, see figure 2.1c. The probe solution is diluted 8× 
(C=-1) or 4× (C=1) in an ethylene carbonate-based hybridization buffer (reference G9415A, Agilent). The 
diluted probe solution was transferred to a microcentrifuge tube (Vaudaux-Eppendorf AG, Basel, 
Switzerland) and denatured at 66°C for 10 min. The probe solution is loaded in the microfluidic setup, and a 
second FC40 oil-flanked syringe is connected to the outlet of the setup. The device was put on a hot plate for 
denaturation (45 °C (T=1) or 66 °C (T=-1), 10 min (td =-1) or 20 min (td=1)). It was cooled down to 45 °C 
with an air flow in the case of the 66°C denaturation, and we used either a continuous (Q =1, see figure 2.4a) 
or discontinuous flow (Q =-1, see figure 2.4b) applied by two synchronized pumps placed at the inlet and 
outlet of the chip, until the end of the incubation step (45 °C during 15 min (th=1) or 30 (th=-1) min). The 
flow rates and the functions of the syringes were defined using the software supplied by Cetoni GmbH. All 
fractional factorial design of experiment combinations are presented in table 2.1.  
Table 2.1 - Analysis of fractional factorial design of the experiments. The experimental conditions are 
summarized in the columns labeled with (1-8). For each of the parameters listed  in the column on the 
left, two values are considered in columns (1-8), as reported between brackets, and associated to an 
arbitrary ‘-1’ or ‘1’ value. The regression coefficients for the 4 different signal outputs are listed in the 
last four columns, namely the average green and red signal diameter (Dgreen and Dred) and contrast (Cgreen 
and Cred), respectively. Here, the contrast is defined as C = (?? ? ??????? ? ???, with ?? the intensity of the 
signal and ?? the intensity of the background. The quality of the linear regression model is assessed with 
the least-square coefficient R2 and the F-test p value. 
 Value of the parameter for this run 
Run # 1 2 3 4 5 6 7 8 
P -1 (No) -1 (No) -1 (No) -1 (No) 1 (Yes) 1 (Yes) 1 (Yes) 1 (Yes) 
Q (nl/s) -1 (10 nl/s discontinuous) 
-1 (10 nl/s 
discontinuous) 
1 (10 nl/s 
continuous) 
1 (10 nl/s 
continuous) 
-1 (10 nl/s 
discontinuous) 
-1 (10 nl/s 
discontinuous) 
1 (10 nl/s 
continuous) 
1 (10 nl/s 
continuous) 
C -1 (8×) -1 (8×) 1 (4×) 1 (4×) 1 (4×) 1 (4×) -1 (8×) -1 (8×) 
T (°C) -1 (66) 1 (45) -1 (66) 1 (45) -1 (66) 1 (45) -1 (66) 1 (45) 
V (?l) -1 (10) 1 (20) -1 (10) 1 (20) 1 (20) -1 (10) 1 (20) -1 (10) 
td (min) -1 (10) 1 (20) 1 (20) -1 (10) -1 (10) 1 (20) 1 (20) -1 (10) 
th (min) -1 (30) 1 (15) 1 (15) -1 (30) 1 (15) -1 (30) -1 (30) 1 (15) 
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Once the hybridization step was complete, the device was cooled down to room temperature using an air 
flow. The slide was then processed with a stringent wash step, in which the slide was immersed in a 1× 
stringent wash buffer obtained from the kit (SSC, buffer with Tween 20 detergent) at 63°C for 10 min, after 
which the specimens were washed twice with the washing buffer included in the kit for 3 min and 
dehydrated in a series of 70%, 85%, and 100% ethanol baths for 2 min each. Finally the slide was 
counterstained with mounting medium containing DAPI, covered with a glass coverslip and sealed with nail 
polish before imaging. In a FISH image, DAPI reveals the position of the nuclei, while Texas Red-labeled 
and FITC-labeled probes reveal the position of HER2 gene and CEN17, respectively, see figure 2.2a. 
 
Figure 2.4 - Flow profiles applied during incubation, as actuated by two (inlet and outlet) syringe pumps. 
(a) For the continuous flow regime, the outlet syringe aspirated and the inlet syringe pump injected with 
a constant flow rate of ±0.1 ?l/s until 4 ?l was displaced, then the flow was reversed and 4 ?l of solution 
was pumped back. The process was repeated until the end of the incubation. A period (one whole cycle) 
took 80 s. (b) For the discontinuous flow regime, the syringe pumps still aspirated/injected at the same 
flow rate, for the same displaced volume (4 ?l) but each half period was split into 2 identical short 
regimes, characterized by a first ± 0.1 ?l/s flow rate for 20 s followed by a quiescent phase for 160 s. 
Then the pumping directions of the two syringes were inverted. Here, the period was 720 s (4 min) and 
was repeated until the end of the incubation. 
2.2.7. MA-CISH protocol 
The pretreatment of slides before the hybridization step in the MA-CISH protocols is the same as in a 
standard CISH protocol from Agilent Technologies (vide supra). Only probe application, denaturation and 
hybridization differed from the standard procedure and were performed based on the microfluidic setup. 
Syringes were mounted on a neMESYS dosing system (Cetoni GmbH) and connected to the fluidic inlet and 
outlet, after being filled with FC-40 oil (Sigma-Aldrich Chemie GmbH, Buchs, Switzerland) and 12 ?l of the 
diluted probe mix. The original probe solution was diluted in a solution based on SureFISH FFPE 
Hybridization Buffer from Agilent Technologies. The probe solution used in MA-CISH and MA-FISH 
protocol are identical. First, only the inlet was connected and the probe mix was injected until complete 
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filling of the chamber, after which the outlet syringe was connected. The device was put on a hot plate for 
denaturation (73 °C, 5 min). It was cooled down to 45 °C with compressed air, and a discontinuous flow 
regime, presented in figure 2.5a, was applied throughout hybridization (45 °C, 2 hours). The flow rates and 
the functions of the syringes were controlled using the software supplied by Cetoni. A volume of 4 ?l 
oscillated at a flow rate of 0.01 ?l/s. The probe was pushed for 100 s pulses (at a 0.01 ?l/s rate), with 200 s 
intervals between each pulse. After 4 pulses, 4 ?l had been moved forward, and the process was reversed, 
moving the 4 ?l backwards. This cycle was repeated for the 2 hours of hybridization. The MA-CISH 
protocol can also be performed using a continuous flow regime (figure 2.5b) by applying 0.01 ?l/s rate back-
and-forth flow with any stop interval inserted. Once hybridization was over, the device was cooled down 
with compressed air, disassembled, and washed with stringent wash solution (SSC buffer with detergent) and 
ethanol. The IHC staining procedure for chromogenic revelation was performed. The staining procedure is 
identical to that of a standard CISH protocol as described in section 2.2.4. It is possible to perform MA-FISH 
first and thereafter MA-CISH, by removing the coverslip in the 2nd wash buffer then pursuing additional 
immunohistochemical staining. 
 
Figure 2.5 - Syringe-induced flow regimes that were used to induce back-and-forth movement of the probe 
solution during hybridization in a microfluidic-assisted chromogenic in situ hybridization (MA-CISH) 
experiment. (a) Discontinuous flow regime. A volume of 4 ?l oscillated at a flow rate of 0.01 ?l/s. The probe 
was pushed for 100 s pulses (at a 0.01 ?l/s rate), with 200 s intervals between each pulse. After 4 pulses, 4 ?l 
had been moved forward, and the process was reversed, moving the 4 ?l backwards. This 220 s cycle was 
repeated during the hybridization time (2 or 4 h). (b) Continuous flow regime. During the hybridization time 
(2 or 4 h), a volume of 4 ?l continuously oscillated at a flow rate of 0.01 ?l/s without quiescent flow periods 
inserted between each back-and-forth flows. 
2.2.8. Image acquisition  
2.2.8.1. Fluorescence microscope for FISH: 
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Figure 2.6 - FISH signal presentation. (a) Evaluation of the MA-FISH signal is based on a set of 3?3 
mosaic z-stack images (typically 21 layers, ?z= 0.2 ?m), recorded at different positions of the tumor area 
after the staining process. The recorded images span a tissue volume of 400 ? 300 ? 4 ?m3. (b) The nine 
images of one layer of the z-stack. (c) Zoom on a region of interest of b, from which the FISH signal can 
be acquired. (d) Projected image of the 3-dimensional region of interest in a single plane, following 
deconvolution of all layers of the z-stack (HRM software, Scientific Volume Imaging B.V., 
Nertherlands) and three-dimensional reconstruction (IMARIS software, Bitplane, Switzerland) of the 
latter. This is a HER2-negative case (i.e. not amplified), which shows 1 to 2 copies of the HER2 gene 
(corresponding to the red signals) per nucleus in the cancerous cells (their large nuclei can be appreciated 
thanks to the blue DAPI counterstain), and an approximately equivalent number of copies of centromere 
17 (CEP17, corresponding to the green signals). (e) Projected image of a HER2-positive case (i.e. 
amplified), in which the cancer cells have large nuclei containing >6 HER2 copies (red signals) per 
nucleus, while the number of CEP17 (green signals) is not increased, yielding a HER2/CEP17 ratio >2. 
(f) The same case as in e, but focusing on a region in the tissue of non-cancerous cells that have smaller 
nuclei and show no amplification of the HER2 gene (internal negative control).  
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The same image acquisition and scoring method were applied for both MA-FISH, ESIMA-FISH, standard 
Pathvysion FISH and standard IQ-FISH. A fluorescence microscope (Carl Zeiss Axio Imager M2m) was 
used for the imaging. Three filter sets of Zeiss were used (02 High Efficiency (HE), 10 HE, and 43 HE) for 
imaging of DAPI, SpectrumGreen fluorophore (Abbott), and SpectrumOrange fluorophore (Abbott), 
respectively. A low magnification (10? objective) was first used to identify the areas of invasive carcinoma, 
which were then imaged at a higher magnification with a 63? oil immersion objective with 1.4 numerical 
aperture (Plan-Apochromat Oil DIC, Zeiss). The images were acquired through the Axiovision LE64 
software to obtain multichannel images. The pixel size was 0.1 ?m ? 0.1 ?m for all the images presented in 
this work. To allow high-quality imaging, z-stacks were obtained for n layers, with n=htissue/?z, where htissue 
is the tissue thickness (~4 ?m) and ?z is the axial increment step (figure 2.6a). This parameter could be tuned 
depending on the purpose of the analysis: for counting signals within a stack, ?z was 0.5 ?m. For a 3D 
image reconstruction for a graphical presentation, ?z was fixed at 0.2 ?m. The explanation of this choice is 
detailed in the section 2.2.8.2.  
With these parameters, 3-channel (blue, green, red) z-stacks were recorded for the regions of interest of the 
slide, each corresponding to a volume of 300 ? 400 ? htissue ?m3 of tissue. To facilitate the acquisition, each 
plane of the xy image was divided into a 3 ? 3 mosaic (figure 2.6b, zoom to a region of interest in figure 
2.6c), for which thereafter the whole 3D volume was reconstructed. The 0.2 ?m step z-stack images were de-
convoluted with the Huygens software (HRM software, AutoDeblur, BitPlane, Switzerland), followed by a 
3-dimensional reconstruction with the software IMARIS (BitPlane, Switzerland). The fluorescence signal, 
for each channel, was then projected on the xy plane. Results for a HER2-negative case and a HER2-positive 
case were selected for the graphical representation in figures 2.6d and 2.6e, respectively. As an internal 
control of the technique, smaller non-cancerous nuclei with normal HER2 status, adjacent to HER2 positive 
cancer cells, are shown in figure 2.6f. 
2.2.8.2. Choice of the z-stack and axial increment step ?z 
FISH signals within a 4?m-thick tissue were recorded by analyzing a z-stack of high resolution (63? 
objective, 1.4 numerical aperture (NA)) images. The axial increment step ?z was chosen based on a 
calculation of the axial resolution (or depth of field) of the microscope. The latter can be computed as 
follows: ???? ? ?????? ?
?
?? ? ?,
1 with ?? the wavelength of the excitation light for the SpectrumGreen 
fluorophore (470 nm) or for the SpectrumOrange fluorophore (550 nm), n=1.515 the refractive index of the 
oil between the coverslip and the objective front lens element, and NA=1.4. The variable e is the resolution 
of the detector equal to 6.45 ?m, and M=63? the lateral magnification. We obtain ????=0.474 ?m for the 
green channel (SpectrumGreen) and ????=0.536 ?m for the red channel (SpectrumOrange). For scoring 
signals, a z-stack composed of at least 9 layers with ?z=0.5 ?m was chosen to record signals within the 
tissue volume. This sampling step ?z=0.5 ?m < 0.536 ?m is sufficiently small to observe all small red 
signals, whereas green signals which always span a much larger area (typically 1 ?m in diameter) are easy to 
detect. Nevertheless, for getting high resolution representation of signals along the z direction, a 
deconvolution process applied to the z-stack images was needed and required a finer ?z=0.2 ?m 
corresponding to the Nyquist criterion [63]. The latter states that the sampling frequency ?(1/?z) should be at 
least twice the sample frequency ?(1/????).  
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2.2.8.3. Bright-field microscope for CISH: 
Slides were placed under a microscope (DM5500, Leica, Wetzlar, Germany) equipped with a motorized XY 
scanning stage, light source shutter and both optical and fluorescence functions. Images were acquired with a 
63 × oil-immersion objective (LEICA HCX PL APO/ OIL).  
2.2.9. Image analysis 
An unbiased, quantitative and automated signal analysis based on an image processing pipeline, was 
developed using the open-access software Cell Profiler [64] (see figure 2.7 and table 2.2). The purpose of 
this analysis is to extract the diameter and intensities of each dot associated to the FISH signal, and allow for 
the comparison of different experimental conditions. Then, a contrast function, defined as ???? ? ????/???? ?
????, with Isg and Ibg the average intensities of the signals associated to either the green or red dot and the 
background, respectively, is computed. The numerical results for the different parameters were compared 
using a student t-test, or a one-way analysis of variance (ANOVA) test followed by a post-hoc Tukey’s 
comparison test to justify our graphical observation, vide infra. The results were presented as mean ± SD, 
obtained by averaging diameter and contrast from 9 images in the selected 3?3 mosaic picture. Prism 
software (Graphpad Software Inc., CA, USA) was used to plot the results. 
 
 
Figure 2.7 - Image processing performed on one focal plane of the z-stack in the MA-FISH protocol. (ai) 
One tile of the 3?3 mosaic picture. (aii) Zoom in one region of interest (ROI) of the picture in ai. (bi-iii) 
DAPI, green and red channel, respectively, of the picture in ai. (ci) Nuclei were identified by 
thresholding the signal in bi. A DAPI mask was created for allowing only selection of signals that are 
inside a nucleus. (cii) CEP17 signals, identified by thresholding the intensity in bii. (ciii) HER2 signals, 
identified by thresholding the intensity in biii. (di) Overlay of the outline of the identified nuclei, of the 
CEP17 signals, and of the HER2 signals with the original image. (dii) A zoom in one ROI of the picture 
di. Scale bar: 10 ?m. 
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Table 2.2 - Different steps of the image processing protocol to measure the CEN17 (green) and HER2 (red) 
signal diameter (Dgreen and Dred) and contrast (Cgreen and Cred). Briefly, the original RGB (red, green, blue) 
image was split in 3 images, corresponding to the DAPI (blue), CEN17 (green), HER2 (red) signals, 
respectively. The HER2 image was thresholded with an appropriate automatic threshold method to define 
non-specific auto-fluorescence. Subsequently, the auto-fluorescence area was discarded in the DAPI image 
and the resulting image was called “DAPI masked”. The area of nuclei was then detected in the “DAPI 
masked” image with an appropriate thresholding method. Afterwards, the background in HER2 and CEN17 
image was suppressed and the images were called afterwards “HER2 filtered” and “CEN17 filtered”. By 
using an appropriate threshold method, the “HER2 filtered” image was thresholded (named “HER2 filtered 
thresholded”). Then, “HER2 filtered thresholded” masked the “CEN17 filtered” image negatively (the 
outside of the “HER2 filtered thresholded” mask in the “CEN17 filtered” image is kept). The resulting image 
was called “CEN17 masked HER2”, which contained only CEN17 signal without auto-fluorescence. By 
using an appropriate threshold method, the CEN17 signal was then detected in the “CEN17 masked HER2” 
image. The CEN17 signal was then transformed to a binary image that masked the “HER2 filtered” image 
negatively. Finally, the HER2 signal was detected in the “HER2 filtered masked” image using an appropriate 
threshold method. The backgrounds in CEN17 and HER2 images were defined as the area outside the 
CEN17 and HER2 signal areas. Afterwards, the program measured signal diameters (Dgreen and Dred) and 
intensities ?? of green and red signal, as well as the background intensity ?? of the HER2 and CEN17 image, 
in the original images based on the identified area to assess the signal quality. 
Operation #  Input Operation Output 
1 RGB (Red, green, blue) Image Color to gray images: DAPI (Blue), CEN17 (green), HER2 (Red) 
2 HER2 Identify Primary Objects* object: Auto-fluorescence 
3 DAPI & Auto-fluorescence Masking** image: DAPI masked 
4 DAPI Identify Primary objects* object: Nuclei 
5 HER2 Enhance Or Suppress Features*** image: HER2 filtered 
6 CEN17 Enhance Or Suppress Features image: CEN17 filtered 
7 HER2 filtered Apply Threshold HER2 filtered thresholded 
8 CEN17 filtered& HER2 filtered thresholded Masking CEN17 masked HER2 
9 CEN17 masked HER2 Identify Primary Objects object: CEN17 dots 
10 CEN17 filtered Apply Threshold Image: Binary CEN17 
11 HER2 filtered& Binary CEN17 Masking Image: HER2 filtered masked 
12 HER2 filtered masked Identify Primary Objects object: HER2 dots 
13 Nuclei& CEN17 dots Masking+ Invert Object:CEN17 background 
14 Nuclei& HER2 dots Masking+ Invert Object:HER2 background 
15 CEN17& CEN17 dots& CEN17 background Measure intensity 
CEN17 signal and background 
intensity 
16 HER2& HER2 dots& HER2 background Measure intensity 
HER2 signal and background 
intensity 
17 HER2 Measure size HER2 dot size 
18 CEN17 Measure size CEN17 dot size 
*Identify Primary Objects: Identification of nuclei, HER2 and CEN17 signals. 
**Masking: Suppress the auto-fluorescence in one channel using another channel. 
***Enhance or Suppress Features: similar to a high-pass filter that retains only speckle-like signal 
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2.2.10. Signal scoring 
To assess MA-FISH and ESIMA-FISH scores, z-stacks (?z= 0.5 ?m) were obtained as detailed above, for 
three independent invasive locations of the sample. Axiovision software (Carl Zeiss, Germany) was used to 
inspect each layer of the z-stack (figure 2.8). For the HER2 status assessment, the average number of HER2 
dots per cell and the average HER2/CEN17 ratio in one or several cluster(s) of 20 cells were calculated. A 
ratio higher than 2, or a number of HER2/cell higher than 6 were considered positive; a number of HER2/cell 
higher than 4 and less than 6 with a ratio lower than 2 was considered equivocal, and anything lower than 
these thresholds was classified as negative, following the ASCO/CAP guidelines for FISH analysis [59]. 
According to these guidelines, two scores, the average HER2 copy number/cell and the HER2/CEP17 ratio, 
should be reported for HER2 status assessment in clinical practice. 
CISH scoring was performed using 2D images obtained from the bright-field microscope (z-stack not 
required). The image contrast was enhanced with FIJI [65], and blue and red signals were counted on clusters 
of 20 cells for each sample.  
 
Figure 2.8 - Example of four consecutive images in a z-stack. For scoring signals in a FFPE tissue that was 
stained using a MA-FISH protocol, a zoom on consecutive images within a z-stack reveals several red and 
green signals that are identifiable in different focal planes. (a-d) 4 successive focal plans. In this example, 4 
green CEP17 signals and 6 red HER2 signals are scored, as these are identifiable by the same signal pattern 
over the different images. To be counted as a signal, it should appear in at least two consecutive focal planes 
of the z-stack. 
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2.3. Microfluidic-assisted FISH (MA-FISH) 
2.3.1. Results 
2.3.1.1. Considerations on the system variables 
To facilitate the analysis and guarantee an optimal diagnostic power, the FISH staining protocol should 
preserve the morphology of the tissue, result in a homogenous staining of nuclei with low auto-fluorescence 
from background materials, and feature well-defined, bright, DNA-specific FISH signals inside the nuclei. In 
a standard setup, DNA hybridization can be tuned by several experimental factors, such as the denaturation 
(Td) and hybridization (Th) temperatures, the denaturation (td) and hybridization (th) times, the composition 
of the buffers, the probe concentration C, etc. However, in the case where FISH is implemented in a 
microfluidic system, the flow rate Q and the microfluidic chamber height h will also all have an effect on the 
outcome of the test. Finally, the probe density d, i.e. the ratio of the total volume of undiluted probe solution 
used in the protocol V to the stained surface area of the section S is also introduced. The probe density can 
be seen as the cost, in terms of volume of undiluted probe solution, of the technique per unit of tissue 
surface, and has the dimension of a distance. This marker was used as a way to allow up-front comparison of 
different experimental techniques (for instance standard vs. MA-FISH) by normalizing the amount of probe 
used for each technique to the surface area of the target. 
From these considerations, the analysis of the effects of the experimental parameters affecting the DNA-
hybridization step in a MA-FISH protocol is a multi-parameter variational problem. However, some of these 
parameters are fixed according to the specificities of the standard protocol, such as Td, Th, or the buffer 
compositions, and others are not independent variables, such as d, and can be computed from other 
parameters (V, S and C). Furthermore, and in order to keep the dead volume to a minimum, h should be kept 
as low as technically possible. Therefore, to ensure that a total volume of probe solution could be used for 
each experiment, h was fixed at 20 ?m and was not modified in this work. Finally, only 3 parameters were 
varied in the following analysis: th, C and Q. The other independent variables (Td, Th, td, V, S, etc.) were left 
unchanged throughout the experiments. For the off-chip standard protocol, a d value of ~21 ?m (~0.021 ?l 
mm-2) had been used for the undiluted probe solution volume, following the recommendations of the 
manufacturer. The parameters th, C and Q were optimized. To ensure that the results for the different 
conditions, for a given parameter, were comparable, only adjacent slides from the same tissue block were 
used. As the tested material (human tissue sections) was limited, only one comparison test was performed for 
each condition for each parameter (th, C and Q). Furthermore, only conditions that were a priori expected to 
improve the technique (shorter times, diluted probes, etc.) and were also expected to not compromise 
dramatically the signal intensity were selected for this optimization. 
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2.3.1.2. Optimization of the dilution factor  
 
 
Figure 2.9 - Experimental parameter study of the MA-FISH protocol: Influence of probe dilution, 
hybridization time, and flow rate. (a) Optimization of the probe dilution. Four adjacent slides originating 
from the same tumor were incubated on-chip during 4 h with three different dilutions (5?, 10?, 20?) of a 
standard commercial probe solution, or off-chip using the standard protocol. The on-chip square-wave 
oscillatory flow was applied with an amplitude of 1 nl s-1 at a frequency of 10-4 Hz. The green bars were 
obtained by averaging the green signal diameter and contrast originating from the CEP17 and the red bars 
were obtained by averaging the red signal diameter and contrast originating from the HER2 probes from a 
mosaic image composed of 9 tiles. The last 2 bars correspond to standard off-chip overnight hybridization 
conditions with an undiluted solution. The different panels represent (ai) the average diameter of a signal, 
(aii) the average contrast of a signal (aiii) the average count of red signals (HER2) per nucleus of a cell 
(HER2/cell) for the three probe dilutions and the standard, obtained from 3 different positions for each slide 
(full line, left axis) and the HER2/CEP17 ratio (dashed line, right axis). (b) Optimization of the hybridization 
time. Four adjacent slides originating from the same tumor were incubated on-chip with a 10? diluted probe 
with a flow rate of 1 nl s-1 at a frequency of 10-4 Hz, using three different hybridization times (8, 4, and 2 h), 
respectively. The last 2 bars in each graph correspond to standard off-chip overnight hybridization 
conditions. (bi) The average diameter of a signal. (bii) The average contrast of a signal. (biii) HER2/cell 
number for the three hybridization times and the standard, obtained from 3 different positions for each slide 
(full line, left axis) and the HER2/CEP17 ratio (dashed line, right axis). (c) Optimization of the flow rate. 
Five adjacent slides originating from the same tumor were incubated on-chip during 4 hours using a 10? 
diluted probe, using five different flow rates of the on-chip square-wave oscillatory flow (0, 1, 10, 100, and 
1000 nl s-1) corresponding to push-pull cycle frequency f = 0, 10-4, 10-3, 10-2, 10-1 Hz, respectively. (ci) The 
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average diameter of a signal. (cii) The average contrast of a signal (ciii) HER2/cell number for the five flow 
rate conditions and the standard, obtained from 3 different positions for each slide (full line, left axis) and the 
HER2/CEP17 ratio (dashed line, right axis).  
To study the effect of C on the MA-FISH capabilities, three adjacent sections, obtained from the same tumor, 
were processed on-chip using the MA-FISH protocol with three different dilution factors (5?, 10?, 20?) of a 
standard commercial probe solution (PathVysion HER-2 DNA Probe Kit), with Q= 1 nl s-1, f= 10-4 Hz and 
th= 4 h. These three sections were processed during three successive days and imaged with identical 
exposition conditions on the same day. A fourth adjacent section from the same sample was processed and 
imaged with the standard FISH method, which used a non-diluted probe, and served as a control. As detailed 
above, several numerical variables (signal diameter and contrast) were obtained to characterize the quality of 
the FISH staining, and are presented in figure 2.9. From the data shown in figure 2.9ai, the 20? dilution 
configuration resulted in smaller diameter of the red and green signals than the 10? dilution (p<0.0001 for 
red and <0.001 for green) and the 5? dilution (p<0.0001 for red and <0.0005 for green) (figure 2.9ai). An 
increased dilution yielded smaller green signal contrast for the 20? dilution than the 10? and 5? dilution 
(p<0.0001 for both), but did not significantly affect the red signal contrast (figure 2.9aii). Finally, the average 
number of HER2/cell and the HER2/CEP17 ratio in 3 clusters of 20 cells were also computed. As the 
sections were obtained from adjacent positions from the same tumor, similar scores are to be expected. 
Indeed, the 10? and 5? dilution yielded similar results as the standard FISH method (figure 2.9aiii), but a 
lower number of HER2/cell was found for the 20? dilution. Overall, these results indicated that the 10? 
dilution factor for the PathVysion probe was the preferable one, as it resulted for our MA-FISH setup into 
comparable results to the standard technique. 
2.3.1.3. Optimization of the hybridization time th 
As above, the effect of th was investigated by incubating 3 adjacent slides originating from the same tumor 
for 2 h, 4 h and 8 h, respectively, in a 10? diluted probe solution with Q= 1 nl s-1 and f= 10-4 Hz (see figure 
2.9b). The sample corresponding to th= 4 h is the same as the one used in the dilution factor analysis for a 
10? dilution, but was analyzed again alongside the other samples. The 4-h hybridization yielded the same 
type of response as for th = 8 h, as suggested from the values of the signal diameter in the red and green 
channels, but a noticeable degradation of the quality of the FISH staining was noticed for the 2-h 
hybridization. Indeed, from the data shown in figure 2.9b, the 2-h hybridization configuration resulted in 
smaller red signals (p<0.0001) and green signals than the 4 h (p=0.001) (figure 2.9bi). It also yielded weaker 
green and red signal contrast than the 4 h (p<0.005) (figure 2.9bii). The signal count on the 2-h hybridization 
MA-FISH slide resulted in a lower number of HER2/cell and lower HER2/CEP17 ratio comparing to the use 
of 4-h and 8-h hybridization times (p<0.0005 for HER2/cell number and <0.001 for the ratio), the latter times 
resulting in the same count than the standard technique (figure 2.9biii). From this analysis, an optimized 
hybridization time of 4 h was chosen, hereby resulting in a significant shortening of the experimental 
duration, in comparison to the standard protocol (16-h hybridization). The green signal in an 8-h 
hybridization MA-FISH test showed fluorescence intensity reduction due to photo-bleaching, possibly 
because of air exposure, which however did not affect the signal count. It proved to be difficult to decrease 
the hybridization time below 4 h, since probe diffusion in the tissue and small DNA hybridization rate in 
formamide solution require sufficient incubation time [44].  
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2.3.1.4. Optimization of the flow rate Q 
In order to find an optimal Q for MA-FISH, five adjacent sections originating from the same tumor were 
incubated on-chip during 4 h in a 10? diluted probe, using five different Q for the on-chip square-wave 
oscillatory flow profile (Q= 0, 1, 10, 100, and 1000 nl s-1). The characteristic parameters for each sample 
were computed and are reported in figure 2.9c.  The Q= 1 nl s-1 configuration resulted in the largest red 
signal diameter with respect to the other flow rates used, while there is a noticeable variation of the green 
signal diameter as function of Q, which is however not critical for interpretation, due to the larger size and 
high intensity of a green signal that represents the centromere-specific probe (figure 2.9ci). The Q= 1 nl s-1 
configuration resulted also in the largest contrast for the red signals with respect to the other flow rates used, 
while variation in the green signal contrast as function of Q again is not critical for interpretation (figure 
2.9cii). The results for the number of HER2/cell and the HER2/CEP17 ratio (figure 2.9ciii) did not allow for 
clearly establishing which Q led to the best results, largely because of the signal variation induced in this 
specific sample by a high level of genetic heterogeneity. The variation induced by the heterogeneity depends 
on the position of the clusters studied, and has a more important impact on the experimental output than the 
variation due to change in flow rate. Therefore no significant difference between the flow rate conditions was 
found [66].  
Summarizing, applying a flow of probe over the sample improves the reactant delivery with respect to the 
delivery by diffusion only and reduces depletion effects of the probe inside the chamber, as present with the 
quiescent flow condition, in which the tissue has consumed all local probes. On the other hand, if the flow 
rate is too high, it can affect the probe-target combination. It was demonstrated indeed that hybridization 
between target DNA and immobilized DNA on a surface of a DNA microarray could be impaired under a 
strong flow rate [67]. Therefore DNA hybridization on a tissue section can also be affected by a strong flow, 
probably because of the presence of shear stresses near the tissue surface that hinder the hybridization events. 
As a consequence, we have chosen to use Q= 1 nl s-1 for the final MA-FISH protocol. In conclusion, the final 
MA-FISH parameter set, chosen from the optimization study, are C= 10? dilution, th= 4h, Q= 1 nl s-1. 
2.3.1.5. Technical comparison between MA-FISH and standard-like coverslip technique but using the same 
10? dilution and 4h hybridization time. 
Chapitre 2 We compared the MA-FISH technique with a standard-like coverslip-based protocol, in which we 
exposed a slide to a 10? diluted probe (standard= 1?) and used a 4h hybridization time (standard= 
hybridization overnight, i.e. 16h). The probe density, presenting the probe solution used per footprint, was 
also kept the same as for MA-FISH (d=3.9 ?m). This experiment was designed to show the signal 
enhancement granted by the hydrodynamic method. 17 sections from 17 different tissue blocs were 
processed with the coverslip method, were imaged by the same protocol than in MA-FISH slides and the 
resulting HER2 status was also compared to the in-house standard FISH and reported in table 2.3. As shown 
in figure 2.10, the MA-FISH results in much stronger signals compared to the coverslip-based technique, 
which showed a quasi-inexistent signal, even though the amount of probe introduced in the system and the 
image acquisition and processing were the same. Among them, 41% (7/17 cases) gave even no specific red 
signal for the scoring process. The reason of this difference is expected to arise from the constriction of the 
diffusion layer near the slide surface under hydrodynamic conditions, thus increasing the flux of probe 
towards the tissue and accelerating the hybridization. This confirmed the critical importance of the 
hydrodynamic conditions in improving the FISH signal. 
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Figure 2.10 - Effect of microfluidics on hybridization. Three adjacent sections originating from the same 
tumor were incubated with a 10?  diluted probe solution during 4 h under a coverslip (abbreviation in the 
graph: “off-chip”), with a 10? diluted probe solution during 4h according to the MA-FISH protocol 
(“MA-FISH”) and with a standard probe concentration (1?) and long hybridization time (overnight) of 
probe under a coverslip (“standard”), respectively. The green bars were obtained by averaging the signal 
contrast and size originating from the CEP17 signals and the red bars were obtained by averaging the 
signal contrast and size originating from the HER2 probes, from a mosaic image composed of 9 tiles. (a) 
Average contrast of a signal. (b) Average diameter of a signal. (c) Average count of red signals (HER2) 
per nucleus of a cell (HER2/cell) (full line, left axis) and the HER2/CEP17 ratio (dashed line, right axis). 
The results were obtained from 3 different positions for each slide (20 cells evaluated for each position). 
In the “off-chip” results, images did not reveal any red signal, explaining the inexistent red signal 
contrast and diameter. The results were presented as mean ± standard deviation (SD). 
Table 2.3- Comparison of the HER2 classification results between an off-chip FISH protocol with 10? 
diluted probe solution and the in-house standard FISH analysis, using HER2 assessment according to 2013 
ASCO/CAP guidelines. 
Concordance table 
 
In-house standard FISH protocol 
Negative Equivocal Positive Sum 
Off-chip FISH protocol 
with 10? diluted probe 
solution and 4 h 
hybridization time 
 
No HER2 signal 4 2 1 7 
Negative  5 1 2 8 
Equivocal 0 0 0 0 
Positive 0 0 2 2 
Sum 9 3 5 17 
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2.3.1.6. Comparison of HER2/cell, HER2/CEP17 ratio and HER2 status between MA-FISH and standard 
FISH protocol 
To test the diagnostic power of the MA-FISH technique, as optimized in the parameter study sections (vide 
infra), we performed a series of tests on a set of 17 breast cancer samples chosen to represent a wide 
spectrum of different HER2 copy numbers per cell and different HER2 statuses. During the initial HER2 
assessment performed at the Institute of Pathology using the standard off-chip protocol, 6 cases were 
classified as HER2-negative, 6 were equivocal and 5 were positive. However, to ensure a maximal 
consistency in the comparison of the MA-FISH technique with the standard protocol, the standard routine 
technique was repeated in our research laboratory to ensure that the use of other reactants, counting 
operators, and microscopic equipment, as well as the storage time of the biopsy sample in the tissue bank, 
did not introduce discrepancies with respect to the standard benchmark. To perform this study, several 
adjacent sections were used for each tissue sample. One section was processed according to the standard 
FISH protocol repeated in our laboratory, to provide the control dataset representing the current state of the 
art, further referred to as “in-house standard FISH”. In parallel, 3 adjacent sections were processed with the 
MA-FISH system to address the question of technical reproducibility. Each slide was then blindly scored for 
i) the count of HER2/cell and ii) the HER2/CEP17 ratio. The counting routine used here based on z-stacks 
with ?z = 0.5 ?m. For each slide, considering the biological variability issue, the average number of 
HER2/cell and the overall HER2/CEP17 ratio of a cluster of 20 cells were obtained for 3 clusters, 
corresponding to 3 separate locations on the tumor area. For the HER2 status assessment, the 2013 
ASCO/CAP recommendations were used [59]. Briefly, the average HER2 copy number/cell and the 
HER2/CEP17 ratio were obtained from 3 MA-FISH slides from the same patient. These scores were then 
averaged and compared to the cut-off values, for each parameter, reported in the 2013 ASCO/CAP 
recommendations to deduce the HER2 status of the patient. The variance among the 3 position scores for 
each slide was also computed, then averaged. The SD represents the scoring difference between clusters, and 
is different from the one obtained by pooling the average numbers of HER2/cell and the HER2/CEP17 ratio 
of the 3 cases and by then calculating the SD. The latter would incorporate slide-to-slide variability effects, 
which is represented by the coefficient of variation of triplicates, obtained by normalizing the SD of the 
triplicates to their mean. On the other hand, the former SD only describes the signal variability in the slide 
and was taken as a more reliable marker of data dispersion due to biological variability.  
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Figure 2.11 - Average number of HER2/cell and HER2/CEP17 ratio results from MA-FISH tests, in the 
full domain (left image) and in the sub-domain of HER2/cell number ?6 and HER2/CEP17?2 (right 
image). The test results that were obtained from slides of the same patient are represented by the same 
symbol in the graph. The dotted lines represent the cut-off values for HER2 status classification 
according to 2013 ASCO/CAP guidelines. In the right panel, some borderline cases, laying close to the 
dotted lines representing HER2/cell=4 and=6, are more likely to result in different clinical 
classifications, hence accounting largely for the assessment discrepancies discussed in the text. The total 
number of tissue slides analyzed here was N= 51 (17 tissues samples, analyzed in triplicates). 
The final MA-FISH conditions using the optimized parameters described above were tested on 17 breast 
cancer samples, and the HER2 results were compared with the ones obtained with the standard protocol. The 
reproducibility of MA-FISH, shown by the consistency of the average number of HER2/cell and the average 
HER2/CEP17 ratio of triplicate slides are shown in figure 2.11. A good reproducibility of the MA-FISH 
results was demonstrated as the coefficient of variation among triplicates was 11.2% for the HER2/cell 
number (95% confidence interval (CI), 8.4 to 14%) and 10.6% for HER2/CEP17 ratio (95% CI, 7.5 to 
13.7%). 
The correlation between MA-FISH and in-house standard FISH scores with respect to the number of 
HER2/cell and the HER2/CEP17 ratio obtained from 17 patients is shown in figure 2.12a and figure 2.12b, 
respectively. The results of figure 2.12 demonstrate Pearson correlation coefficients (see appendix B for the 
explanation of the Pearson coefficient) between the MA-FISH and standard protocol datasets of r=0.98 
(number of HER2/cell) and r=0.95 (HER2/CEP17 ratio), respectively. Also a linear regression was computed 
for these datasets, with a regression coefficient ?=0.78 (R2=0.97) and ?= 0.93 (R2=0.89), respectively. While 
the first regression coefficient may appear low, it mainly results from the lower fluorescence intensity for the 
highly amplified HER2 cases due to the use of diluted probes. However, in these cases, the diagnostic 
outcome of the MA-FISH technique with respect to the standard protocol does not change (vide infra). 
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Figure 2.12 - Comparison of the MA-FISH with the in-house standard FISH protocol. Comparison 
between the results obtained for the MA-FISH and standard technique for (a) HER2/cell number in the 
full domain (left image) and in the 0 to 6 sub-domain (right image) and (b) the HER2/CEP17 ratio in the 
full domain (left image) and in the 0 to 2 sub-domain (right image). The results shown here correspond 
to 17 independent cases. The data represented for each point were the mean scores of 3 MA-FISH 
adjacent sections versus the mean scores of an in-house standard FISH adjacent section, obtained from 
the same tissue block. The vertical error bars represent the SD, with respect to the average of each 
specific slide, defined as the square root of the average of the variances obtained for each slide of the 
triplicates. The horizontal error bars are the SD of the scores among 3 positions in standard FISH slides. 
The dotted lines represent the cut-off values for HER2 status assessment according to 2013 ASCO/CAP 
guidelines. The linear fits show a good correlation of the FISH results (HER2/cell number and 
HER2/CEP17 ratio) between the MA-FISH and the standard FISH (Pearson’s correlation coefficients 
were 0.98 and 0.95 respectively). 
To compare the HER2 statuses obtained from MA-FISH with the ones from the standard FISH, the 
concordance between the average results of 17 MA-FISH triplicates from 17 independent tissue biopsies and 
standard FISH test results is reported in table 2.4. Table 2.4 also indicates that some of the borderline 
positive or negative slides, according to the standard test, became equivocal with the MA-FISH processing, 
and vice-versa. The likeliest explanation is that the biological variability is here critical, as most of the slides 
CHAPTER 2: MICROFLUIDIC-ASSISTED IN SITU HYBRIDIZATION 
72 
 
were initially scored as equivocal, thus maximizing the risk for slide-to-slide variations (figure 2.11, right 
images). Nevertheless, no positive case was classified as negative and vice versa, which ruled out the risk for 
false positive or false negative HER2 status classification.  
Table 2.4 - Comparison of the HER2 classification results of the MA-FISH protocol and the in-house 
standard FISH protocol based on a cut-off HER2/CEP17 ratio of 2. 
The concordance between a FISH result and another method, such as IHC, or between two FISH methods 
was studied in the literature, solely based on the comparison of the HER2/CEP17 ratio, taking a cut-off value 
for the ratio of 2 or 2.2 [68-71]. A general strategy for comparing clinical outcomes involving two techniques 
makes use of Cohen’s Kappa K, which is a parameter quantifying the agreement between two sets of 
qualitative ratings [72]. This analysis was applied to our MA-FISH and standard FISH datasets. By setting 
the HER2/CEP17 ratio cut-off at 2 and using it as a single criterion to separate the positive and negative 
FISH populations (i.e. there is no equivocal class), the concordance between the MA-FISH and in-house 
standard FISH results is evaluated with a score K=1.00 (100% concordance) (see table 2.4). The cut-off 
value for the HER2/CEP17 ratio was the one recommended in the 2013 ASCO/CAP recommendations [59].  
Table 2.5 - Comparison of the HER2 classification results of the MA-FISH protocol and the standard initial 
FISH assessment done at the Institute of Pathology, based on a cut-off HER2/CEP17 ratio of 2. We observe 
that there is only one sample that is negative for the MA-FISH method but positive for the Institute of 
Pathology’s standard FISH method. As our in-house standard FISH also indicated that this sample is 
negative, we think that this discordance is due principally to the HER2 intratumoral heterogeneity causing a 
variation of HER2 scores between different positions in the tissue. 
 
On the other hand, if the assessment is based on 3 classes described for the number of HER2 copies per cell 
(negative, positive and equivocal) in the 2013 ASCO/CAP recommendations [59], the resulting Cohen’s 
Kappa K is 0.71 (95% CI, 0.41 to 1.00), still showing a good concordance of MA-FISH and in-house 
 
  
In-house standard FISH 
  
Negative Positive Sum 
MA-FISH protocol 
Negative 13 0 13 
Positive 0 4 4 
Sum 13 4 17 
 
  
Institute of Pathology standard FISH 
  
Negative Positive Sum 
MA-FISH protocol 
 
Negative 12 1 13 
Positive 0 4 4 
Sum 12 5 17 
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standard FISH clinical results [72]. A similar analysis comparing the MA-FISH results to the initial clinical 
HER2 assessments as obtained at the Institute of Pathology, showed that the results are highly consistent 
with the clinical standard methods (see table 2.5). 
2.3.2. Discussion 
The roughness of the tissue was considered as a possible source of inaccuracy by inducing different diffusion 
pathways for different tissue areas, resulting in non-uniform staining. However, the hydrodynamic flow was 
applied in a cycling fashion and helped mixing the probe inside the chamber, thus avoiding local depletions. 
Moreover, the diffusion distance of probe during the hybridization time of 4 hours is approximated by 
x=2??? =0.88 mm, with D=1.33 10-7 cm2/s [73].  The effect of this thickness variation, expected to be at 
most 10 nm [31], was therefore assessed as negligible. It was also investigated as a possible source of 
inaccuracy for FISH image readout. Here, the variation of the tissue thickness should be avoided because it 
might lead to a change of the average HER2 signals per cell, one of the two recommended scores for HER2 
classification [59]. However, once again, comparing to the tissue thickness of 4 ?m, the very limited 
roughness expected here should not dramatically alter the validity of the analysis. 
From a technical standpoint, this study showed that MA-FISH is an advantageous, reliable technique to 
assess HER2 status on FFPE breast cancer tissue. On the one hand, by recirculating a diluted probe solution 
on the surface of the tissue during the hybridization time, the use of expensive probe can be optimized and 
the cost of a FISH experiment drastically reduced. Comparing to a standard FISH protocol using 10?l of 
probe per test, MA-FISH uses only 1 ?l per test, reducing the cost by 10. If we consider the cost per 
footprint, the reduction is 5 times. Moreover, thanks to fast fluidic exchange within the microfluidic system 
[31], the diffusion of FISH probe from the probe solution to the targets situated in the tissue is also enhanced, 
resulting in short 4 h hybridization time (instead of an overnight incubation as in a standard FISH technique). 
The assay duration can be shortened to one working day (8 h) with the microfluidic method. The 
hybridization time can be further decreased by using a highly-reactive HER2 IQ-FISH PharmDxTM probe 
(see section 2.4). However, the MA-FISH has a drawback is that the signals obtained are still weaker than 
that of a standard method, we demonstrate in section 2.5 that discontinuous flow regime can enhance the 
hybridization efficiency and increase the signal quality.  
2.4. Extra-short incubation microfluidic-assisted FISH (ESIMA-FISH) 
2.4.1. Results  
2.4.1.1 Optimization of ESIMA-FISH protocol 
The optimal experimental condition was chosen based on linear regression models of 4 different outputs 
(responses): the contrast (Cred) and diameter (Dred) of the red dots, and the contrast (Cgreen) and diameter 
(Dgreen) of the green dots, which were all required to be maximized to improve the quality of the images. 
These parameters were obtained and averaged for 3 different positions of the tissue for each combination of 
experimental conditions. At each position, a mosaic of 9 images (300 ?m ? 400 ?m) was recorded. Each 
mosaic image displayed more than 20 cells. These outputs, and the array of input conditions, were then fitted 
to each other using a linear regression model:  
output= const + aP × P + aQ × Q + aC × C + aT × T + aV × V + ad × td + ah × th (2.1) 
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where aP, aQ, aC, aT, aV, ad, ah are the coefficients of the linear regression for the corresponding input 
variables presented above. The quality of the linear regression model was assessed with the least-square 
coefficient R2 and the F-test p-value (see table 2.6).  
Table 2.6 - Signal outputs and corresponding p-values. The top row represents the signal outputs: average 
green and red signal diameter (Dgreen and Dred) and contrast (Cgreen and Cred) with their p-values. The 
coefficients of the linear regression ai=1, 2, …7  are represented in the various columns for each signal output. In 
equation (2.1), the coefficients of the regression were normalized to const. The positive or negative sign of a 
coefficient indicates correlation or anti-correlation of an experimental variable with the output signal, 
respectively. The higher the contribution of an experimental variable to an output signal, the smaller the p-
value; only a p-value < 0.05 (in bold) will be retained for interaction analysis between the important 
experimental variables. 
 Dgreen p-value Dgreen Dred p-value Dred Cgreen 
p value 
Cgreen 
Cred p-value Cred 
Normalized 
const 1.000 0.000 1.000 0.000 1.000 0.000 1.000 0.000 
aP (P) 0.314 0.000 0.054 0.109 0.338 0.001 0.123 0.012 
aQ (Q) -0.111 0.113 -0.038 0.248 -0.132 0.126 -0.016 0.721 
aC (C) 0.133 0.061 0.127 0.001 0.197 0.029 0.009 0.833 
aT (T) 0.110 0.115 -0.055 0.100 0.212 0.020 0.123 0.012 
aV (V) 0.002 0.979 0.001 0.986 -0.051 0.547 -0.019 0.673 
ad (td) 0.044 0.516 0.071 0.040 0.022 0.788 0.028 0.522 
ah (th) 0.072 0.291 0.081 0.021 0.067 0.427 0.047 0.297 
The linear regressions corresponding to equation (2.1) resulted in R2=0.53 (p=0.055), 0.67 (p=0.005), 0.686 
(p=0.004) and 0.68 (p=0.004) for Cred, Cgreen, Dred, Dgreen, respectively. The product of an input variable to its 
corresponding coefficient (e.g. ah × th) is the contribution of this input to the output (diameter or contrast). 
Therefore, the optimal coded values for the inputs (i.e. -1 or 1, vide supra) should have the same signs as 
their coefficients in order to obtain a positive contribution, and an improvement of the signal output. The 
linear regression results is detailed in table 2.6. In this instance, each linear regression coefficient aP, aQ, aC, 
aV, ad, and ah had the same sign, when considering either contrast (see figure 2.13a) and diameter (see figure 
2.13b) as output variable. Therefore, the optimized values of these parameters can be straightforwardly 
selected. The sole ambiguous case was for the parameter aT, as the HER2 diameter indicated a negative sign 
(figure 2.13b): T, red) compared to 3 other positive coefficients (figure 2.13a: T, red and green, figure 2.13b: 
T, green), we chose the positive value of T, corresponding to 45°C. 
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Figure 2.13 - ESIMA-FISH optimization protocol using human tissue samples (a) Optimization of the 
contrast for HER2 (in red) and CEN17 (in green) signals. The plot shows the linear regression 
coefficients of the HER2 and CEN17 signal contrasts, corresponding to 7 experimental parameters, 
namely the absence or presence of a post-fixation step (P), the flow rate during hybridization (Q), the 
probe concentration (C), the denaturation temperature (T), the total volume of probe used (V), and the 
duration of the denaturation (td) and hybridization steps (th). (b) Optimization of the diameter for HER2 
(in red) and CEN17 (in green) signals. The plot shows linear regression coefficients of the HER2 and 
CEN17 signal diameter, corresponding to the same 7 parameters as (a). From our analysis, we find as 
optimal condition: post-fixation step present, discontinuous flow, 4× dilution, no denaturation (td = th = 
45°C), 12 ?l probe volume and 35-minute hybridization. 
Based on the results of this regression, an optimized set of parameters maximizing the signal while reducing 
both the probe consumption and the duration of the experiment was identified. Comparing to our MA-FISH 
technique, using a formamide-based probe, the flow rate for ESIMA-FISH was faster (0.1 vs 0.001 ?l/s), 
quiescent flow periods were inserted between each back-and-forth probe flows (discontinuous flow), see 
figure 2.4b, and the denaturation step was skipped. Overall, the optimized microfluidic protocol (figure 
2.14a) was twice faster (35 instead of 70 min of denaturation and hybridization) than the standard IQ-FISH 
assay (figure 2.14b) and the probe consumption was reduced by 70%.  
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Figure 2.14 - Comparison of ESIMA-FISH and standard IQ-FISH (a) Deconvoluted z-stack (0.2 ?m-
step) from an ESIMA-FISH-treated tissue slide. (b) Deconvoluted z-stack (0.2 ?m-step) from a standard 
IQ-FISH-treated tissue slide adjacent to that in (b). The HER2 signal obtained from ESIMA-FISH tends 
to have a weaker intensity than that of the standard IQ-FISH technique. The images were acquired using 
a fluorescence microscope with a 63? objective. Scale bars: 5 ?m. 
Based on the optimized protocol, ESIMA-FISH was performed on a SKBR3 cell line slide, resulting in 
further reduction of experimental time and probe consumption (post-fixation step present, continuous flow, 
8× dilution, no denaturation, and 15 min hybridization, see figure 2.15 aii). In these conditions, quantitative 
comparison between signals obtained by the ESIMA-FISH and “off-chip IQ-FISH”, using the standard 
coverslip method and the same probe dilution (8×) and hybridization time (15 min), performed on the same 
cell line is likely to show an improvement of HER2 signal (diameter and contrast) for the microfluidic 
method. 
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 Figure 2.15 - Comparison of standard IQ FISH, ESIMA-FISH and “off-chip” IQ FISH obtained from a cell 
line slide (SKBR3). Standard IQ FISH (non-diluted probe and 1h hybridization) and off-chip IQ FISH (8× 
diluted probe and 15 minute hybridization) were performed using the coverslip technique (see the standard 
IQ FISH protocol in section 2.2.4.2). ESIMA-FISH and off-chip IQ FISH were implemented using the same 
probe concentration (8×) and hybridization time (15 min). (a) Image of a single focal plane of: (ai) an off-
chip IQ FISH image stack (aii) an ESIMA-FISH image stack and (aiii) a standard IQ FISH image stack. 
Scale bar: 10 ?m. (b) Quantitative analysis of HER2 signal in standard IQ FISH, ESIMA-FISH and “off-
chip” IQ FISH images shown in (a): (bi) Contrast measurements (bii) Diameter measurements. The datasets 
were compared using an ANOVA test followed by a Tukey multiple comparison test:* for p<0.05, ** for 
p<0.01, *** for p<0.001. 
2.4.1.2 ESIMA-FISH tests on clinical samples 
The superiority of ESIMA-FISH over off-chip IQ-FISH was not, however, observed in ESIMA-FISH-treated 
tissue samples. These samples are less permeable to the probes and require a higher probe concentration and 
a longer hybridization time. Furthermore, for both tissue and cell line samples, the HER2 signals (dots) 
obtained by ESIMA-FISH using reduced concentration and time conditions typically show smaller diameters 
than that of the standard IQ-FISH in the conditions recommended by the manufacturer, i.e using an undiluted 
probe solution and 1 h incubation, see figure 2.16a, b for tissue and figure 2.15aii,iii and bi,ii for the cell 
lines. For CEN17, the dot diameter obtained by ESIMA-FISH is similar or slightly inferior to that of a 
standard IQ-FISH technique (see figure 2.15bii, iii for cell line and 2.16 for tissue). 
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 Figure 2.16 - Comparison between ESIMA-FISH and standard IQ-FISH obtained from 2 adjacent tissue 
slides. Two adjacent slides from the same breast cancer sample were processed with ESIMA-FISH (4× 
diluted, 35 min incubation) and the standard IQ-FISH protocol, respectively, after which they were 
imaged using the same exposition conditions and then assessed using an automatic image processing 
routine. (a) Contrast of the red and green signal (dots) from two methods. (b) Diameter comparison of 
red and green signals from the two FISH methods. The red signal diameter of ESIMA-FISH is strongly 
decreased in comparison to the standard method. However, this did not affect the interpretation of the 
signal. The different datasets (ESIMA-FISH vs. standard IQ-FISH) were compared using a Student’s t-
test: * for p <0.05; ** for p <0.01;*** for p <0.001. 
Nevertheless, the signal quality obtained with the optimized ESIMA-FISH conditions is high and allows for 
the accurate scoring of HER2 status using unprocessed z-stack images. Indeed, HER2 status assessments 
with ESIMA-FISH and standard IQ-FISH were compared by running the optimized ESIMA-FISH and 
standard IQ-FISH protocols on 2 adjacent sections of 9 different human breast cancer samples, after which 
the tissues were imaged and scored (figure 2.17). Quasi-identical FISH scores (HER2/cell number and 
HER2/CEN17 ratio) were obtained for these two techniques (see table 2.7). 
Table 2.7 - Comparison of HER2 status assessment results of ESIMA-FISH and standard IQ-FISH. There is 
a good agreement between these methods. Only one sample was classified as negative with ESIMA-FISH 
and as equivocal with the standard IQ-FISH technique. This minor difference could be explained by the 
biological intratumoral heterogeneity of HER2 copy numbers per cell. The results were obtained from 9 
tissue blocks using a blind counting of FISH signals (number of HER2 gene copies and the corresponding 
centromere CEN17 per cell). 
  
The Pearson correlations between the two datasets were rHER2/cell = 0.99 and rHER2/CEN17= 0.98 and the 
regression coefficients of the ESIMA-FISH score as a function of the standard IQ-FISH score were ? HER2/cell 
 
 Standard IQ-FISH 
 
 Negative Equivocal Positive 
ESIMA-FISH 
Negative 3 1 0 
Equivocal 0 2 0 
Positive 0 0 3 
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=1 (R2=0.98) and ? HER2/CEN17 = 0.88 (R2=0.96), for HER2/cell and HER2/CEN17, respectively. Among the 9 
cases considered in this study, only one discordance was reported (see table 2.7): a negative result with 
ESIMA-FISH was classified as equivocal with the standard IQ-FISH technique. This minor difference could 
be explained by the biological intratumor heterogeneity of HER2 copy numbers per cell. For the SKBR3 cell 
line using 8× dilution and 15 min incubation, a HER2/CEN17 ratio of 3.66 is obtained using ESIMA-FISH, 
compared to a ratio of 3.67±0.22 found in the literature [74]. 
  
Figure 2.17 - Comparison between ESIMA-FISH and standard IQ-FISH on human tissue slides. (a) Plots 
of HER2 copies per cell (HER2/cell) obtained by ESIMA-FISH versus standard IQ-FISH in a set of 
clinical breast cancer samples with HER2/cell ranging (ai) from 0 to 15 and (aii) from 0 to 5. The dotted 
lines represent the threshold for negative, equivocal or positive HER2 classifications. (b) Plots of the 
HER2/CEN17 ratio (HER2/CEN17) obtained by ESIMA-FISH versus standard IQ-FISH in the same set 
of clinical samples than in (b) with HER2/CEN17 ranging (bi) from 0 to 5 and (bii) from 0 to 2. The data 
shown here are mean ± SD obtained from the scores measured in 3 different clusters of 20 cells in each 
slide. The dotted lines represent the threshold for negative/equivocal or positive HER2 classifications. 
CHAPTER 2: MICROFLUIDIC-ASSISTED IN SITU HYBRIDIZATION 
80 
 
2.4.2. Discussion 
In comparison to other FISH techniques that use a formamide-based probe solution, the probe solution from 
the IQ-FISH assay used in this work is based on an ethylene carbonate hybridization buffer. This buffer 
promotes low-temperature denaturation of the target DNA strands and faster probe-target DNA hybridization 
[44]. Even though an ESIMA-FISH protocol is based on the same microfluidic-assistance principle 
developed in the MA-FISH method, the radically different protocols and incubation mechanisms used for the 
IQ-FISH probes required the development of specific hydrodynamic conditions and customized operation 
parameters. These considerations motivated the complete redesign of the assay protocol to accommodate the 
specificity of the IQ-FISH probes in a microfluidic format. 
Hydrodynamic flows can improve the signal quality for FISH assays, as the microfluidic chamber allows for 
the continuous replenishment of the probe solution and improves mass transport. When the diffusion in the 
bulk liquid is not the bottle-neck for efficient hybridization, the hybridization rate at the DNA sites 
themselves is supposed to the rate-limiting factor. However, even when using a high-hybridization rate IQ-
FISH solution combined to a hydrodynamic flow regime, the hybridization time for HER2 signal revelation 
cannot be reduced drastically. This might be because of the limited diffusion inside the tissue or cell itself, 
which is not influenced by hydrodynamic flows. Indeed, in figure 2.13a and b, post-fixation factors have the 
most impact on the outputs. This fact hints that post-fixation might influence the tissue structure, thus 
changing the probe permeability, and limiting diffusion inside the tissue. 
2.5. Microfluidic-assisted chromogenic in situ hybridization (MA-CISH) 
2.5.1. Results 
2.5.1.1. MA-FISH and MA-CISH optimization results   
The hybridization step in the MA-CISH protocol was optimized based on the FISH image of the tissue after 
hybridization and stringent wash steps (without the immunohistochemical steps for bright-field revelation).  
Optimization was based on a FISH image rather than on a CISH image, because FISH signal provides a 
better contrast allowing a precise quantification of the signals. Only the diameter and contrast of HER2 dots 
were considered in the optimization process because the CEN17 signal is always strong thanks to abundant 
alpha-satellite DNA present in the centromere. Because of the preciousness of human tissue samples, the 
number of tests required for optimizing the procedure was reduced using a multivariate optimization process, 
combining fractional factorial design with linear regression analysis [75]. The values of each parameter are 
presented by a numerical number, either -1 or 1, corresponding to: 4? or 8? dilution for the probe 
concentration, 1 h or 2 h for the hybridization time and continuous or discontinuous for the flow regime. 
Signal outputs (diameter or contrast) were obtained and averaged at 3 different positions in the tissue for 
each experimental condition combination and represented as:  
output = const + at × th  + aC  × C+ af × Q (2.2) 
where ai=t,C,f are the coefficients of the linear regression for the input variables hybridization time th, probe 
concentration C and flow regime Q, respectively. The chosen input values (-1 or 1) should be positively 
correlated to the coefficients in order to obtain a positive contribution to the signal output. The detailed 
experimental table representing all parameter combinations (Table 2.8) is presented as follows. 
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Table 2.8- Fractional factorial design of experiments used for MA-FISH optimization. 
 Hybridization time Probe dilution Flow regime 
Experiment 1 -1 (2 h) -1 (4?) 1 (Discontinuous) 
Experiment 2 1 (4 h) -1 (4?) -1 (Continuous) 
Experiment 3 -1 (2 h) 1 (8?) -1 (Continuous) 
Experiment 4 1 (4 h) 1 (8?) 1 (Discontinuous) 
Linear regression fittings of equation (2.2) resulted in a sum of square R2=0.52 and 0.93 for contrast and 
diameter, respectively. Each linear regression coefficient at, aC, af had the same sign, when considering either 
diameter or contrast as output variable (see figure 2.18a). Based on the results of this regression, the final 
configuration obtained from the optimization study was the following: hybridization time is 2 hours (8 times 
faster than standard CISH), the probe was diluted 4 times (resulting in a 70% probe consumption reduction, 
since 12 ?l were used compared to 10 ?l for standard CISH), and a discontinuous flow regime was used. 
Compared to our previous MA-FISH results, obtained by performing continuous back-and-forth flow at a 
flow rate of 0.001 ?l/s, the flow regime applied for MA-CISH was faster (0.01 ?l/s) and had quiescent flow 
periods inserted between each back-and-forth probe flow (see figure 2.5a and b). A fluorescence image of a 
SKBR3 cell line obtained with our microfluidic method is presented in figure 2.18b and 2.19a.  
Figure 2.18 - (a) Optimization of the hybridization step using FISH images of a series of cell lines. The 
plot shows linear regression coefficients of the two HER2 signal outputs (contrast and diameter), 
corresponding to 3 experimental parameters, namely the hybridization time, the probe dilution, and the 
type of flow regime used. The signal quality is assessed by measuring the diameter and contrast of the 
red and green fluorescence signals (dots). From our analysis (see section 2.5.1.1), we find as optimal 
conditions a 2 hours hybridization time, a 4 ? probe dilution and the application of discontinuous flow. 
(b) Result of an optimal microfluidic-assisted FISH protocol applied on a cell line. The cell is marked 
with 3 colors corresponding to the 2 probes (HER2 in red and CEN17 in green) and DAPI 
counterstaining for nucleus revelation (in blue). HER2 probe is labeled with Texas Red and the CEN17 
probe is labeled with FITC. Scale bar: 5?m. 
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Figure 2.19 - Results of optimized microfluidic-assisted FISH (MA-FISH) and MA-CISH protocol using 
a discontinuous flow regime. (a) MA-FISH image of a cell line slide (SKBR3). (b) Comparison of HER2 
signal output (diameter and contrast) in two SKBR3 cell line slides obtained by MA-FISH and standard 
FISH, respectively. The same dot diameter and a higher contrast are obtained by MA-FISH compared to 
standard FISH. The datasets (on chip vs. standard) were tested with a one-way ANOVA followed by a 
post-hoc Tukey test: p-value: ***<0.001. (c) MA-CISH image of the cell line slide shown in (a) after 
performing the protocol shown in figure 2.2b. The slide is marked with 3 colors corresponding to 2 
probes (HER2 in red and CEN17 in dark blue) and hematoxylin in violet for nucleus revelation. (d) 
CISH image obtained using a standard CISH protocol performed on an SKBR3 cell line slide. Scale 
bars: 20 ?m. 
A quantitative comparison of signal quality between MA-FISH and standard FISH is presented in figure 
2.19b, showing the same diameter and a better contrast of the obtained MA-FISH signal. This can be 
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explained by a reduction of non-specific DNA binding of the fluorophore to the nuclei. Following the 
optimization of MA-FISH, we started the MA-CISH protocol. Figure 2.19c shows the same cells as figure 
2.19a. Moreover, MA-CISH allowed better visualization compared to a standard CISH image originating 
from same cell line (figure 2.19d). Overall, the optimized MA-CISH protocol was faster (1 day instead of 2) 
and cheaper (70% reduction of the probe consumption), while maintaining a good signal in comparison to 
standard CISH. Additionally, when performed using high probe dilution (8?) and short hybridization time (2 
hours), MA-CISH still resulted in a recognizable signal while the traditional coverslip technique did not give 
any HER2 signal in these extreme conditions (see figure 2.20). 
 
Figure 2.20 - Comparison of (a) MA-CISH (on chip) and (b) off chip CISH (using the coverslip method) 
performed on 2 adjacent tissue slides using the same conditions (8?dilution, 2 h hybridization). MA-
CISH was implemented using a discontinuous flow regime (figure 2.5a). MA-CISH still resulted in a 
recognizable HER2 signal (a black arrow points to one red dot) while an off chip CISH did not give any 
HER2 signal in these conditions. The slides are marked with 3 colors corresponding to 2 CISH probes 
(HER2 in red and CEN17 in dark blue) and hematoxylin in violet for nucleus revelation. 
2.5.2.2 MA-CISH tests on clinical samples 
The established MA-CISH protocol (4? dilution, 2 h hybridization) was conducted on a set of 4 tissue 
samples. MA-CISH and standard CISH were performed for each sample on adjacent tissue slides, and the 
HER2 status was evaluated by assessing the average number of HER2 signals per cell and the HER2/CEN17 
ratio. Good correlation between MA-CISH and standard CISH results was found (see figure 2.21ai,ii). No 
difference of HER2 classification was observed. The HER2/CEN17 ratio obtained from the MA-CISH 
SKBR3 cell line sample (3.14) is similar to the result found in the literature (3.67) and points to positivity of 
the HER2 classification [76].  
Finally, as we obtained a fast CISH protocol, the result read-out becomes a bottle-neck for high throughput 
analysis. An automatic CISH scoring software was developed based on a FIJI program interface to 
automatically count the HER2 and CEN17 signals [65]. This program splits the single bright-field image to 
cyan, magenta, yellow, and key (CMYK) channels, allowing detection of dark blue dots representing the 
CEN17 signal in the cyan channel and quantification of the red dots representing the HER2 signal in the 
magenta channel. The quantification of the red dot is based on measuring the sum of pixels intensity of each 
of the HER2 dot in a cell. The HER2/CEN17 ratio and the average number of HER2 signals per cell obtained 
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by automatic and manual counting in the MA-CISH images are presented in figure 2.21bi,ii, showing good 
correlation between the two methods. 
 
Figure 2.21 - Correlation study between the optimized MA-CISH and the standard CISH protocols for 4 
tissue slides and one cell line. HER2 and CEN17 signals in a cluster of 20 cells are scored to obtain the 
average number of HER2 gene copies per cell (HER2/cell) and the ratio between the total number of 
HER2 and CEN17 signals in 20 cells (HER2/CEN17 ratio). (a) Comparison between MA-CISH and 
standard CISH results. (ai) Correlation of HER2/cell number between MA-CISH and standard CISH 
performed on two slides generated from the same set of 4 clinical tissues and one cell line (SKBR3). (aii) 
Correlation of HER2/CEN17 ratio between MA-CISH and standard CISH performed using the same set 
of samples. (b) Correlation between automatic scoring and manual scoring using the MA-CISH images 
used in (a). (bi) Correlation of HER2/cell number (bii) Correlation of HER2/CEN17 ratio. Full lines 
show the fitting curves of a linear regression model. Dotted lines represent the threshold for negative, 
equivocal or positive HER2 classification. 
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2.5.2. Discussion  
In a first approach, MA-FISH was based on a continuous flow regime, which results in a typically-weaker 
signal than those obtained from a standard FISH method. In this phase, we discovered that stronger signal 
contrast and larger signal diameter were obtained using a discontinuous flow (figure 2.5a). Compared to the 
standard FISH, the discontinuous MA-FISH achieves a better contrast of HER2 signal, while having 8 times 
shorter hybridization time and requiring only 30% of the standard probe used per experiment. The 
discontinuous flow possibly helps to diffuse the ISH probe in the nuclei without creating shear stress that can 
break the weak probe-target bond at the early stages of hybridization. For ESIMA FISH, although we cannot 
demonstrate the same performance improvement for the HER2 FISH signal quality using either continuous 
or discontinuous flows, the signals are still strong enough for an accurate detection. 
MA-CISH was optimized based on the new MA-FISH protocol and proved to be reliable for the assessment 
of the HER2 status in breast cancer. MA-CISH combines advantages of the standard CISH method, such as 
the use of a simple optical microscope, preservation of histological features and provision of stable 
unbleachable signals. This principle can be applied to another type of CISH probe or to the larger family of 
bright-field ISH techniques, such as Silver-ISH [77]. Additionally, CISH allows recording a single image for 
each position in the tissue instead of taking z-stack images as in FISH. This allows fast assessment of the 
signal using an image processing program. It should be noted that, in general, a CISH image of a high 
HER2-amplified cell shows a cluster of red signals (whether in standard or MA-CISH), making it hard to 
accurately count them individually. However, this limitation can be overcome using our image processing 
program that measures the cluster intensity and size to calculate the areal number of red dots inside a cluster. 
Moreover, automatic scoring can be applied to a large area of the tissue slide, allowing detection of possible 
tumor intra-heterogeneity (different scores in different tumor areas) [66]. In the future, the 
immunohistochemical staining procedure could easily be implemented on a chip, allowing automation of the 
whole protocol.  
2.6. Conclusion of chapter 2 
In conclusion, new techniques such as MA-FISH, ESIMA-FISH and MA-CISH have several advantages 
compared to their corresponding standard ISH techniques. They achieve similar performances to the standard 
methods, while requiring much less time and significantly reducing the consumption of the probe. The 
complete procedure for MA-FISH and MA-CISH can be performed in a single day, instead of 2 for the 
standard techniques. For ESIMA-FISH the duration of the test is only half-a-day. Using a combination of 
MA-CISH and automatic image analysis, more precise, faster, and cost-effective HER2 assessment in tissue 
samples can be obtained. Overall, the intrinsic advantages of standard ISH such as technical robustness and 
accurate interpretation are still retained for the microfluidic ISH techniques [57].  
Beside cost and duration, two other limitations of FISH method are the complexity of the procedure and the 
difficulty of interpretation. The latter is mainly based on manual count directly via a microscope ocular [78, 
79]. This process is long, the number of cells counted is limited and the cells counted are not traceable, i.e. 
lost after the scoring is done. Future developments of automatic protocols, from experimental staining 
procedure to signal scoring, would overcome these issues and improve the user-friendliness and 
reproducibility of FISH. The system used here is still a prototype. Further technical implementations could 
focus at tissue microarrays, automation or multiplexing to increase the MA-FISH throughput. The principle 
of using hydrodynamic flow for optimizing DNA hybridization provides the basis for improving further 
genetic investigations (DNA microarrays, RNA FISH, etc…). Last but not least, it was shown that MA-FISH 
CHAPTER 2: MICROFLUIDIC-ASSISTED IN SITU HYBRIDIZATION 
86 
 
can be applied for either large centromere-targeted CEP17 probe or small locus-specific probe such as HER2 
probe. Therefore, other FISH tests using small size range probes such as break apart-probes or single gene 
gain/loss probes could also be improved using the principle of MA-FISH [80]. Therefore, other diagnostic 
applications of FISH on cancer tissues, such as the analysis of ALK gene rearrangements in lung cancer, can 
also be improved using microfluidics, opening an alternative for facilitated analysis of the genetic state of the 
tumor. While precision medicine is opening a new era in cancer treatment, microfluidics provides the tools to 
decrease drastically the cost and time of genetic testing, thereby facilitating the dissemination of personalized 
therapy.  
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3. MICROFLUIDIC EXTRACTION AND MICROARRAY DETECTION 
OF BIOMARKERS FROM CANCER TISSUE SLIDES  
In this chapter, a new microfluidic method allowing for the quantification of human epidermal growth factor 
receptor 2 (HER2) expression levels from formalin-fixed breast cancer tissues is described. An overview of 
this method is introduced as follows. After partial extraction of proteins from the tissue slide, the extract is 
routed to an Ab microarray for HER2 titration by fluorescence. Then the HER2-expressing cell area is 
evaluated by IF staining of the tissue slide and used to normalize the fluorescent HER2 signal measured from 
the Ab microarray. The number of HER2 gene copies measured by FISH on an adjacent tissue slide is 
concordant with the normalized HER2 expression signal. This work is the first study implementing 
biomarker extraction and detection from cancer tissue slides using microfluidics in combination with a 
microarray system, paving the way for further developments towards multiplex and precise quantification of 
cancer biomarkers. 
3.1. Introduction 
Assessment of tissue biomarker expression is of utmost importance for diagnosis and treatment. IHC is 
widely used in the clinic because it represents several advantages: low complexity, assessment of biomarker 
levels with a small fraction of cells, and preservation of tissue morphology [81]. However, conventional IHC 
is not quantitative, and its assessment is often subjective. In breast cancer, for example, equivocal results in 
HER2 assessment by IHC require the use of an additional test such as FISH using fluorescent DNA probes to 
verify the presence of genetic aberrance that causes protein deregulation. Furthermore, conventional IHC can 
detect only a limited number of biomarkers due to few available options of adaptive chromogenic markers 
[59]. Other robust proteomic detection techniques, such as Western Blot, ELISA, or conventional mass 
spectrometry can be quantitative but are destructive, i.e., the morphological information of tissue is lost. 
They also have different limitations in clinical use, such as high complexity of the technique, and 
consumption of a relatively large amount of tissue materials [82]. An Ab microarray is a quantitative, high-
throughput technique that uses Abs immobilized on a substrate (mostly a functionalized glass slide) to detect 
and quantify multiple proteins in a blood plasma or tissue lysate solution. The proteins captured from the 
solution are then directly detected by a fluorescent label, which is either directly linked to the proteins or via 
the use of a secondary-Ab labeling step. The main drawback of microarrays for identification of tissue 
biomarkers is that histological information on the tissue slide (e.g., number of cancer cells among healthy 
cells) is not preserved because this method requires destructive protein extraction from the tissue. Therefore, 
although a precise quantification can be obtained by standard proteomic techniques or microarrays, the 
correlation between the areal protein expression level evaluated on a tissue slide and its corresponding 
measured signal from extracted solutions has not been demonstrated.  
We show here the proof-of-concept of protein extraction from standard clinical Formalin Fixed Paraffin 
Embedded (FFPE) tissue slides in a highly-controlled, reproducible manner using the MTP. First, we used 
This chapter is adapted from the following publication: 
 
H.T. Nguyen, L.N. Dupont, A.M. Jean, T. Gehin, Y. Chevolot, E. Laurenceau, M.A.M. Gijs. 
Microfluidic extraction and microarray detection of biomarkers from cancer tissue slides, Journal of 
Micromechanics and Microengineering (in press). 
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several standard techniques to optimize and benchmark this new method. More specifically, the extraction 
protocol was optimized based on the total protein mass obtained by a bicinchoninic acid (BCA) assay [83]. 
The presence of proteins was then verified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE). The detection and quantification of some protein biomarkers (vide infra) were performed by 
liquid chromatography tandem-mass spectrometry (LC-MS/MS) [84, 85]. Second, we connected the MTP to 
a detection microfluidic chip (DMC), in which Ab microarrays were integrated for HER2 detection. After 
performing partial protein extraction protocol, the remaining proteins allowed the tissue slide to be analyzed 
by IF to reveal histological information, as well as the number of cancer cells expressing HER2 proteins. In 
particular, as the extracted HER2 protein quantity depends on the number of cancer cells, the microarray 
signal related to the quantity of extracted HER2 is normalized to the surface area of cancer cell membranes. 
However, using only the HER2 signal, it is hard to distinguish the area of cancerous cell membranes to that 
of non-cancerous cells, particularly in HER2-negative-samples. Indeed, HER2 can be expressed in both 
cancerous and non-cancerous cells. Therefore, a CK tumor labeling technique was used for quantitative IF 
[62]. As epithelial cancer cells overexpress CK, this marker is used as a mask to distinguish cancer from 
normal cells. We proposed thus a method to calculate the HER2 biomarker density representing the average 
HER2 expression of a cancer cell. Finally, we demonstrated that the HER2 biomarker density was correlated 
with HER2 gene copy number per cell obtained by FISH analysis of a small breast cancer tissue sample 
cohort, suggesting that the microfluidic-microarray technique allows discriminating HER2-positive patients 
from HER2-negative patients.  
3.2. Materials and methods 
3.2.1. Materials 
3.2.1.1. Reagents 
All reagents were purchased from Sigma-Aldrich (MO, USA), unless stated otherwise, and were used 
without further purification. All fluidic connectors, tubes, and fittings were purchased from ThermoFisher 
Scientific (MA, USA). Borosilicate flat glass slides (76 mm × 26 mm × 1 mm) were purchased from Schott 
(Mainz, Germany). All proteins used for microarray spotting were stored as aliquot at -20°C or -80°C 
complying with manufacturer specifications. PBS 1× (pH 7.4) was prepared by dissolving the content of one 
pouch of dried powder in 1 L of ultrapure water. 0.05 M carbonate buffer at pH 9.6 was prepared by 
dissolving the content of one pouch of dried powder in 100 mL of ultrapure water. Washing buffer contained 
PBS 1× and 0.1% Tween 20 (PBS-T) at pH 7.4. Blocking solution was prepared by dissolving 10 g of BSA 
(Bovine Serum Albumin) in 100 mL of PBS-T. 
3.2.1.2. Tissue samples 
FFPE breast cancer tissues were obtained from the Institute of Pathology of the University Hospital CHUV 
in Lausanne, according to the ethical convention BB514/2012 established with the Ethical Commission of 
Clinical Research of the state of Vaud. All patients did not oppose the use of their tumor sample for research 
purpose. 4 ?m-thick tissue sections were mounted on Super Frost Plus slides (Menzel-Glazer, Germany). 
HER2 statuses of the tissue samples used in this study are known, according to a FISH test. The slides are 
named by the convention: patient number (P) - slide number (S) - extraction number (E) and successively 
named in an increasing order throughout the study. 
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3.2.2. Methods 
3.2.2.1. Protein extraction by the MTP  
The extraction protocol was based on the incubation of a patient tissue in an extraction solution at a high 
temperature (95°C during 20 min, followed by 80°C during 2 h) inside the microfluidic chamber of the MTP. 
The detailed protocol is as follows. 
FFPE breast cancer tissue slides were heated at 65°C for 5 min on a hot plate (Scilogex MS-H280-Pro, 
Thomas Scientific, NJ, USA), then cooled down to room temperature (RT). Then, each slide was dipped in 
three different Histo-clear II (National Diagnostics, GA, USA) solutions for 5 min, and dipped successively 
in 5 solutions containing 100%;100%; 95%; 70%; 40% ethanol (2 min each). Then, the slide was kept at RT. 
A syringe was loaded with an extraction solution using a Nemesys pump (Cetoni GmbH, Germany). The 
extraction solution was composed of different concentrations of Tris/HCl and SDS (10, 20, 300 mM 
Tris/HCl and 0.5% or 2%SDS) according to table 3.1.  
Table 3.1 - Total mass of protein recovered as a function of extraction conditions. Four different 
protocols were performed using 5 different breast tissue section slides obtained from the same patient 
(P1). Total protein mass was obtained by BCA assay. Protocol 4 (in bold) was chosen as the optimal 
protocol for further experiments. 
 
 
The tissue slide was then clamped to the MTP half-chamber in a copper holder. The fabrication and design of 
the MTP and holder are described in chapter 2. The extraction chamber volume formed by the MTP and the 
slide has a height of 27 ?m. A schematic presentation of the tissue slide in the microfluidic chamber of the 
Protocol 
number 
 Slide 
identification 
Extraction conditions Results 
Composition pH Temperature and time Total protein mass 
(?g) 
1 P1-S1, P1-S5 
(two 
replicates) 
10 mM Tris 
HCl; 100 mM 
NaCl; 0.5% SDS 
7.5 T= 95°C t = 30 min 4.5 and 7 
2 P1-S2 300 mM Tris 
HCl; 2% SDS 
8 T=90°C t=2 h 21 
3 P1-S3 20 mM Tris 
HCl; 2% SDS 
9 T= 95°C t=20 min; 
Incubation T=60°C t 
= 2 h 
18 
4 P1-S4 20 mM Tris 
HCl; 2% SDS 
9 Incubation on ice 5 
min; T=95°C t=20 
min; T=80°C t=2 h 
28 
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MTP is presented in figure 3.1a. During the protein extraction protocol, the assembled MTP-slide setup was 
placed on a hot plate and covered by a thermally insulating polystyrene chamber (figure 3.1b). 
 
Figure 3.1 - Design of the protein extraction system. (a) Schematic view of the MTP/tissue slide stack. (b) 
Cross-section view of the setup during the experiment. The tissue section slide is incubated with 
tris(hydroxymethyl)aminomethane hydrochloride (Tris/HCl) buffer supplemented with sodium dodecyl 
sulfate (SDS) inside the microfluidic chamber. After incubation, the extract is either collected for standard 
proteomic analysis, such as a bicinchoninic acid (BCA) assay, sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE), liquid chromatography tandem-mass spectrometry (LC-MS/MS), or injected 
to the detection microfluidic chip (DMC). 
The chamber was filled with the extraction solution at the flow rate of 1 ?l/s. Then, bubbles were removed 
by a strong flow rate (20 ?l/s). As soon as the extraction solution reached the outlet and the chamber was 
bubble-free, a blocking cap closed the fluidic system for the incubation. Then, the whole setup was cooled 
down to 4°C for 5 min. The temperature was controlled by an external thermometer and adjusted by an air 
flow. The MTP setup was then heated to 95°C using the hotplate, and the temperature was maintained for 20 
min before being cooled down to 80°C by air flow. After two hour incubation at 80°C, the MTP setup was 
cooled down to room temperature using air flow. The blocking cap was replaced by a pipe fitting to extract 
the solution to either microcentrifuge tubes for standard proteomics analysis such as BCA, SDS-PAGE, LC-
MS/MS or to the DMC. For LC-MS/MS analysis, successive 10 ?l volumes of tissue extract were retrieved. 
To perform the BCA assay and SDS-PAGE analysis, 50 ?l tissue extract were collected from the MTP. The 
slide was then removed from the MTP and received IF staining following the protocol detailed in section 
3.2.2.4. This is possible because during the extraction protocol, proteins in the tissue slide are only partly 
dissolved in the extraction buffer. Therefore, the remaining part of proteins can be still detected by an IF 
staining. 
The total mass protein extracted was quantified by BCA, and the presence of proteins in the protein 
extraction solution was verified by SDS-PAGE. Standard protocols for BCA and SDS-PAGE were used 
[86]. LC-MS/MS identified and quantified proteins based on peptide fragment-ion spectra [84, 85]. The LC-
MS/MS protocol is detailed in section 3.2.2.6. 
3.2.2.2. Ab microarray design 
Capture Abs, carbonate buffer and F555-labeled streptavidin were spotted (sciFLEX-ARRAYER S3, 
Scienion, Germany) on N-hydroxysuccinimide (NHS)-activated silanized glass slides (Schott, Germany) as 
described in [87, 88]. Anti-uPA capture Ab (mouse monoclonal, Thermo Scientific, code: MON U-16-02) 
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and sheep polyclonal anti-HER2 capture Ab (Abcam, code: ab28324) were diluted at 4.5 ?M in carbonate 
buffer (pH 9.6). Proteins were spotted on two areas of a slide. Each area received 15 anti-HER2 spots, 10 
anti-uPA spots, 5 spots for each streptavidin concentration (4 ?g/mL, 2 ?g/mL, 1 ?g/mL, 0.5 ?g/mL, Thermo 
Scientific, code: S21381) and 5 carbonate buffer spots, see figure 3.2a. All spots had a diameter of 150 ?m. 
uPA protein is expected to be absent in the extract, and is considered as a negative control, just like the 
carbonate buffer spots. Streptavidin-F555 was spotted as fluorescence intensity calibration and protein 
immobilization control. Indeed, the measured fluorescence intensity can vary depending on light intensity. 
Therefore, fluorescence intensity calibration using Streptavidin-F555 helped evaluate and correct possible 
variations of fluorescence signals. After being spotted, proteins were reacted with the glass slide surface 
under saturated carbonate buffer vapors overnight at 4°C. 
3.2.2.3. Detection microfluidic chip (DMC)-based microarray detection 
The Ab microarray slide, on which two identical Ab arrays (figure 3.2a) were spotted, was sandwiched by 
two in-house 3D-printed DMCs (figure 3.2b). A DMC was composed of two parts. One part was composed 
of a serpentine channel created by a thin soft-plastic layer (Tango Black Plus Full Cure 980, Stratasys Ltd., 
MN, USA) deposited on a hard-plastic substrate (VeroClear Full Cure 810, Stratasys Ltd., MN, USA). The 
second part (also made of VeroClear Full Cure 810) was composed of a window to observe the channel 
through the glass slide. Figure 3.2b shows 2 DMCs and the Ab microarrays in an upside-down configuration 
to visualize spot positions. After clamping the DMCs and the Ab microarrays slide, all spots should be inside 
the serpentine chamber created by the first part of the DMCs (figure 3.2c). 
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Figure 3.2 - Design of the DMC system and principle of the FISH technique. (a) Design of the Ab 
microarray. The array was composed of 5 replicated columns. Each column consisted of 4 spots of 
fluorescently F555-labeled streptavidin at 4 different concentrations (4 ?g/mL, 2 ?g/mL, 1 ?g/mL, 0.5 
?g/mL) for fluorescence signal control calibration; 2 replicated spots of anti-urokinase Plasminogen 
Activator (uPA) capture Ab at 4.5?M for negative control; 3 replicated spots of anti-HER2 capture Ab at 
4.5 ?M; and one spot of carbonate buffer for negative control. (b) Exploded view of the setup consisting 
of a microscope slide spotted with 2 Ab microarrays sandwiched by two DMCs. One DMC, named 
“assay”, received the protein extract and the other DMC, named “control”, received only the extraction 
buffer (free from proteins). Scale bar: 2 cm. Each DMC consisted of a serpentine microfluidic channel 
and an observation window. (c) The spotting design of one array placed inside the serpentine channel. 
(d) Schematic presentation of  HER2 detection steps on the Ab microarray: (1) immobilization of anti-
HER2-capture Ab on an NHS-activated glass slide; (2) capture of HER2 protein from the tissue extract; 
(3) recognition with anti-HER2 Ab (mouse anti-human HER2); (4) detection with goat anti-mouse Ab 
labeled with Cy3. (e) Schematic representation of uPA detection steps on the Ab microarray: (1) 
immobilization of anti-uPA-capture Ab; (2) capture of uPA protein; (3) recognition with biotinylated 
anti-uPA Ab (mouse anti-human HER2); (4) detection with F647-labeled streptavidin. 
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During the protein detection protocol, first, Ab microarrays were incubated with the blocking solution then 
washed with the washing solution PBS-T through the DMCs. Then the protein extraction solution (8 ?l) 
from the MTP was routed to the “assay” DMC. In parallel, protein-free extraction solution (8 ?l) was 
injected into the “control” DMC for a negative control. Discontinuous back-and-forth flows generated by a 
syringe pump were maintained for one hour to enhance protein- capture Ab recognition (figures 3.2d1,2 and 
3.2e1,2) and avoid dead-volume issues (see figure 3.3a for the flow regime).  
 
Figure 3.3 - Flow regimes used during the DMC protocols. (a) Flow regime applied during incubation of 
protein extraction solution with Ab microarray (b) Flow regime applied during the detection steps on the 
Ab microarray. 
Then both DMCs and the MTP were washed with a suction flow of PBS 1× solution. The MTP setup was 
then disconnected to release the patient tissue slide for subsequent IF staining (see 3.2.2.5). Indeed, the 
protein extraction protocol leads to partial extraction of tissue proteins allowing IF staining of the remaining 
proteins in the patient tissue slide. Then, the DMCs (“assay” and “control”) were connected directly to two 
syringe pumps that generated back-flows to perform the following detection (figures 3.2d3,4 and 3.2e3,4) 
and washing steps. First, a mixture of biotinylated anti-uPA Ab (diluted 2 times from Femtelle® kit, 
American Diagnostica Inc) and anti-HER2 Ab (0.05 mg/mL, Thermo Scientific, code: MA5-12998) diluted 
in 4% BSA/PBS-T was loaded into the chamber and incubated with the Ab microarrays during 30 min. Then, 
PBS-T washing solution was applied at 1 ?l/s flow during 180 s. Streptavidin labeled with F647 (0.01 
mg/mL diluted in 1% BSA/PBS 1×, Thermo Scientific, code: S21374) was loaded to the channel and 
incubated with Ab microarrays during 30 min followed by PBS-T wash (1 ?l/s during 180 s). Then Cy3-
labeled goat anti-mouse Ab (0.015 mg/mL diluted in 1% BSA/PBS-T, Jackson ImmunoResearch, code: 115-
165-008) was incubated during 30 min followed by PBS-T wash (1 ?l/s during 180 s). After removing the 
Ab microarray slide from DMCs, the slide was washed with PBS-T, dried and stored at -20°C until 
fluorescence scanning. During all incubation steps using Abs, discontinuous flows were generated (see flow 
regime in figure 3.3b). 
Ab microarray slides were scanned using an Innopsys microarray scanner (InnoScan 1100AL) at excitation 
wavelengths of 532 nm and 635 nm with low laser power. Fluorescence signal acquisition and data treatment 
were accomplished with the Mapix 2Go software package (Innopsys). The median and the SD for 
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fluorescent signals were calculated from replicate spots of each Ab microarray (15 replicates for HER2, 10 
replicates for uPA, 5 replicates for each streptavidin concentration and carbonate buffer, see figure 3.2a). The 
median background level obtained from the carbonate buffer spots was subtracted from all fluorescent 
signals. 
3.2.2.4. Quantification of protein area by IF 
IF staining for HER2 and CK was performed on the tissue slide. The slide was cover-slipped with primary 
Ab cocktail of rabbit anti-human c-erbB-2 oncoprotein (Code: A0485) with a concentration of 1.28??g/mL 
and mouse anti-human CK (code: M3515) with a concentration of 1.02 ?g/mL. The primary Abs were 
purchased from Agilent Technologies (Santa Clara, CA, USA). The incubation occurred at 37°C in a humid 
chamber for 5 min, followed by washing with PBS 1×. For fluorescent detection, secondary Ab cocktail of 
Alexa Fluor 594 (AF594) goat anti-rabbit IgG (Code: A-11037) and Alexa Fluor 647 (AF647) goat anti-
Mouse IgG (Code: A-21236) from Life Technologies (CA, USA) with a concentration of 50 ?g/mL was 
applied on the tissue slide, coverslipped and incubated for 5 min. After washing with PBS 1× and distilled 
water (DIW), SlowFadeTM Gold Antifade Mountant (Life Technologies, CA, USA) containing DAPI and 
fluorescence-antifading agents were applied on the tissue slide for nuclear counterstaining and coverslip-
mounting. The IF signal was recorded using a fluorescence microscope (Axio Imager M2m, Zeiss, Germany) 
with a 10× microscope objective (EC Plan-NEOFLUAR, Numerical aperture 0.3) in 2 × 2 binning mode. 
The IF image is used, together with obtained microarray fluorescence signal, to estimate the HER2 protein 
per unit surface (see section 3.2.2.7).  
3.2.2.5. HER2-gene detection by FISH 
The Pathvysion® HER2 FISH (ABBOTT, CA, USA) kit was used to perform FISH detection of HER2 gene 
and CEN17 in breast cancer tissues. In FISH, an HER2 DNA probe labeled with spectrum orangeTM 
fluorophore combines with its DNA target to reveal the different position of HER2 oncogene copies inside 
the nucleus. The centromere of the chromosome is visualized using a DNA probe labeled with spectrum 
greenTM fluorophore. After performing the FISH protocol, count of red and green dots allows HER2 
classification. FISH was implemented in our experiment to compare the FISH score and the protein density 
using two slides originating from the same sample. The deparaffinization protocol for FISH was identical to 
that applied for protein extraction (see 3.2.2.1). After removing the paraffin and rehydrating in successive 
ethanol solutions from 100% to 40%, the 4-mm breast cancer sections were dipped in washing buffer, 
containing Tris/HCl solution (Agilent Technologies, CA, USA). Then, they were transferred to a Coplin jar 
containing 2-[N-morpholino] ethanesulfonic acid (MES) solution 1× buffer (Agilent Technologies, CA, 
USA) heated at 95-97°C for 10 min. Next, the Coplin jar was cooled down to RT for 20 min before dipping 
in washing buffer (twice for 3 min). Protein digestion was performed by applying protease during 10 min at 
37°C. Then, the slides were washed twice with the washing buffer and dipped in post-fixation solution 
composing of 1% formaldehyde (Merck Millipore, Germany), PBS 1× and 20 mM MgCl2, for 10 min.  The 
slide was then washed with PBS 1×, dehydrated with ethanol 40-100% and dried. HER2 FISH probe was 
applied, and the slide was coverslipped, sealed with rubbers (Agilent Technologies, CA, USA) and 
denaturated at 73°C for 5 min. Then, overnight hybridization was performed at 37°C. In the next day, the 
coverslip was removed, and the slide was transferred to a stringent washing buffer, containing 2× SSC, 0.3% 
Tween 20 (Bio Rad, CA, USA) for 2 min. Then, the slide was washed in SSC Tween (SSC 2×, 0.1% Tween 
20) for 2 min, SSC 2× for 2 min, distilled water for 5 seconds and dehydrated in successive ethanol 40-100% 
for 2 min each before DAPI mounting medium was applied to the dried slide. Finally, the slide was 
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coverslipped for fluorescence microscope observation. A cluster of cancer cells was imaged using a high 
magnification (63×) objective (Plan-Apochromat Oil DIC) in several focal planes for scoring the number of 
HER2 signals per cell. HER2 copy numbers from FISH analysis were obtained for each breast cancer patient 
using adjacent slides of those used in protein extraction. 
3.2.2.6. Liquid chromatography tandem-mass spectrometry LC-MS/MS 
10 ?L of different tissue extracts were put in different gel wells (12% polyacrylamide), separated by SDS-
PAGE and then stained with Coomassie blue. Each sample was excised from the gel, cut into slices and 
proteins were in-gel digested using trypsin as follows. Briefly, the samples were reduced in 10 mM 
dithioerythritol (DTE) and alkylated with 55 mM iodoacetamide (IAA), the gel pieces were dried by vacuum 
centrifugation. Dried samples were reconstituted in 12.5 ng/mL trypsin and incubated overnight at 37°C. 
Tryptic peptides were extracted in 70% ethanol, 5% formic acid from the gel slices and dried. Extracted 
peptides were desalted on stageTips [85] and dried again. For LC-MS/MS analysis, resuspended peptides 
were separated by reversed phase chromatography on a Dionex Ultimate 3000 RSLC nano UPLC system 
connected in-line with an Orbitrap Fusion (Thermo Fisher Scientific, Waltham, USA). Data acquisition was 
either performed using a data-dependent acquisition mode or using an accurate inclusion list prioritizing 
MS/MS sampling from a list of targets at +/- 10 ppm mass tolerances. Database search was performed using 
Mascot (Matrix Science, Boston, USA), MS-Amanda [84] and SEQUEST in Proteome Discoverer v.1.4. 
against a human Uniprot protein database (Release 2015-06). Data were further processed and inspected in 
ScaffoldTM 4. (Proteome Software, Portland, USA). 
3.2.2.7. Calculation of protein density 
We decomposed the ratio between the extraction signal and the control signal (ECR), which is proportional 
to the total concentration of HER2 protein in the extraction solution, to ECR1 and ECR2: 
ECR ? ECR1+ ECR2 (3.1) 
where ECR1 is associated with cancer cells and ECR2 with non-cancer cells. We also suppose that the 
quantity of the HER2 protein extracted from one cell is proportional to the sum of all IF signal intensity of 
HER2 protein detected in the membrane of the cell of interest. Therefore, the ECR1 and ECR2 should be 
respectively proportional to the sum of all IF HER2 signals in the membranes of all cancer (? IC) and non-
cancer (? ?nc) cells of a tissue. We obtain the following equation: 
 
ECR1
ECR2
=
? ?C
? ?nc 
(3.2) 
where ?? is the intensity of one pixel of the HER2 image, located in a cancer cell membrane area (C), and 
???the intensity of one pixel of the HER2 image situated in a non-cancer cell membrane area (nc).  ?? and ???  
of all cells can be obtained using the image processing program FIJI (see section 3.2.2.8) [3].  
By solving the system of equations (3.1) and (3.2), ECR1 was obtained. The HER2 protein density D, which 
characterizes the HER2 protein quantity in the extract per cancer cell area, is calculated by normalizing the 
ECR1 to the surface of the total cancer cell membrane area S: 
D=
ECR1
S
 
(3.3) 
S was obtained by applying a threshold to obtain the positive-CK cells’ membranes by using the image 
processing program FIJI [65], see section 3.2.2.8.  
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3.2.2.8. Calculation of the IF HER2 intensity and area of the cancer and non-cancer cell membranes. 
In this section, the image processing program for computing ? IC and ? ?nc is detailed. First, after images in 
the 3 signal channels, corresponding to DAPI, HER2 and CK presence, were obtained using the 10× 
objective on the whole tissue (see main text), they were stitched into a large mosaic image. Next, the CK 
channel of the mosaic image was thresholded by an automatic threshold (Huang) using FIJI [89], giving the 
CK mask for selecting epithelial cells. Next, the HER2 channel was thresholded manually to select all 
membrane positions (cancer and non-cancer) where HER2 proteins are present. Note that, although non-
cancer cells displayed low expression, the HER2 pixel intensity of the cell membrane could always be 
assessed by selecting an appropriate threshold manually. Finally, HER2 pixels inside the CK mask are 
originating from HER2 proteins from cancer cells, giving IC, and HER2 pixels outside CK mask are from 
non-cancer cells, giving ?nc. Using the integrated intensity function of FIJI, ? IC and ? ?nc were obtained. S 
was obtained by measuring the surface of the HER2 signal inside and outside the CK mask, respectively. 
3.3. Results 
3.3.1. Protein extraction protocol optimization 
Four protocols that resulted in protein extraction from FFPE slides but preserved tissue morphology and 
protein activity were selected based on previous studies [86, 90-92] and were performed using the MTP. The 
concentrations of Tris/HCl and of SDS, the pH and the temperature were varied (see table 3.1). Five tissue 
slides (S1 to S5) from the same patient P1 were used for optimizing the extraction protocol. To characterize 
the protein extraction efficiency, the total mass of protein recovered from the FFPE slide, as measured by the 
BCA assay, and the molecular mass range of extracted proteins, as revealed by SDS-PAGE analysis, were 
evaluated. The optimal protocol was defined as recovering the highest total mass of extracted proteins. After 
extraction, 50 ?l of protein extraction solution were retrieved from the microfluidic chip and split into two 
aliquots, one for BCA and one for SDS-PAGE analysis. Results are reported in table 3.1 and figure 3.4.  
The total protein mass recovered varied from 4.5 ?g (protocol 1) to 28 ?g (protocol 4). SDS-PAGE analysis 
(figure 3.4a) validated the variable protein content, as could be observed by the different smear profiles. 
Protocol 4 led to a total of 28 ?g of extracted proteins and numerous protein bands ranging from 9 to 57 kDa, 
as observed by SDS-PAGE analysis (see figure 3.4a). This protocol was thus selected and applied for further 
experiments.  
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Figure 3.4 - SDS-PAGE for optimization and reproducibility analysis. (a) SDS-PAGE of protein 
extraction solutions obtained from different extraction protocols (S1 to S5) of the same breast cancer 
tissue patient (P1). M is the reference mass ladder. P1-S1 and P1-S5 are two replicates of the same 
protocol. (b) SDS-PAGE of protein extraction solutions obtained with protocol 4 from different breast 
cancer tissue patients (P2, P3, P4, P5, P6, P7). Protein extraction solutions obtained from adjacent 
sections of the same breast cancer tissue patient are number S1, S2, S3. Protein extraction solutions 
obtained from two successive extractions from the same breast cancer tissue section of the same patient 
are number E1 and E2, respectively. (i) Tissue slides P2-S1-E1, P2-S1-E2, P2-S2, P2-S3, P3-S1. (ii) 
Tissue slides P4-S1, P4-S2, P5-S1, P6-S1, P7-S1, P7-S2. 
3.3.2. Reproducibility and efficiency of the protein extraction protocol 
To study protein extraction reproducibility, protocol 4 (from table 3.1) was performed on tissue samples 
from six other breast cancer patients, named as P2 to P7. Two or three tissue slides (S1, S2, S3) from breast 
cancer patient P2, P4 and P7 were treated using the protocol 4 in order to study the reproducibility of the 
protocol. Moreover, the tissue slide S1 from patient P2 was treated twice successively (E1 and E2) using 
protocol 4 to check whether all proteins were extracted from the tissue slide or not (slide P2-S1-E1, P2-S1-
E2). The total mass of extracted proteins obtained by BCA is reported in table 3.2. The corresponding SDS-
PAGE pictures are presented in figure 3.4bi, ii.   
 
Results from table 3.2 indicate that protocol 4 performed on different tissue slides from the same breast 
cancer patient (P2, P4 or P7) led to similar total protein yields. In particular, less than 10% deviation was 
obtained from samples P2-S1-E1, P2-S2, and P2-S3, suggesting the good reproducibility of the protein 
extraction protocol 4. The deviation obtained from other samples (P4-S1 and P4-S2, P7-S1 and P7-S2) was 
higher, but the number of replicated samples was lower than those of the P2 sample, which was a limitation 
for statistical study. One of the most important factors influencing the extraction yield was the possible 
partial evaporation of the extraction solution during the high-temperature incubation (95°C). Moreover, the 
presence of bubbles inside the microfluidic system could also reduce the effective extraction area. However, 
the total extracted protein mass depended on the area of breast cancer tissue section within the microfluidic 
chamber and on its cell composition. We also noticed that the second extraction of the sample P2-S1 (P2-S1-
E2) yielded about half less protein mass than the first extraction (P2-S1-E1), although the protein quantity 
was still significant. This result indicates that not all proteins were extracted during the first extraction and 
remaining proteins could be further detected.  
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Table 3.2 - Reproducibility study of the protein extraction protocol 4. Protein extraction solutions were 
analyzed by BCA and the total protein mass is reported. Samples are defined with the number of the 
patient (P), the number of the adjacent tissue slide of the same patient (S), and the number of successive 
extractions from the same slide (E). 
Identification Protein mass (?g) 
P2-S1-E1 15 
P2-S1-E2 9 
P2-S2 13 
P2-S3 14 
P3-S1 10 
P4-S1 19 
P4-S2 14 
P5-S1 13 
P6-S1 12 
P7-S1 6 
P7-S2 8 
 
3.3.3. Identification and quantification of breast cancer biomarkers in the protein extraction 
solutions using targeted LC-MS/MS 
Identification of breast cancer biomarkers present in the optimized protein extraction solutions was 
performed using a targeted LC-MS/MS technique. 5 breast cancer biomarkers were selected: HER2, PR, ER, 
Plasminogen activator inhibitor-1 (PAI-1), and uPA [93]. For each protein, an LC-MS/MS spectra count, 
defined as the total number of spectra from peptide originating from the proteins, was obtained. Among the 7 
protein extraction solutions obtained from 5 different breast cancer tissue patients (P8 to P12) that were 
analyzed, HER2 was detected in all samples; PR was detected in only one sample (see table 3.3). The other 
breast cancer biomarkers (ER, PAI-1, uPA) were never detected in the protein extraction solutions obtained 
from the tissues, suggesting that they were probably not soluble in the extraction buffer. The analysis of the 
LC-MS/MS results indicated that protein concentrations highly varied in the extract. Indeed, some proteins 
that are abundant in the tissue such as keratin also tend to be strongly presented in the protein extraction 
solution. Therefore, the protein extraction efficiency depends on the presence of the proteins in the tissue and 
their solubility in the extraction solution. Among abundant proteins present in protein extraction solutions, 
the clinically interesting SERBP1 (Plasminogen activator inhibitor 1 RNA binding protein, a marker for 
favorable prognosis) was always detected [94]. On the contrary, uPA was detected in none of the samples by 
LC-MS/MS; therefore, it was chosen as a negative control for the microfluidic-microarray technique (vide 
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infra). At last, the reproducibility of our protein extraction method was confirmed with similar HER2 spectra 
counts recorded by the LC-MS/MS technique from 2 replicated extractions of the same breast cancer tissue 
patient (P12-S1 and P12-S2 in table 3.3).  
Table 3.3 - Comparison of LC-MS/MS, microfluidic microarrays and FISH. For each protein extraction 
solution, the spectral counts for PR (second column) and HER2 from LC-MS/MS analysis (third column), 
the mean ECR obtained by microfluidic-microarray method (fourth column; with SD), and the average 
number of HER2 signal per cell by FISH (HER2/cell, fifth column) are reported. LC-MS/MS and FISH were 
obtained from adjacent tissue sections of the breast cancer tissue sample analyzed by the microfluidic-
microarray technique. NA is “not acquired” due to the lack of human tissue sample. 
 LC-MS/MS spectral counts for PR 
(Unity) 
LC-MS/MS 
spectral counts 
for HER2 
(Unity) 
Mean HER2 ECR 
from microfluidic-
microarray (Unity) 
HER2/cell by 
FISH (Unity) 
P8-S1 28 11 2.04(SD=0.11) 1.6 
P9-S1 
P9-S2 
0 18 2.34(SD=0.18) 
2.22(SD=0.28) 
3.5 
P10-S1  NA NA 3.99(SD=0.22) 8 
P11-S1  0 37 5.36(SD=1.34) 11.4 
P12-S1 0 90 NA 5.7 
P12-S2 0 76 NA 5.7 
  
 
3.3.4. Detection and quantification of HER2 biomarkers using the DMC 
We next demonstrated a method to detect and quantify HER2 protein expression in tissue extracts using our 
customized Ab microarray slide combined with the DMC (figure 3.2b). First, HER2 protein was titrated 
from the fluorescence signals measured on Ab microarrays (figure 3.5a). Microarrays results were 
benchmarked with LC-MS/MS analyses obtained from adjacent sections of the same breast cancer tissue 
patient. Second, the global cancer cell membrane area per slide was evaluated from IF images of the breast 
cancer tissue slide after protein extraction. Finally, the HER2 protein density of each breast cancer tissue 
slide was calculated by normalizing the HER2 microarray fluorescence signal to the cancer cell membrane 
area obtained by IF. Results were benchmarked with FISH analyses performed on an adjacent section of the 
same breast cancer tissue patient. 
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Figure 3.5 - Microarray and IF results. (a) Fluorescence image of the “assay” array of the Ab microarray 
after incubation of the protein extraction solution in the DMC. The positions of spots are the same as in 
figure 3.2a, c. In particular, positions of HER2 spots are indicated by white arrows. Fluorescence 
intensities from F555-streptavidin and HER2 were measured at 532-nm excitation wavelength (green 
channel), whereas those from uPA were measured at 635-nm excitation wavelength (red channel). The 
two fluorescence images were then merged into a single two-color image. (b) Fluorescence intensities 
(arbitrary unit, left axis) of HER2 detection signals from “control” (green bars) and “assay” (red bars) 
microarrays obtained from 5 protein extraction samples. These samples were prepared from 5 tissue 
sections of 4 different breast cancer patients (P8-11), two of them (P9-S1 and P9-S2) being adjacent 
sections of the same breast cancer tissue patient (P9). Fluorescence intensities from replicate spots in 
figure a were averaged and the SD was calculated. The ratio between “assay” and “control” signals is 
plotted as the extraction-to-control ratio (ECR) (dots, right axis). The error bars are obtained from the 
assay and control SDs. 
A batch of 5 tissue sections (P8-S1, P9-S1, P9-S2, P10-S1, P11-S1) from 4 different breast cancer patients 
were analyzed by the microfluidic-microarray method. The HER2 statuses of these patients were assessed 
previously using the FISH technique. Patients P8 and P9 were HER2-negative, whereas patients P10 and P11 
were HER2-positive. Ab microarrays were scanned using two excitation wavelengths: 532 nm to detect 
streptavidin-F555 (fluorescent calibration) and HER2 protein, and 635 nm to detect uPA (negative control). 
The average fluorescent signal intensities for HER2 in the “assay” and “control” DMCs are presented in 
figure 3.5b. For all protein extraction samples, HER2 fluorescence signals of the assays were higher than 
these of the controls (all t-test p values <0.01) (see figure 3.5b). No significant difference between the assay 
and the fluorescent control signals was obtained for uPA, which is consistent with the LC-MS results that 
indicated no presence of uPA. In order to estimate the quantity of extracted HER2, we normalized the signal 
intensity of the assay to that of the control. Indeed, low fluorescence signals were obtained in the negative 
control positions. First, the fluorescence intensities of the two slides P9-S1 and P9-S2 obtained from the 
same patient P9 displayed significantly-different HER2 signals. However, comparison of the tissue surfaces 
for P9-S1 and P9-S2 showed less than 10% variation suggesting that tissue size variation is not the reason for 
this apparent discrepancy. Second, fluorescence signals obtained from streptavidin-F555 spots indicated that 
protein immobilization (both streptavidin and capture Abs) on functionalized glass slides was efficient (see 
figure 3.6).  
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Figure 3.6 - Comparison of fluorescence intensities obtained from “assay” Ab microarray (blue bars) and 
“control” Ab microarray (red bars) after performing the incubation of protein extraction solution in the 
DMC. (a) Detection of HER2 and uPA biomarkers in protein extraction solution from breast cancer 
HER2-negative patient (P9-S2). (b) Detection of HER2 and uPA biomarkers in protein extraction 
solution from breast cancer HER2-positive patient (P11-S1). HER2 status was classified by FISH. 
Fluorescence intensities from various F555-labelled Streptavidin concentrations (4 ?g/mL, 2 ?g/mL, 1 
?g/mL, 0.5 ?g/mL) demonstrated that the slide–to-slide variation for 532 nm excitation wavelength was 
not significant (ratios of SD to mean are in the range of 0.08 to 0.3). uPA fluorescence signals displayed 
the same level in the “assay” and ”control” microarrays while HER2 fluorescence signals were 
systematically higher in the “assay” microarray than in the “control” one. 
Third, the HER2 fluorescence intensity of the control array representing non-specific adsorption of detection 
Abs and molecules, showed the same variation as the HER2 fluorescence intensity of the assay array 
representing the specific detection of HER2 in the protein extraction solution. Thus, we thought that the 
variation in the HER2 fluorescence signal between slides P9-S1 and P9-S2 could be due to variable washing 
efficiencies leading to variation in non-specific adsorption. Hence, in order to characterize the specific HER2 
signal, the ratio between extract and control fluorescence signal (extraction-to-control ratio or ECR) was 
calculated. In particular, the ECR of slides P9-S1 and P9-S2 were identical as can be seen in figure 3.5b. 
Furthermore, ECR calculated from analysis of breast cancer patient samples (P8 to P11) displayed a good 
correlation (R2=0.95) with total spectra counts obtained by LC-MS/MS analysis of adjacent sections (see 
figure 3.7 and table 3.3).  
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From these results, we conclude that ECR might reflect the amount of HER2 proteins extracted from each 
breast cancer tissue slide. However, this amount of HER2 proteins can originate from both cancerous and 
non-cancerous cells: ECR=ECR1+ECR2 where ECR1 is associated with cancer cells and ECR2 with non-
cancer cells. Therefore, we propose a method to obtain ECR1 from ECR, and then HER2 protein density 
from ECR1 normalized with the membrane surface of CK-positive cells (see section 3.2.2.7). 
As shown in section 3.2, the extraction of proteins from tissue slides using the MTP was not total. Therefore, 
IF staining of CK and HER2 proteins could be performed to characterize the number of cancer cells and their 
membrane area (figure 3.8a). We assumed that the ratio ECR1/ECR2 was equal to the ratio of the total 
HER2 signal intensities of cancer area to non-cancer area obtained by IF (see section 3.2.2.8). Therefore, 
ECR1 and ECR2 could be determined by solving a 2 variables-2 equations’ system (see sections 3.2.2.7 and 
3.2.2.8). Then HER2 protein density was calculated by normalizing the obtained ECR1 to the area of the 
cancer cell membrane determined by CK marker detection. HER2 protein densities were computed for the 5 
breast cancer tissue slides from patients P8 to P11 (figure 3.8b). As all standard slides used in this study have 
the same thickness (4 ?m), HER2 protein density relates to HER2 protein expression per cell membrane 
volume unit. To verify if our HER2 protein density is an intrinsic characteristic of the sample which reflects 
the HER2 overexpression, we benchmarked it with FISH, the gold-standard for quantitative HER2 
assessment [59]. Figure 3.8c is an image of a HER2-positive breast cancer tissue slide. The result presented 
in figure 3.8d demonstrates a good correlation between the HER2 protein density and the HER2 copy 
number (R2=0.975). 
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Figure 3.7 - Correlation study of four mean ratios between extract and control signals (ECR) obtained 
from all microfluidic-microarray spots and the LC-MS/MS analysis spectral counts. Each point 
represents HER2 protein quantity in the protein extraction solutions obtained from two adjacent sections 
from the same breast cancer tissue patient, measured by the two methods (P8-S1, P9-S1, P9-S2, P11-S1 
in table 3.3). 
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Figure 3.8 - HER2 protein density obtained from IF and FISH analysis. (a) IF image of a HER2-positive 
breast cancer tissue slide (P11-S1) after protein extraction and immunostaining. The red signals indicate 
HER2 proteins and the green signals show cytokeratin (CK), while the blue signals give the location of the 
nuclei. The red arrow points to cancer cells (strong expression of CK) and the white arrow indicates non-
cancerous cells (weak expression of CK). (b) Normalized HER2 protein density, representing HER2 protein 
expression level of cancer cells, calculated from ECR obtained on DMC, per unit of cancer area obtained 
from IF analysis of the tissue slides. The error bars are obtained from the SD of the ECR divided by the 
cancer cell membrane area. (c) FISH image obtained from the HER2positive tissue slide P11-S2 adjacent to 
the slide P11-S1 presented in A. HER2 gene copies are stained in red, CEN17 are stained in green and nuclei 
are stained in blue with DAPI counterstaining. More than six HER2 gene copies are detected in all cancer 
cell nuclei indicating that the HER2 gene was amplified. (d) Correlation study between the HER2 protein 
density, obtained by our microfluidic-microarray technique, and the number of HER2 gene copies per cell, 
obtained by FISH analysis in a cluster of 20 cells from 5 breast cancer tissues (patients P8 to P11). 
3.4. Discussion  
This study offers a new method to quantify cancer biomarkers in FFPE tissue slides using microfluidics 
combined with protein microarrays. Although the design of the MTP was already reported [31, 62, 95], its 
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function is completely different in this study: it is used as a high-temperature incubator and collector of 
proteins. The DMC’s channels were designed to have a similar microfluidic volume than the MTP (7-8 ?l) 
for an effective Ab microarrays analysis of the protein extraction. The slides and microfluidic devices are 
simply assembled by scaffolding. The unique queuing of bio-chemical steps allows detection of the target 
molecules (HER2) with accuracy.  
Compared to standard protein extraction from FFPE tissue, our microfluidic method yields lower total 
protein extraction mass (6-27 ?g proteins per mm3 compared to ~36 ?g per mm3 in the standard method). 
However, the protein concentrations of our extraction solutions display a similar range (857-4000 ?g/?l) 
than the one obtained with the standard method (330-3440 ?g/mL), as the proteins are diluted in a smaller-
volume solution (7 ?l compared to 50 ?l) [96]. Furthermore, the microfluidic-microarray protocol is simple, 
uses a smaller amount of cancer tissue (1 ?g instead of 2-3 ?g) and does not require steps such as 
centrifugation, debris filtering, as in conventional extraction methods. Most importantly, the microfluidic-
microarray method preserves the morphological information of the tissue sample, allowing subsequent IF 
analysis. In particular, the detection signal of HER2 proteins obtained with the Ab microarrays (ECR) was 
related to the surface of cancer cell membrane expressing HER2, as determined by IF. By combining 
quantitative results from Ab microarrays and morphological information from IF, we demonstrated a proof-
of-concept for quantitative HER2 biomarker assessment. More specifically, HER2 protein density was 
correlated to HER2 gene amplification, therefore, to HER2 gene expression. Compared to IHC that may be 
more subjective to interpretation, quantitative evaluations of biomarkers can improve the accuracy and 
minimize errors. Moreover, the result of HER2 protein quantification could be compared to LC/MS-MS 
results. This method can be easily integrated into the diagnostic routine due to the simple working principle, 
infrastructure and automatable workflows. Comparing to the literature, this study advances the knowledge in 
the field of non-destructive extraction of proteins from FFPE tissues. Formalin fixation is the best method for 
long-term storage of clinical tissue samples, hence several studies focused on optimization of protein 
extraction from FFPE tissue. Chu et al. showed that it was possible to extract proteins and immune-stain the 
tissue after performing the extraction [90]. This pioneering study combined heat-induced antigen retrieval for 
fixed tissues by using Tris/HCl solution and protein extraction thanks to SDS detergents [86]. Proteins were 
partly extracted from the tissue surface, leaving other proteins still present in the tissue for subsequent IF 
analysis. The microfluidic control and standardization of the Ab microarray signals to the cell membrane 
surface, allow relating the microarray signals to the areal expression of the protein. Moreover, in our 
microfluidic method, dead-volume effects are minimum, leading to efficient quantification of the extracted 
proteins. Therefore, the fluorescence signal measured by the microfluidic-microarray method could reflect 
the total amount of biomarkers. 
Despite interesting results were obtained, this investigation is still a proof-of-concept study due to the limited 
number of clinical samples tested. However, any generic microfluidic device could reproduce our work and 
perform extraction and detection on a larger clinical sample cohort to study the diagnostic accuracy. A 
calibration by using solutions with known protein concentrations can provide an exact concentration of 
proteins inside the extract. In the future, the microfluidic extraction step could be improved by increasing 
extraction yield for some specific biomarkers. Indeed, the extraction protocol was optimized based on the 
total retrieved protein mass. However, most of the extracted proteins are not exploitable for breast cancer 
diagnosis. Also, some interesting biomarkers such as ER or uPA, PAI-1 and ER were probably not extracted. 
Therefore, modifications of extraction solution, such as SDS substitution by Triton X-100 or pH alteration, 
are envisaged to improve the solubility of target biomarkers and increase their extraction efficiency.  
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3.5. Conclusion of chapter 3 
In this study, a proof-of-concept of a new biomarker detection and quantification method was proposed. The 
microfluidic-microarray technique allows antigen retrieval of FFPE tissues, protein extraction and detection 
in a microfluidic chip that was combined with microarrays. The performance of this new technique is 
verified by standard methods. This work paves the way for implementing high-throughput, multiplex, 
standardized analysis of biomarkers. In future, optimization of extraction and detection protocols would give 
higher biomarker extraction yield and higher sensitivity of the detection. Based on our preliminary results, 
we anticipate that the microfluidic-microarray technique has a potential application in precision medical 
diagnostics. 
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4. HIGH-CONTENT, CELL-BY-CELL ASSESSMENT OF HER2 
OVEREXPRESSION AND AMPLIFICATION IN BREAST CANCER 
TISSUES. 
IHC and FISH are the two standard clinical methods for the assessment of Human Epidermal Growth Factor 
Receptor 2 (HER2) status in breast cancer, to select patients who could benefit from a HER2-targeted 
therapy. However, in current clinical practice, IHC is not quantitative and often subjective, while FISH is 
based on a quantitative evaluation of only a small part of the tissue. Therefore identification of eventual 
HER2 heterogeneity within the same tumor on a large scale is precluded. As HER2 heterogeneity is often 
associated to resistance to HER2-targeted therapy and to high relapse probability, early detection of the 
former can guide better treatments. In this work, we propose an experimental and analytical methodology 
that provides a high-content assessment of HER2 overexpression and amplification that enables for the first 
time the evaluation of both protein expression and gene prevalence in individual cells over a large area of a 
tissue slide. The technique consists of performing sequential steps: an IF assay using a microfluidic protocol, 
an elution step for removing the IF staining agents, a standard FISH staining protocol, and finally an 
automated quantitative cell-by-cell image processing over the whole tissue slide. With our method, we 
obtained both cancer cell’s protein expression by assessing HER2 and CK proteins, and the corresponding 
gene amplification by scoring the number of loci of HER2 and the number of CEP17. The image processing 
involved, first, the cancer area selection by filtering out the cells expressing low CK. Then, we quantified 
HER2 overexpression and amplification in CK-positive cells by using the ratio between HER2 protein signal 
and the CK signal (HER2/CK ratio), and the ratio between HER2 loci and CEP17 (HER2/CEP17), 
respectively. We demonstrated that both parameters obtained with our method correlate with standard 
HER2/CEP17 ratios obtained from a standard FISH technique, as evaluated by a pathologist. These results 
demonstrate the opportunity to use the cell-by-cell HER2/CK ratio for quantitative HER2 assessment. 
Moreover, we used large-scale automatic FISH scoring to accurately detect intra-tumoral heterogeneity in 
both cluster and mosaic form. 
4.1. Introduction 
In 15-20% of breast cancer cases, HER2 is overexpressed, causing rapid progression and poor prognosis of 
the desease. This cancer subgroup (HER2-positive) can be treated efficiently using HER2-targeted therapies 
(e.g., Trastuzumab and Pertuzumab). According to the 2013 ASCO recommendation [59], IHC and FISH are 
two validated techniques for HER2 assessment and routinely performed in clinics. With respect to IHC, 
HER2 protein expression in tissue and cell samples is characterized by the staining intensity in the cell 
membrane caused by labeled, specific Abs. For FISH, the HER2 gene location is identified using a 
fluorescent DNA probe, and HER2 gene amplification assessed by scoring the number of HER2 signals and 
chromosome 17 (where the HER2 gene is placed) in each cell, for 20-100 cells. Conventional IHC is 
inherently subjective and qualitative, as the evaluation relies on the experience and judgment of the 
pathologist. Interpretation difficulty in IHC usually can be a source of diagnostic errors. Compared to IHC, 
FISH is more quantitative, but only a small tumor area, corresponding to 20-100 cells, can be assessed using 
the standard manual scoring method. More importantly, assessment of HER2 intratumoral heterogeneity 
(ITH) is challenging for both methods as, it is characterized by differences in HER2 status among different 
subclones in different regions of a tumor [97]. HER2 ITH is often associated with poor prognosis and 
resistance to HER2-targeted therapy [98]. Two forms of HER2 ITH exist: coexistence of discrete focal 
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clones of cells (i.e., “cluster” heterogeneity) or individual cells placed in a dominant background of the 
opposite status (i.e., “mosaic” heterogeneity) [66]. In clinics, the presence of “cluster” ITH can be confirmed 
if the proportion of the area of a minority phenotype within that of the majority is above 10 % [59]. 
However, the “mosaic” heterogeneity is more difficult to assess, as it is confirmed only, if the proportion of 
heterogeneous cells, as obtained by the manual scoring of FISH signals, is between 5-50 % of all cancer cells 
scored [99]. It means that in a population of 20-100 cells that were scored per patients, only a presence of 1 
to 5 heterogeneous cells were enough to confirm the mosaic heterogeneity, which was not a statistically-
large quantity. 
To improve HER2 overexpression assessment, some recent studies have proposed using IF instead of bright-
field IHC and computational analysis to quantify the HER2 protein presence [24, 31, 100]. Our group has 
demonstrated that digital IF quantification can improve diagnostic accuracy [31, 100]. For FISH analysis, 
automatic counting was developed to decrease the image analysis time and reduce human errors during FISH 
scoring [101-107]. However, as high magnification objectives (63?) with a small depth of focus that require 
z-stack images for different focal planes were used for recording FISH signals, the computational power and 
memory requirements were too large, still resulting in a small area analyzed.  
Here, we develop a method based on microfluidics and image processing for high-content analysis of HER2 
overexpression and amplification in large breast cancer tissue areas. After IF staining, tissues are imaged by 
a fluorescence microscope. All proteins and markers are then removed from the slide using protein digestion, 
followed by a standard FISH protocol, after which the slides are scanned again to obtain the FISH image. 
The IF and FISH images are then aligned using an image-processing software. In each cell, we quantify the 
HER2 protein intensity and its background, CK protein intensity (from IF), number of HER2 gene and 
CEP17 (from FISH), and cell positions. We study the accuracy of these scores for HER2 classification in 
tissues and cell lines. As a result, the power of this method thus lies in its ability to analyze HER2 
overexpression and amplification cell-by-cell, achieving unprecedented accuracy and content. Indeed, using 
a low magnification (20 ×) objective, the whole slide can be recorded and analyzed, allowing automated 
elaboration of 104-105 cells. Therefore, the presence of ITH can be detected, and its severity can be assessed 
using quantitative spatial analysis of protein overexpression and gene amplification. We demonstrate that 
both cluster and cell ITH can be detected and quantified in a large tissue area based on the local Moran’s I 
method [37]. Finally, we achieved obtain a quantitative estimation of cluster and mosaic ITH for each patient 
in a cohort of 20 tissue slides. We benchmarked the mosaic ITH with a computing model to assess its 
significance.  
4.2. Materials and methods 
All cancer tissues were retrieved from the Institute of Pathology of the University Hospital CHUV in 
Lausanne (ethical convention BB514/2012, Ethical Commission of Clinical Research of the state of Vaud). 
20 FFPE tissue samples were either primary breast cancer (16 cases) or metastatic cancer tissues in bones (2 
cases) or stomach (2 cases). All breast cancer patients did not oppose the use of their tissues for research 
purposes. Tissue samples were anonymized and codified. Tissues were sliced using a microtome and had a 
thickness of 4 ?m. All FFPE cell lines were purchased from AMS Biotechnology (Europe) Ltd - 
Switzerland. Cell lines were fixed by 10% Neutral Buffered Formalin, sliced into sections of 5-?m thickness. 
PBS 10× and Tween20 were acquired from Sigma-Aldrich Chemie GmbH, Buchs, Switzerland. PBS1× was 
obtained by diluting concentrated PBS stock in distilled DIW. For immunostaining, primary Abs: rabbit anti-
human c-erbB-2 oncoprotein primary Ab (HER2, code: A0485) and mouse anti-human CK (code M3515) 
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were purchased from Agilent Technology Schweiz (Basel, Switzerland) and diluted from the stock in PBS 
supplemented with Tween 0.05 % (PBST 0.05 %) to get a final concentration 2.4 ?g/ml (for HER2), CK 
1.72 ?g/ml (for CK). Secondary Abs AF594 goat anti-rabbit IgG (H+L, code: A-11037) and AF647 goat 
anti-mouse IgG (code: A-21236) were purchased from Thermo Fisher Scientific, Waltham, USA and diluted 
in PBST 0.05 % to get the final concentration of 50 ?g/ml. FISH HER2 Pathvysion® kit was obtained from 
Abbott Diagnostics (Santa Clara, CA, USA). 
We focused on most-challenging cases in diagnostics, which are borderline cases in both IHC and FISH. 16 
selected cases are classified as equivocal in IHC (2+), and in FISH (HER2/CEP17<2 and 4?HER2/cell<6) 
[66]. 4 other cases are HER2-positive for both FISH and IHC. All FFPE tissue slides were previously 
assessed by a pathologist to determine the area of an invasive component of a ductal carcinoma using a HE 
staining. Cell lines and tissues are divided into batches; each batch had one HER2-negative (MD-MB-468), 
two HER2-positive cell line (SKBR3) and several tissue slides. For two SKBR3 cell line slides, one was a 
control slide for the staining (i.e., it received only secondary Abs), and the other was processed with the 
same protocol as the other cell and tissue slides.  
4.2.1. Microfluidic IF staining and imaging protocol 
The protocol for microfluidic HER2 and CK IF staining was described previously [31, 100]. Shortly, tissue 
and cell slides were deparaffinized in 3 Histoclear II solutions (National Diagnostics, USA) for 5 min each. 
Then, they were transferred to gradual ethanol series of 100%, 100%, 95%, 70%, 40%, for 2 min each and 
stored in PBS 1 ? until the staining process. Next, they were immuno-stained by using the MTP [31, 100] 
(figure 4.1ai). During the experiment, the chip was mechanically clamped to a slide together with a plastic o-
ring, creating a 100 ?m chamber above the slide to flush specific Abs and buffer solutions homogeneously 
onto the surface of the tissue section or cell pellet via the tree-like microfluidic channels. An automatic 
syringe pump system delivered to the slide via the microfluidic system the following solutions: PBST 0.05% 
(flow rate 10 ?l/s during 5 second), HER2 and CK primary Ab mix (flow rate 2 ?l/s during 50 second then 
0.01 ?l/s during 2 min), PBS 1× wash (flow rate 10 ?l/s during 30 second), AF 594 and AF647 secondary 
Ab cocktail (flow rate 2 ?l/s during 50 second then 0.01 ?l/s during 2 min), PBS (flow rate 10 ?l/s during 30 
second) and distilled water (DIW, flow rate 10 ?l/s during 30 second). After these automatic reagent flushing 
steps, the slide was removed from the setup and cleaned again in DIW before receiving SlowFadeTM Gold 
Antifade mountant (Life Technologies) containing DAPI. The slide was coverslipped and stored in the fridge 
before imaging. All other slides in the batch were treated in the same manner. The whole microscope slide 
was then scanned tile by tile (10% overlap) using the microscope Axio Imager M2m (Zeiss, Germany) with a 
20? objective (Plan-Apochromat, numerical aperture =0.8) in 2 ? 2 binning mode. The light intensity was 
fixed maximum; the exposure time was first adjusted using the SKBR3 slide that received primary Abs to 
reach 80%  of the highest non-saturated exposure time. These exposure time and light intensity were kept 
constant for all slides and in all batches. The control SKBR3 was checked, any non-specific signal should be 
reported. In each position, emissions of 3 fluorophores AF594, AF647, and DAPI, corresponding 
respectively to HER2, CK and nucleus signals, under adaptive excitation lights were recorded and merged 
into an image, see figure 4.1aii. IF images were represented by three colors (blue, green and red) 
corresponding respectively to the nucleus, CK and HER2 signals. After scanning, tiles were stitched using 
the Axiovision software.  
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Figure 4.1 - High-content analysis of microfluidic IF and FISH. (a) Sequential IF/FISH staining. i)  
Immunostaining of cell pellet or tissue biopsy via the MTP (microfluidic tissue processor, see chapter 1) 
clamped onto the tissue-carrying glass slide to deliver the reagents in a highly-controlled fashion. ii) In 
the IF protocol, HER2 protein is tagged with a rabbit anti-human HER2 Ab, and CK is tagged with a 
mouse anti-human CK Ab. Fluorescent labeling is then achieved by using AF594-labeled goat anti-rabbit 
IgG Ab and AF647-labeled goat anti-mouse IgG Ab. Nuclei are marked with DAPI. The whole slide is 
scanned using a low magnification objective (20×). The image of a cluster of cells is presented. HER2, 
CK, DAPI signals are respectively displayed in red, green and blue. iii) In an elution step, staining agents 
are removed from the slide using proteolytic enzymes. iv) In the FISH protocol, the HER2 loci are 
labelled with fluorescent HER2 probes, and centromeres of chromosome 17 are labelled with fluorescent 
CEP17, and nuclei are marked with DAPI. An image of the same cells as in ii is shown. HER2 loci, 
CEP17 centromeres and nuclei are respectively displayed in red, green and blue. (b) Image-processing of 
the IF and FISH images obtained after the protocol from A. IF and FISH images, aligned using the 
common DAPI channel, are sequentially processed. i) For IF analysis, clusters of cells are segmented 
into an individual cell or a smaller group of cells based on nuclear analysis from the DAPI and CK 
channels. The HER2 signal also defines the membrane area in which the mean HER2 and CK intensities 
for each cell are measured. ii) For FISH analysis, nuclei define the area where HER2 and CEP17 signals 
for each cell are scored. (c) Data analysis protocol.  The cell HER2 expression given by IF is merged 
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with the cell HER2 amplification obtained from FISH, followed by a filtering step that selects the cells 
of interest. For each sample, scores for HER2 overexpression and amplification based on the analysis of 
all the cells are obtained. Then, intra-tumoral heterogeneity analysis using spatial association is 
performed. Scale bars: 10 ?m. 
4.2.2. Successive FISH and imaging protocol 
After IF image acquisition, the coverslip of the slide was removed. The slides were immersed in a Coplin jar 
containing MES 1× buffer (Agilent Technologies, Santa Clara, CA, USA) heated at 95-97°C for 10 min. 
Next, the Coplin jar was cooled down to RT for 20 min before dipping in washing buffer (twice for 3 min). 
Protein digestion was performed by applying protease (Agilent Technologies) at 37°C in 10 min (Figure 
4.1aiii) then immersed in 2 washing solutions (Tris/HCl) for 2 min each.  Then, the slides were dipped in 
post-fixation solution composing of 1% formaldehyde (Merck Millipore, Germany), PBS 1× and 20 mM 
MgCl2 Sigma-Aldrich (MO, USA), for 10 min.  The slide was then washed with then in PBS 1×, ethanol 
solution with concentrations from 40-100% in 2 min each and dried. HER2 Pathvysion® FISH probe (from 
the FISH kit), containing a mix of DNA HER2 probe and CEP17 probes, was applied on the surface of the 
tissue and cell line, coverslipped and sealed with a removable rubber. The tissue and probe were denatured at 
73°C for 5 min, following by an overnight incubation at 37°C. After the incubation, the rubber parts and 
coverslips were removed, and the tissue slide was washed in a stringent wash buffer, containing 2× SSC 
(Sigma-Aldrich, MO, USA), 0.3 % Tween 20 (Bio-Rad, CA, USA) for 2 min. Stringent wash buffer 
removed for non-specific adsorptions of DNA probes on the tissue. Then, the slide was washed in SSC 
Tween (SSC 2×, 0.1 % Tween 20) for 2 min, SSC 2× for 2 min, distilled water for 5 seconds and dehydrated 
in successive ethanol 40-100% for 2 min each before DAPI mounting medium was applied to the dried slide. 
Finally, the slides were coverslipped with DAPI mounting medium and sealed with a nail polishing solution. 
After the FISH staining, the slides were scanned tile-by-tile (10% overlap) using adaptive excitation lights 
and filter sets and with the same 20× objective as in the IF (without binning). The location of FISH imaging 
was selected based on the IF image (Figure 4.1aiv). In the end, all scanned tiles were stitched to reconstruct 
the large tissue area of 4 mm × 4 mm using the Axiovision software.   
4.2.3. Image processing 
The stitched IF and FISH images were then aligned using the common DAPI channels, sampled into small 
tiles having an area of 112 ?m × 112 ?m to decrease the computer memory requirement during the image 
processing process. Next, in the image processing protocol of IF signals, each IF image was segmented into 
cells or small clusters of cells based on nuclei and CK channels. More specifically, the CK channel was 
subtracted from the nucleus channel, and the local maxima were identified for determining the cell area. 
After this step, cells were segmented (Figure 4.1bi). In the following step, the HER2 intensity was enhanced 
and thresholded, defining the membrane area where HER2 and CK signals were measured. HER2 and CK 
protein expressions for each cell were computed by averaging the intensity of green and red pixels located in 
the cell membrane area. The mean background of each small tile was measured. For each cell, we calculated 
the (HER2 signal - mean HER2 background) / CK signal. The signals were obtained from the mean of all 
pixels of the selected area. Later, for short, we call this ratio the adjusted HER2/CK ratio or simply 
HER2/CK ratio.  
In the FISH images, the nuclei were determined based on a combination of several image processing 
technique to enhance the signal and detect the nuclei such as edge finding, segmentation using local maxima, 
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and thresholding. By the end of this step, the regions of interest defining the nuclei were determined (figure 
4.1bii) and associated to a cells identified in the IF image. Note that as the IF images were recorded in 2 ? 2 
binning mode, they are smaller than the FISH images. Therefore cell and nuclei coordinates in the tissue 
were also linked by a factor of 2. For each cell, the numbers of CEP17 and HER2 signals were scored based 
on local maximum detection. In particular, as CEP17 marks the alpha-satellite regions in the center of the 
chromosome, CEP17 dots were counted as one per local maxima position. Therefore, the total number of 
CEP17 for each cell was counted as the sum of local maxima in the green channel, within the area of a 
nucleus of a cell. For HER2, as HER2 genes appeared as small dots, some HER2 signals could overlap and 
form indistinguishable clusters in the low-resolution 20?-objective images. Clusters of HER2 signals are 
usually brighter and larger than an individual HER2 signals. It is one of our main targets to estimate the 
number of HER2 loci in each cluster to retrieve information from clustered signals. First, local maxima of the 
red signal within a nucleus (cluster positions) were identified. Second, in the HER2 channel, areas 
proportional to the full-with-half-maximum of each local maximum, corresponding to the area around the 
maximum, were assigned to each cluster. The cluster size and integrated intensity (sum of all signal pixels 
within a cluster) were measured. Last, the total number of HER2 dots per cell was the sum of all HER2 dots 
in all HER2 clusters. The number of HER2 signals inside each HER2 cluster was estimated using a 
regression between the number of red dots counted in a higher magnification (63?) and the integrated 
intensity of the HER2 cluster (not shown). Note that in both red and green channels, autofluorescence was 
also detected together with signals, but was filtered out later, as it was detected in both channels or did not 
satisfiy several criteria concerning contrast and size. Also, some cells are overlapped and cannot be 
segmented. Therefore, the number of HER2 per nucleus was adjusted by dividing to the number of 
overlapped/clustered nuclei that is obtained to the mean size of cancer cells (supposed that most cells are not 
clustered) and rounding it to the lower integral value.  
After image processing, IF and FISH signal characteristics such as immunostaining intensity, FISH scores, 
were obtained and merged into a single database (Figure 4.1c). For tissue analysis, the data processing was 
followed by a spatial analysis (vide infra). After the data acquisition, each nucleus defines one cell with all 
characteristics: HER2 protein intensity and its background, CK protein intensity (from IF), number of HER2 
loci and CEP17 (from FISH), nucleus size and cell positions in X and Y coordinates. 
4.2.4. Data analysis  
To select cells of interest, we applied a series of filtering based on the following parameters: CK signals, 
nucleus size, the number of red and green signals. A selected nucleus has a size in the range of 50-1000 ?m2 
and contains at least one HER2 and one CEP17 signal. Furthermore, it should have a relatively strong CK 
signal comparing to other cells in the tissue, to make sure that the cell is an epithelial cancer cell and not a 
normal cell. For this aim, we applied a filter based on the histogram of the CK signals in all cells. Non-
epithelial cells with CK signal less than Mean - 0.5?SD were discarded. For all remained cells, we computed 
the mean adjusted HER2/CK ratio, the number of HER2 loci and HER2/CEP17 ratio per cell and their 
corresponding SDs. Then, HER2 classification was performed based on the ASCO/CAP 2013 guideline for 
FISH assessment. We computed the ratio between the sum of all HER2 loci and CEP17 for all cells in the 
tissue. This ratio, called overall HER2/CEP17 ratio, is slightly different to the HER2/CEP17 ratio per cell, 
which is the average of ratios. The HER2 status is determined as the follows. If an overall HER2/CEP17 
ratio ? 2, or a number of HER2/cell > 6 is found, the sample was considered positive. If 4? HER2/cell ?6 and 
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overall HER2/CEP17 ratio < 2 are found, the sample was considered equivocal, and all scores lower than 
these thresholds are associated with a negative sample, following the ASCO/CAP 2013 guidelines.  
4.2.5. Analysis of local indication of spatial association 
 Spatial heterogeneity is characterized by a local Moran’s I analysis that indicates the correlation and anti-
correlation between the IF or FISH scores obtained in one cell and the neighbors of this cell. We define a 
variable of interest X having a value ?? at each cell i that varies through a Cartesian space. Classical local 
Moran’s I calculates a scalar product ?? at each cell i with its neighbors j as 
?? ? ? ?? ???????
?
 
With ?
?? ? ??????   is the normalized value of ?? to its mean ?? and SD ? ? ?
?????? ?
?  
???: weight matrix which defines neighborhood. ??? ? ? if i and j are not neighbors of each other. ??? ? ? if 
i and j are neighbors of each other. 
? ??????  is the sum of all normalized values of ?? all neighbors j 
In our study, this variable X can be the adjusted HER2/CK or the HER2/cell number. We want to compare 
the cell scores with a fixed value instead of a mean and a SD of the cell population, which can vary from one 
tissue sample to another. Therefore, we define a variable ??? by centering the variable X to a fixed threshold 
?? (for example for the variable HER2/cell ??=5), and normalizing it to the SD ? of the population.  
??? ?
?? ? ??
? ?? 
The sum of neighbor values becomes ? ??????? . 
Cells are classified into five groups, high-high (HH), low-low (LL), high-low (HL), low-high (LH), non-
classified (NC) depending on the value ??? of the cell and the value ? ???????  of its neighborhoods. One cell is 
classified as High (respectively Low) if the its variable ?? is higher (respectively lower) than a high threshold 
?? (respectively low threshold ??). This is equivalent to ??? higher (respectively lower) than a high threshold 
?????
? ?(respectively low threshold 
?????
? ). The thresholds ?? and ?? of the variables such as the adjusted 
HER2/CK or the HER2/cell number are fixed for all tissues studied and have the average value equal to??? 
(???????? ? ??). For the variable HER2/cell ??=6 and ??=4, based on the ASCO 2013 guideline [59], see the 
section III.3.a. For the variable HER2/CK, they are chosen based on a study on the HER2-positive cell line 
SKBR3 (see the section III.1.a). Neighborhood are classified as High (respectively Low) if ? ???????   is 
higher (respectively lower) than 0, which means the mean of all neighborhood’s values is higher 
(respectively lower) than ??. An HH cell is a positive cell that is placed in a positive cluster, the analogy is 
applied for HL, LH, and LL cells. They are NC otherwise, i.e. the value is not high or low enough to 
conclude about the positivity or negativity of the cell signal. In our analysis, neighborhoods of a cell i are all 
cells within a distance of 100 ?m to the cell i. 
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Finally, we define cluster heterogeneity and mosaic heterogeneity as the following. In the cluster 
heterogeneity, if more than 10% of all cells have a different status, for example, negative cells in positive 
samples or positive cells in negative samples, and form a cluster (HH or LL cells), this case is identified as 
cluster heterogeneity. For the mosaic heterogeneity, we calculate the proportion of HL cells in a HER2-
negative sample and LH cells in a HER2 positive sample. As cells are sliced during the tissue preparation, 
the mosaic heterogeneity is usually confounded to the cell truncation errors of the FISH technique. Therefore 
the mosaic heterogeneity is only concluded, when there are more heterogeneous cells originating from 
biological variations than from truncation errors (see section 4.3.3.2).  
4.2.6. Statistical modeling of the HER2-loci-per-cell number in a homogeneous cell population. 
By using a statistical model, we will demonstrate that even a homogeneous cell population can display 
heterogeneous cells due to truncation errors. To achieve this aim, first, the geometry of a truncated cell is 
presented, see figure 4.2.  
4.2.6.1. Geometry of a truncated cell 
A cell is modeled sphere having a radius R. Given an X axis having an origin at the center of the sphere, the 
cell cut has a center at x and a thickness of ?.  
 
Figure 4.2 - Schematic presentation of a nucleus with several HER2 loci. Left: section of thickness t 
selects only some among all HER2 loci. Right: 2D presentation of the section and the nucleus. 
The mathematical background allowing to calculate the probability density function of the HER2/cell 
number (the number of HER2 signals contained in the cell section) in function of the position ? is presented 
in the following section.  
Two extremities of the cut on the x axis are called ?? and ?? with ?? > ??. The position of the center of the 
cut ? is arbitrary chosen, in between –R and R on the x-axis. This position ? follows a uniform probability 
law with a probability density of f(x) with 
???? ? ????  with ?? ? ? ? ? (4.1) 
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For each position ?, we obtain a volume ????? of the cut calculated as: 
????? ? ? ????????
??
??
 
(4.2) 
With ???? is the radius of a section of the sphere at position x, ????? ? ?? ? ?? (Pythagore). The 
calculation of ????? is detailed in Appendix C. From ????? we can calculate the probability ???? for one 
HER2 locus to be placed inside the cell section. Indeed, the number of HER2/cell obtained in a FISH image 
(measured HER2/cell) is the number of HER2 signals that are, by “chance”, placed inside the cell section. 
Hence, considering one HER2 locus, it can belong to a domain inside the cut or outside the cut. Its 
probability to be placed inside the cut is the ratio between the volume of the cut and volume of the cell. In 
the Appendix C, we demonstrate that the number of number of HER2/cell follows a binomial law of 
probability. From ???? we calculate the probability mass function of the HER2/cell number variable used for 
generating a population of cell section to build truncation error model (vide infra). 
4.2.6.2. Simulation of number of HER2/cell of a population of truncated, homogeneous cells 
First, we generated a uniformly-distributed population of M elements between 0 and 1. M corresponds to the 
number of cells in a tissue or cell pellet. This population was used to create a set of values having a binomial 
distribution using the invert function of the binomial cumulative-distribution-function (cdf). The binomial 
cdf was the sum of all probabilities ? ???? ?? ??????????  for n=1 to N, for a given N and ????. For N, we 
suppose that the theoretical number of HER2 loci in all cells is identical and equal to N. We generated a 
random variable ? from a continuous, uniform distribution and calculate ???? using the relation presented in 
[6]. In equation [6], the cut thickness ? is equal to 4 ?m for tissue slides and 5??m for cell line slides and the 
value of the radius of nuclei R is unknown and to be estimated from the measurements. The theoretical 
radius of nuclei ? is supposed to be identical in all cells in the tissue.  
 
Figure 4.3 - Relation between the apparent radius ???and true radius ?. ? is the center of the cut relative 
to the center of the nucleus. The position of the two boundaries of the cut are ??, ??. 
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In our analysis, we can measure the value of the area of a cell section that is a disk with a radius ?? (the 
apparent radius of a cell). Here, we will demonstrate how R can be calculated from the measured ? of cell 
section. Indeed, these radii ?? and ? are related by the Pythagore equation (Figure 4.3): 
?? ? ?? ? ??????? (4.3) 
If we consider a population of cell, ? can be considered from a statistical point of view as a random variable 
presenting the center of the cut relative to the center of the nucleus.  
As ? is a uniform random variable between –?? and ?, it has an expected value ????=0 and a variance 
?????? ? ??????????? ?
??
?  
By definition, the variance of ? can be presented in function of expected value of ? and ??: 
?????? ? ????? ? ????? 
Thus the expected value of the variable ?? is equal to 
??????? ? ??????? ? ??????=? ????? ?
??
?  (4.4) 
Therefore from the equations ????? and ????? the value of the theoretical radius of a nucleus R can be 
presented as a function of the expected value of ??: 
?? ? ????? ? ????????? ?
??
? ? ???????
?? 
Or 
???????
???
?  
 
(4.5) 
After measuring the apparent radius ????? and computing ?????? for all cells in all tissues of the batch, we 
obtained the mean cancer cell radius???7.0 ?m from the equation (4.5). For cell lines, ? is slightly bigger 
and equal to 7.3 ?m.  
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For tissue slides, we performed 10 simulations using the following set of parameters: M= 20000 (the typical 
number of cells in a tissue slide area), ? =7 ?m,?? =4 ?m. For cell slides, 10 simulations were performed 
using the following set of parameters: M= 5000 (the typical number of cells of a cell pellet area), ? =7.3 
?m,?? =5 ?m (the thickness of the cell pellet obtained from the supplier’s specification). All simulations and 
calculations were performed by MATLAB (MathWorks Inc, MA, USA). For tissue slides, we performed 10 
simulations using the following set of parameters: M= 20000 (the typical number of cells in a tissue slide 
area), ? =7 ?m,?? =4 ?m (for example, the distribution of a truncation model having the total number of 
HER2 loci N=25 is presented in figure 4.4). For cell slides, 10 simulations were performed using the 
following set of parameters: M= 5000 (the typical number of cells of a cell pellet area), ? =7.3 ?m,?? =5?m 
the thickness of the cell pellet obtained from the supplier’s specification). The mean HER2/cell of each cell 
population was obtained by averaging the number of HER2 loci of all truncated cells in the simulation.  
 
Figure 4.4 - Simulated HER2 loci histogram of a truncation model. The cell section can contain different 
numbers of HER2 loci varying from 1 to N, where N is the theoretical number of HER2 loci which is 
identical for the 20000 truncated cells generated. The x axis represents the number HER2 loci in each 
cell. The y axis shows the number of cells having a given number of HER2 loci. Here the total number of 
TC M= 20000, theoretical TC radius ? =7 ?m, thickness of the cut?? =4 ?m and N=25. 
4.2.6.3. Heterogeneity assessment in the current clinical practice. 
According to ASCO 2013 guideline [59],the presence of cluster ITH is stated, if more than 10% of the total 
cells are strongly positive (HER2 copy/cell?6) and clustered (equivalent to HH cells in the local Moran’s I 
analysis of FISH HER2/cell image) in a HER2-negative sample or 10% of the total cells are negative and 
clustered in a HER2-positive sample (LL cells in local Moran’s I image of FISH HER2/cell). For mosaic 
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heterogeneity, the selection criteria are less obvious. Indeed, according to the literature, the presence of 
cellular ITH of each patient is confirmed for a HER2-negative/equivocal sample (mean HER2/CEP17 ratio 
<2 and mean HER2/cell < 6) if there is a presence of heterogenous individual cells having HER2/cell >6 in 
HER2 negative clusters (HL cells in local Moran’s I image of FISH signal); and for a positive sample (mean 
HER2/CEP17 ratio ? 2 or mean HER2/cell ? 6) with a presence of heterogeneous HER2-negative cells 
HER2/cell < 4  (equivalent to LH cells in local Moran’s I image of FISH signal) [66]. According to the 
literature, mosaic ITH is confirmed if there is 5 to 50% heterogeneous cells [59, 79]. 
4.3. Results 
4.3.1. High-content analysis of HER2 overexpression and amplification in cell lines and tissues 
4.3.1.1. Cell line overexpression and amplification analysis 
 
Figure 4.5 - HER2 positive- and negative- cell line characterization by both IF and FISH technique. On 
the horizontal axis: the mean HER2/cell number obtained from an automatic scoring of FISH signals. On 
the vertical axis, the mean HER2 intensity of an IF image. Triplicates of HER2-negative (HER2-) and 
HER2-positive (HER2+) samples were performed. 
To assess the robustness of HER2 overexpression and amplification with our technique, we performed 
IF/FISH staining and analyses on well-defined HER2 controls: a HER2-positive cell line (SKBR3) and a 
HER2-negative cell line (MD-MB-468). Mean values of HER2 intensity from an IF image and automatic 
HER2 loci per cell (HER2/cell) scores from FISH are plotted in figure 4.5. The automatic FISH counting 
scores were calculated from the total pixel intensity in clusters of red dots in a 20× image (see section 4.2.3). 
The horizontal and vertical error-bars are large, showing a wide range of variation of HER2 IF signals and 
the number of HER2 loci among cells. When the HER2 intensity of the image’s background (i.e. areas that 
express low HER2 signal) is substracted from the HER2 protein signal of a cell and the result is normalized 
to the CK signal (HER2/CK ratio) of the cell, we found that the mean ratio of all cells is similar between the 
replicates (see Figure 4.6a). Also, smaller variations between cells and a sharper distinction between negative 
and positive cell lines are observed, suggesting that HER2/CK ratio is a value characteristic of each cell line 
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sample, independent of between-batch variations. For FISH, the HER2/cell variation is explained by a 
“truncation error”, i.e., the number HER2 loci/cell scored by FISH can take a random value between 0 to N, 
where N is the exact number of the HER2 copy of this cell, because it was sliced into sections. Thus, we 
normalize HER2 copy numbers to CEP17 signal numbers for each cell to limit the truncation error effects on 
the mean HER2/CEP17 score thanks to the large population of cells. Indeed, the probabilities of both HER2 
and CEP17 signals contained in the cut are proportional to the thickness and size of the cell cut. Finally, the 
two selected parameters are the mean HER2/CK ratio and the mean HER2/CEP17 ratio. As SKBR3 is a 
weakly HER2-positive cell line [74], its IF staining intensity is closed to the HER2 negative-positive 
borderline. We used it to define the threshold between HER2-negative and positive tissues for quantitative 
IF. The analysis of SKBR3 cell slides gives a mean HER2/CK ratio of 0.316 and a SD of 0.021. A t-test to 
determine the confidential interval of the mean HER2/CK ratio gives a 95% confidential interval of [0.251, 
0.380]. The lower bound of the 95% confidential interval 0.251 is used as the threshold for HER2 
classification in tissues (vide infra). Control SKBR3 slides that did not receive the primary Abs did not 
display any specific signals, proving that the staining is specific to the biomarkers HER2 and CK. 
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 Figure 4.6 - HER2 assessment of cell lines and tissues using automatic and quantitative IF-FISH 
analysis. (a)  HER2 overexpression (given by the cell-by-cell ratio between the HER2 and the CK 
signals) versus HER2 amplification (given by the cell-by-cell ratio between the number of HER2 loci 
and CEP17) for HER2 positive (+) and HER2 negative (-) cell lines. Data are plotted as a mean ± SD. (b) 
Assessment of HER2 overexpression and amplification with the same methodology as in A for HER2+ 
and HER2- tissues. The HER2 status is obtained from pathological assessment by a standard FISH 
technique. (c) IF image of a HER2-negative tissue. (d) Cell-by-cell representation of HER2/CK. and 
HER2/CEP17 signals. Cells are represented by dots. The contours of the dots (in yellow scale) denote the 
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normalized HER2/CK ratio, while the inside of the dots (in red scale) indicate the HER2/CEP17 ratio of 
the cells in C. Normalization of the HER2/CK ratio (yellow scale) is obtained by allocating the value 1 
to the maximum HER2/CK ratio that was obtained from all tissues. The maximum of the red scale is 
chosen as 8 for easy distinction between positive and negative cells. (e) IF image of a HER2-positive 
tissue. F) Cell-by-cell representation of the tissue in E with the same methodology as in D. Colors in IF 
images: Blue=DAPI, Green=CK, Red=HER2. 
4.3.1.2. Tissue analysis using the high-content IF-FISH technique 
Combining the IF and FISH automatic analyses, all mean HER2/CK ratios obtained from IF and 
HER2/CEP17 ratios obtained from FISH were computed for all tissues. The results are plotted in Figure 
4.6b.  The error bars represent the variation of these scores among cells in the tissue. In general, we observe 
the higher range of HER2/CK ratios and HER2/CEP17 ratio in the HER2-positive cases compared to that in 
the equivocal-negative cases, except for one positive case which has significantly lower HER2/CK ratios and 
HER2/CEP17 ratio. This is a heterogeneous case that will be discussed in the following sections. A cell-by-
cell representation of a HER2-negative tissue (assessed previously by a pathologist using a standard IHC and 
FISH technique) is shown in Figure 4.6c. For the HER2-negative tissue (Figure 4.6c), both the HER2/CK 
ratios are codified in yellow scale (contours, Figure 4.6d) and the HER2/CEP17 ratios are codified in red 
scale (inside of the dots, Figure 4.6d). These parameters were lower than these  same parameters for a HER2-
positive tissue (Figure 4.6e,f). 
4.3.2. Accurate diagnostics based on quantitative IF/FISH 
Our quantitative IF/FISH method was applied to a small clinical cohort of breast cancer cases. To verify its 
performance compared to the conventional diagnostic method, we studied the correlation between 3 scores 
obtained by our method (i.e. HER2/CK, HER2/cell number and HER2/CEP17 ratios) and the pathologist’s 
scores (i.e. standard HER2/cell and HER2/CEP17 ratios). For HER2/CK and HER2/CEP17 ratios, we also 
propose new criteria for HER2 status assessment based on these variables and compared them with the ones 
currently used in the clinic. 
HER2/cell and HER2/CEP17 ratios from a pathologist were based on a count of HER2 and CEP17 signals in 
a cluster of 20-100 cells, followed by dividing the number of the total HER2 loci to the total number of cell 
counted, and the number of HER2 loci in all cells to the number of CEP17 in all cells. This overall 
HER2/CEP17 ratio is different from the cell HER2/CEP17 ratio in our method, which calculates the 
HER2/CEP17 ratio for each cell first, then averages them over the complete cell population. There is a nearly 
perfect-correlation between these two ratios (figure 4.7). The cell-based HER2/CEP17 ratio is required in our 
high content method because normalization of HER2 signals to CEP17 signals for each cell renders less 
variation of the HER2 signals in the cell level.  
The results from tissue analysis was pooled with the results from the HER2- and HER2+ cell line study from 
section 4.3.1, in which the standard HER2/cell and HER2/CEP17 ratios were obtained in our laboratory 
using the same manual scoring method as done by pathologists.  
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Figure 4.7 - The ratios of the mean HER2 and CEP17 signals versus the mean of HER2/CEP17 ratios for 
different tissue slides. Nearly perfect correlation is found (R2=0.98). 
We benchmarked our method with HER2/cell and HER2/CEP17 ratios instead of the IHC scores because 
FISH is more quantitative than IHC. In figure 4.8a, the HER2/CK ratio obtained by automatic IF analysis 
was compared to the standard HER2/CEP17 FISH scores obtained from manual counting. In figure 4.8a, the 
correlation between these two quantities has a sum-of-square R2 equal of 0.64. The dotted lines are the 
thresholds, defined as the following. For IF, we obtained from cell line analysis a threshold of 0.273 for 
positivity determination. For the overall HER2/CEP17, we used the same threshold as in standard diagnostics 
routine, which is equal to 2. By using these thresholds, all but two cases are correctly classified. For the 
false-positive IF score, the tissue is a metastatic case of breast cancer in bones, for which the CK staining is 
weaker than usually, which increases the HER2/CK ratio. For the false-negative IF score, this case is a 
heterogeneous case, which is challenging for the decision-making. Therefore, we analyzed local indicators of 
spatial association (local Moran’s I) for this heterogeneous case (see section 4.3.3.1). Without these two 
particular cases, R2=0.80, suggesting an acceptable correlation between the two scores. 
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Figure 4.8 - Validation of our quantitative and automatic IF-FISH scoring method by comparison with the 
standard HER2 assessment for tissue and cell line samples. (a) Correlation between HER2 overexpression 
(HER2/CK ratio obtained from the microfluidic staining protocol and automated IF image-processing) and 
HER2 amplification (HER2/CEP17 ratio obtained from standard FISH scoring). The threshold for positivity 
of HER2/CK obtained by IF (horizontal dotted line) is defined as the lower bound of the 95% confidence 
interval obtained from a t-test on the mean HER2/CK scores of three HER2-positve cell line slides. The 
threshold for positivity of HER2/CEP17 obtained by FISH (vertical dotted line) is obtained from the ASCO 
2013 guidelines. (b) Correlation between the HER2 loci number per cell obtained from our automated 
counting algorithm and from the standard FISH technique. Thresholds for positivity for the variable 
HER2/cell is taken as 6 (dotted lines), obtained from the ASCO 2013 guidelines. (c) Correlation between the 
HER2/CEP17 ratio obtained from our automated counting algorithm and from the standard FISH technique. 
In our automatic method, the HER2/CEP17 ratio is calculated as the mean of the HER2/CEP17 ratios in all 
CK-positive cells of a tissue, while in the standard method it is calculated as the ratio of mean HER2 and 
CEP17 signals in a cluster of 20-100 cells chosen by the pathologist. The threshold for positivity for the 
automatic HER2/CEP17 ratio (horizontal dotted line) is 2.4 (see text). The threshold for positivity of 
HER2/CEP17 obtained by FISH (vertical dotted line) is obtained from the ASCO 2013 guidelines. 
In figure 4.8b, the mean number of HER2/cell from an automatic FISH method is plotted against HER2/cell 
scores from a standard FISH scoring. For simplification, we presented only the threshold of 6 for separating 
positive and non-positive samples for HER2/cell (the equivocal class is considered as negative). A good 
correlation between the two scores is obtained (R2= 0.88). If the heterogeneous case is not included in the 
dataset R2= 0.93, which validate the use of the automatic scoring method for tissue analysis. In general, 
slightly smaller HER2 signals are obtained by the automatic scoring than a standard method. The difference 
between automatic scores and manual scores can be explained by the effect of scoring through a section of 
tissue that could make signals placed deep in the tissue less visible. Moreover, the automatic scoring method 
is based on an estimation of the number of HER2 dots, not the exact count, if two HER2 signals are closed 
and dim, they can be counted as one. Besides, if there are more than 2 signals per location, the obtained 
intensity might not be a linear function of the number of signals and often less signals are counted in this 
situation. However, according to ASCO 2013 guideline [59], no major misclassification (positive to negative 
and inversely) of HER2 status is found. Our automatic analysis gave similar scores compared to 63? z-stack 
scoring while having many more cells analyzed (at least two orders of magnitude). This statistical power is 
the basis of our high-content analysis. 
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Finally, in figure 4.8c, the cell HER2/CEP17 ratio by automatic FISH is plotted against the overall 
HER2/CEP17 ratio by the standard FISH method. This graph shows a good correlation between these two 
ratios R2=0.81. If the heterogeneous case is not included, R2=0.93. The threshold for the cell HER2/CEP17 
ratio is obtained by adjusting the threshold of 2 in the case of overall HER2/CEP17 ratio, to 2.4. This 
adjustment is obtained from a correlation study, between the automatic cell HER2/CEP17 ratios of tissue 
samples in the cohort and their automatic overall HER2/CEP17 ratios (see figure 4.9). This nearly-perfect 
correlation (R2=0.98) gives a regression equation linked the two ratios: cR=1.26?oR-0.105, with cR is the 
cell HER2/CEP17 ratios and oR is the overall HER2/CEP17 ratios. The latter has a threshold of 2 (ASCO 
2013) [59]. Thus, the threshold of the cell HER2/CEP17 ratio is equal to 1.26?2-0.105=2.4. All three 
automatic scores correlate with the standard scores, thus underlining the clinical values of this method. 
 
 
Figure 4.9 - Correlation between HER2/cell number and HER2/CEP17 ratio obtained in all tissue and 
cell line slides tested. 
4.3.3. Spatial analysis and evaluation of ITH 
4.3.3.1. Cluster heterogeneity 
In this part, ITH detection and quantification using high-content analysis of IF-FISH are presented. Cluster 
ITH is characterized by the proportion of different tumor areas having different HER2 protein expression or 
gene amplification. We use the local Moran’s I to characterize ITH, as this method can quantitatively 
discriminate cluster and mosaic ITH by comparing the variable of interest for each cell with that of its 
neighbors. A correlation between a cell and its neighbors reflects that they are clustered while an anti-
correlation between a cell and its neighbors indicates that the cell is heterogeneous and has a different status 
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than its neighbors. For ITH characterization, the two parameters used are the HER2/CK ratio and HER2/cell 
number. HER2/CEP17 is not considered for this cell-level analysis because in addition of truncation errors 
from HER2 signals, it also contains the truncation errors from CEP17 signals, which requires a complicated 
deconvolution of the two effects. Nevertheless, HER2/cell number and HER2/CEP17 ratio are proportional 
(see figure 4.9); hence sole HER2/cell number can indicate the ITH.  
As described in the section method, cells are classified into 5 groups: HH, HL, LH, LL, and NC based on the 
values of the considered parameter (HER2/CK and HER2/cell), calculated for each cell and its 
neighborhood, in comparison to a high and low threshold ?? and ??. For the HER2/CK ratio, ?? is equal to ?? 
(single threshold) and defined as the lower boundary of the confidential interval of a t-test on SKBR3 cell 
lines’ HER2/CK (see section 4.3.1.1). ?? =??= 0.25. Cells and neighbors having HER2/CK ?0.25 are 
classified as H and <0.25 are L. For the parameter HER2/cell, as this is a standard variable, we used the 
current guideline for ?? and ??, with ??=6 and ??=4 [66]. Cells having a HER2 copy number>6 is 
unambiguously positive and if <4 is unambiguously negative. If the cell’s HER2 copy number is between 4 
and 6 or equal to 4 or 6, we cannot conclude about its status (equivocal).  
CHAPTER 4: HIGH-CONTENT, CELL-BY-CELL ASSESSMENT OF HER2 OVEREXPRESSION AND 
AMPLIFICATION IN BREAST CANCER TISSUES. 
125 
 
 
Figure 4.10 - Analysis of a heterogeneous tissue using correlation of HER2 signals of neighboring cells. (a) 
IF image of a tissue with definition of two regions of interest c and d, in which we will analyze the genetic 
heterogeneity. The red and green colors respectively representing the HER2 and Cytokeratin markers are 
almost colocolized, making orange in the area where tumor cells are located. Blue color represents the 
nuclei, equivalent to hematoxylin staining in a bright-field image. (b) Model of the tissue in a using the same 
cell-by-cell representation as in figure 4.6d,f. (c) Heterogeneity analysis of a HER2 FISH-positive region of 
the tissue in a. i) IF image: blue=nuclei, red=HER2, green=CK. ii) Correlation status of the cells in i. Cells 
are classified based on their own HER2 IF-status (High or Low) and on the IF-status of their neighbors (High 
or Low), resulting in: High-High (HH), High-Low (HL), Low-High (LH), Low-Low (LL)-type cells. Cells 
and their neighbors are classified as High (respectively Low) if their HER2/CK ratio is higher (respectively 
lower) than a threshold of 0.25. This threshold is the lower boundary of the 95% confidence interval of a t-
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test on the HER2 FISH-positive cell lines’ HER2/CK obtained from figure 4.6a. iii) FISH image of the 
region. Blue=nuclei, green=CEP17, red=HER2. iv) Automatic scoring of HER2 loci and CEP17 of the 
region in iii. v) Spatial association status of the cells in iv. Cells are classified as High (respectively Low) if 
their HER2 loci number is ?6 (respectively <4).They are non-classified (NC) in the intermediate interval of 
HER2 loci number from 4 to 6, where the FISH HER2 status is equivocal. (di-v) Heterogeneity analysis of a 
HER2 equivocal region of the region of interest d of the tissue in a, following the same procedure as in c. 
While the IF readout is similar, the FISH status is clearly distinct. (e) Spatial association analysis of the 
HER2 protein expression by IF for the whole tissue in a. (f) Spatial association analysis of HER2 
amplification by FISH for the whole tissue in a, showing cluster heterogeneity, i.e. having clusters of HH 
cells that span in area more than 10% of the tissue. Scale bars: 10 ?m. 
In the following part, we demonstrate that the cluster ITH in the particular heterogeneous case mentioned in 
section 4.3.2 can be effectively identified and quantitatively characterized using the local Moran’s I analysis. 
First, we observe that the IF image of the CK-positive cells in a large tissue area of the tissue displays a 
fairly homogeneous staining of HER2 in red and CK in green (see figure 4.10a). The co-presentation of IF 
overexpression by the HER2/CK ratio (contours in yellow scale) and FISH amplification by HER2/CEP17 
ratio (inside of the dots in red scale) of CK-positive cells in the tissue do not display remarkable cluster ITH, 
as shown in figure 4.10b. However, this is a case having genetic heterogeneity, as proved by local Moran’s I 
analysis (vide infra). In figure 4.10ci, IF image of a FISH-positive cluster of the tissue is displayed. local 
Moran’s I analysis of the parameter HER2/CK from the IF image shows only LL cells are in this region, 
confirming that the HER2 expression is clustered and homogeneously negative in this area (figure 4.10cii). 
However, in the FISH image (figure 4.10ciii) this cluster is displayed with a majority of positive cells, as 
highlighted by the automatic analysis of FISH signal (figure 4.10civ). In figure 4.10cv, the local Moran’s I 
map for FISH indicates that most cells are HH, meaning that they are amplified (HER2/cell number>6) and 
clustered, while two other cells are non-classified (4?HER2/cell number?6). In figure 4.10di, IF image of a 
FISH-equivocal cluster (HER2/cell in between 4 and 6) of the tissue is displayed. While the cell’s IF signal is 
still classified as negative and clustered (figure 4.10di, ii), FISH image (figure 4diii) shows most are non-
classified cells, except one cell that is highly amplified. The automatic scoring of FISH signal and local 
Moran’s I analysis both confirm that this area has the majority of FISH-equivocal cells and one 
heterogeneous HL cell (figure 4.10div, v). In figure 4.10e, a local Moran’s I map of the IF HER2/CK ratios 
of CK-positive cells in the tissue area is presented, indicating that the staining is fairly homogeneous, except 
in some areas where there is cluster ITH. In 4.10f, local Moran’s I maps of the HER2/cell from the FISH 
image of the tissue area are plotted. We observe the presence of a FISH-positive area and a FISH-
negative/equivocal area. Finally, the proportion of HH, HL, LH and LL cells among all CK-positive cells are 
obtained for heterogeneity quantification (vide infra). 
4.3.3.2. Mosaic heterogeneity 
The second objective of the study is quantitative assessment of mosaic ITH that is represented by the 
proportion of individual heterogeneous cell (positive/negative) in a cluster of cells having a different status 
(negative/positive). In our study, after the local Moran’s I analysis, the mosaic ITH is the proportion of HL 
cells (for a HER2-negative patient) or LH cells (for a HER2-positive patient) in all CK-positive cells. 
However, this proportion can be biased by the truncation errors, because a positive cell can also display a 
small number of HER2/cell depending on the position of the cut and the probability that the HER2 signals 
are placed inside the cut. Therefore, we simulated the truncation errors from a homogeneous cell population 
in function of the number of HER2/cell to distinguish these errors to the real mosaic ITH. We assumed that 
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the cells were randomly scattered in the space. Therefore, the truncation errors that are presented by the 
number of cells having different status in the whole cell population are also considered as heterogeneous cell 
(HL cells in case of negative FISH HER2 and LH cells in case of positive FISH HER2). In figure 4.11a, we 
present both the truncation error model (dots) and the measured mosaic ITH in all tissues and cell lines 
(lines). The mosaic ITH of cell lines is certainly linked to the truncation error, hence used as a benchmark for 
the tissue analysis. The theoretical curve representing the truncation error is explained as follows. First, there 
is no highly amplified cell for the low HER2/cell value. When the number of HER2/cell increases, the HER2 
loci population shifts to a higher value, thus more cells are recognized as positive. Using a fitting function, 
we found that the truncation errors increases following a polynomial function if the mean HER2/cell still 
inferior 6. The population passes at peak at around 6 when a large amount of cells are positive but the mean 
value is still less than 6. After the mean passes 6, the criterion for selecting heterogeneous cells changes to 
LH cells, resulting on a sharp reduction of the proportion of heterogeneous cells. When the mean increases 
further, the truncation errors decreases drastically following an exponential function. We compare now our 
truncation model with the mosaic ITH obtained after local Moran’s I analysis in all tissue slides. The mosaic 
ITH fits well to the truncation error model for most cases. Moreover, when the cell line’s homogeneous 
population was analyzed by local Moran’s I analysis, we found that positive cell lines also have a strong 
mosaic ITH (6.2-10.8%), which can also be explained by the truncation error model for cell lines. Therefore, 
if the apparent mosaic ITH is lower or similar than the model, we can thus associate the measured mosaic 
ITH to the truncation errors. Lower mosaic ITH compared to the model are observed in two tissues and 2 
HER2-positive cell slides. For the tissues, we obtained a lower mosaic ITH because these two tissue display 
highest percentage of the clustered heterogeneous cells (7.7 and 11.7%) among all tissues analyzed (all are 
other are less than 4%), see table 4.1. In these two tissues, the mosaic heterogeneity cells were only 
considered in the dominant parts of the tissues, hence decreasing the overall percentage of the mosaic 
heterogeneous cells in the whole cell population. For positive cell lines, the difference between the mosaic 
ITH and the model is larger than that of most tissues. We could explain that by the smaller number of cells 
considered in cell line slides (usually 2-5 times less). Furthermore, the mean HER2/cell of positive cell lines 
measured by the automatic scoring is slightly smaller than that of the manual counting technique. The 
measured mosaic ITH of the HER2-positive cell line having a high value of mean HER2/cell, corresponds 
now with a smaller value of mean HER2/cell that is affiliated with higher theoretical truncation errors. 
Finally, one tissue sample with much higher mosaic ITH than the model is suspected having a real mosaic 
ITH (figure 4.11a, the triangle marked with b). Indeed, we can observe in the automatic scoring FISH image 
in one tissue position that the presence of heterogeneous cells of the true mosaic ITH tissue (figure 4.11b) is 
more important than that of a homogeneous tissue (figure 4.11c). Therefore, we can conclude that our 
method has successfully confirmed the presence of cluster and mosaic ITH in all cases. Finally, a simple 
graph recapitulating the HER2 phenotypic and genotypic characteristics of each tissue as well as their cluster 
and mosaic heterogeneity can be plotted (figure 4.11d). We can distinguish one case with mosaic 
heterogeneity and one case with cluster heterogeneity among all tissues tested. In the future, this graph can 
be later used to assist the clinical decision.  
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Figure 4.11 - Interpretation of mosaic intratumoral heterogeneity (ITH) by comparison to a statistical 
truncation model. (a) The mosaic ITH is measured in all tissue samples and benchmarked with the readout of 
the two cell lines: it is defined as the ratio of the number of individual heterogeneous cells (i.e. cells with 
positive/negative FISH status in a cluster of cells of negative/positive FISH status), divided by the total 
number of cancer cells in a tissue. For a HER2 positive sample (mean HER2/cell?6 or HER2/CEP17?2), 
mosaic ITH cells correspond specifically to LH cells of a spatial association analysis, like the ones marked 
by the + symbol in figure 4.10f. For a HER2- negative and equivocal sample (mean HER2/cell<6 and 
HER2/CEP17<2), mosaic ITH cells correspond to HL cells of a spatial association analysis, like the ones 
marked by the × symbol in figure 4.10f. For each cell line and tissue, the apparent mosaic ITH of a 
homogeneous population can be artificial when it is due to truncation errors. Indeed, truncated cells having 
random position of the nucleus with respect to the cut contain a number of HER2 dots that follows a 
binomial law of probability. The full line represents a model simulation that describes such truncation errors 
in a homogeneous population of cells as a function of varying HER2 loci number. Data points lying above 
the model curve can be considered as exhibiting true mosaic ITH (figure 4.10b), while points on the curve 
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represent a false apparent mosaic ITH, as due to truncation errors (figure 4.10c).  (b) The automatic scoring 
FISH image of a true mosaic ITH. Heterogeneous cells are indicated by white arrows (c) The automatic 
scoring FISH image of a false mosaic ITH case. Less heterogeneous cells are observed.  Scale bars: 20 ?m. 
(d) HER2 overexpression versus HER2 amplification for all tissues with additional heterogeneity 
information. It shows one patient with true mosaic ITH (the same than in figure 4. 11b) and one patient with 
cluster heterogeneity (data of figure 4.10f) among the 20 patients tested. Thresholds for positivity are defined 
as before and indicated by the dotted lines. 
Table 4.1 - High-content, automatic analysis IF/FISH results for all tissues, positive and negative cell lines. 
In columns (left to right): identification number (ID) of the samples; mean of the scores HER2/CK ratio, 
HER2/CEP17 ratio, HER2/cell; proportion of cluster and mosaic heterogeneous cells.  
 ID HER2/CK-IF Cell 
HER2/CEP17-
FISH 
HER2/cell-
FISH 
Cluster 
heterogeneity 
(%) 
Mosaic 
heterogeneity 
(%) 
Tissue 
1 0.21 1.63 4.83 0.17 0.09 
2 0.19 1.77 3.33 0.00 0.05 
3 0.15 1.09 3.08 0.00 0.02 
4 0.43 4.88 11.76 0.00 0.11 
5 0.21 1.27 2.28 0.00 0.01 
6 0.08 1.65 3.50 0.00 0.06 
7 0.16 1.35 3.20 0.01 0.07 
8 0.23 1.82 3.68 0.00 0.06 
9 0.12 2.19 3.58 0.00 0.09 
10 0.42 2.51 6.36 0.04 0.26 
11 0.23 1.75 3.58 0.00 0.08 
12 0.17 2.12 3.98 0.03 0.12 
13 0.10 1.87 4.72 0.08 0.12 
14 0.12 2.15 3.45 0.00 0.06 
15 0.14 2.03 4.05 0.01 0.11 
16 0.23 1.88 3.72 0.00 0.09 
17 0.37 1.43 3.34 0.00 0.07 
18 0.14 1.88 2.59 0.00 0.01 
19 0.48 5.04 12.99 0.00 0.15 
20 0.17 1.73 3.40 0.01 0.06 
HER2-
positive 
cell line 
1 0.29 3.71 11.09 0.00 0.08 
2 0.34 3.93 3.93 0.00 0.06 
3 0.31 3.50 10.77 0.00 0.11 
HER2-
negative 
cell line 
1 0.10 1.30 1.30 0.00 0.00 
2 0.06 0.94 1.45 0.00 0.00 
3 0.06 1.27 1.98 0.00 0.00 
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4.4. Discussion 
In this work, we proposed an experimental and analytical method for quantitative assessment of both HER2 
amplification and overexpression of the same breast cancer tissue slide. This technique can overcome 
inherent drawbacks of classical IF and FISH techniques by performing a controlled staining using the MTP 
and cell-by-cell computation of IF signals. Indeed, by using a short flushing of Abs, the microfluidic system 
keeps the IF signal in a non-saturated mode, favoring the discrimination of HER2-positive and negative 
cases. This advantage of microfluidic IF staining was already reported. The novelty of this method is in the 
unique queuing of (bio-chemical/computational) steps used for protein and gene biomarker quantification, 
with application to diagnostics and heterogeneity assessment. First, this research shows an improvement of 
quantification of the IF signals. Indeed, in previous reports on microfluidic IF for HER2 quantification, IF 
scoring was based on the histogram of HER2 signals [62]. Thus, the relation between the IF scores and the 
ISH scores was not a directly a linear relation. Moreover, the scores proposed there were not standardized 
because the obtained scores were not stand-alone as a variable but needed to be normalized to a reference 
signal, for example, a known positive tissue slide. We show here that the adjusted HER2/CK ratio averaged 
in segmented cells is a quantitative indication of HER2 overexpression, demonstrated by its linear correlation 
with the standard HER2/CEP17 ratio.  Besides, this new IF quantification method does not require the use of 
benchmark tissues with a known status for staining comparison.  
On the side of FISH quantification, our imaging technique uses a 20× objective with a ~5?m depth-of-focus, 
which is larger than the thickness of a tissue slide. This avoids extensive high-resolution z-stack imaging by 
a 63? objective, which allows acquiring a large region of interest of a tissue or cell sample of 4mm × 4mm. 
We can also perform analysis in a large area of 16 mm ? 16 mm, defined by the microfluidic chamber of the 
MTP, but the excess number of cells usually does not change the clinical conclusion. If heterogeneity is 
detected, more areas can be analyzed to confirm the state of the disease. By using both quantitative IF and 
automatic FISH scoring at a cell level, accurate HER2 clinical assessments can be obtained based on the high 
number of analyzed cells.  
More importantly, this research paves the way to study ITH quantitatively. We highlight that the mechanism 
responsible for the presence of ITH and its biological consequences are not well understood [10]. The main 
challenge is the lack of a suitable analysis tool that can record and analyze a large number of cells. To 
address this need, quantitative assessment of ITH has been recently developed, principally based on imaging 
of IHC and bright-field ISH staining [108-110]. However, limitations of the number of markers used, 
difficulty of cell segmentation, non-linearity of IHC signal impede cell-by-cell analysis of both protein 
expression and gene amplification. In this study, by using local Moran’s I analysis of IF/FISH images, the 
occurrence of cluster and mosaic ITH can be quantitatively assessed. One cluster ITH was successfully 
identified using the local Moran’s I analysis. In general, IF and FISH status in cluster heterogeneous cases 
are usually concordant [111], but in this case the IF staining is fairly homogeneous, only the gene 
amplification can reveal heterogeneity. Thus, both overexpression and amplification analyses are needed to 
fully assess the two types of heterogeneity (cluster and mosaic). Without a high-content analysis of the FISH 
image, it is very challenging to conclude about the cluster heterogeneity in this case. Heterogeneity 
assessments using both IF and FISH give thus a reliable and robust conclusion about heterogeneity which 
can be considered during a clinical decision. For mosaic heterogeneity, we demonstrated that in most cases, 
truncation errors caused coexistence of cells with different status. However, one real mosaic heterogeneous 
case was successfully identified, as it had an unambiguously higher heterogeneous cell proportion than the 
one corresponding to truncation error. In the future, based on the results of this heterogeneity analysis, more 
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retrospective studies for ITH analysis can be done to establish better the link between ITH and cancer 
prognostics. Therefore, cases currently identified with ITH (estimated to be one fourth of all breast cancer 
cases [111]) could be reassessed to determine their true heterogeneity nature.  
Nevertheless, the number of HER2/cell scored are different than that of a standard technique depending on 
computational estimation of the number of signals (figure 4.8b). Moreover, the standard method is biased by 
under-sampling. For borderline cases (HER2/cell in between 4 and 6), this can change the assessment, for 
example from equivocal to negative (HER2/cell less than 4). In the whole tissue, the proportion of cells’ 
HER2 classification errors due to the small changes in the HER2/cell scored is small. Therefore, for all non-
cluster-heterogeneous cases, no major change from positive to negative status or vice versa is recorded. We 
also expect that the local Moran’s I analysis give a very high accuracy of ITH status. Finally, we highlight 
that the aim of this study is not to replace the standard scoring technique, but to (1) provide a quantitative 
method for IF scoring, (2) verify the quantitative assessment in a large number of cells (3) detect ITH with 
local Moran’s I analysis. In the future, larger clinical cohort may be studied to further explore the power of 
this technique to identify ITH.  
4.5. Conclusion of chapter 4 
In conclusion, we successfully established a new method for accurate HER2 assessment in breast cancer 
tissue using high-content analysis of microfluidic IF and automatic FISH scoring. The study has shown that 
quantitative evaluation of HER2 IF signal can be obtained by calculating the HER2/CK in all cells on the 
tissue slide. By combining quantitative IF and automatic scoring FISH, this powerful method characterizes 
the whole tissue by its cell-by-cell HER2 overexpression and amplification. Indeed, the mean HER2/CK and 
HER2/CEP17 ratio of all cancer cells correlate with the HER2/CEP17 ratio obtained from a standard FISH 
technique, underlining the capability of taking into account a large number of cells to obtain an adequate 
sampling statistics. Finally, using local Moran’s I analysis, ITH was detected in both cluster and mosaic 
form, by excluding truncation errors with numerical simulations. Cases currently identified with mosaic 
heterogeneity (~1/4 of all cases) can be reviewed using our method for determining those having true mosaic 
heterogeneity. It is our perspective that cancer treatment in the future can be more personalized, as we can 
analyze tumors at an individual cancer cell level using automatic, high-content methods.  
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5. CONCLUSION AND PERSPECTIVE 
5.1. Conclusion 
In this dissertation, several new methods related to microfluidic technology for improving cancer diagnosis 
were presented. In chapter 1, an overview of breast cancer and some diagnostic tests was introduced. We 
knew that fast, inexpensive and accurate assessment of onco-genes or proteins is of utmost important in 
modern cancer treatment. We also understand the theoretical background of convection-diffusion-reaction 
mechanism in a microfluidic system, which explains the role of flows in a reaction-limited system. 
Moreover, literature reviews related to general microfluidic technologies as well as the particular chip used 
were presented. Finally, the reliability of the microfluidic chip was carefully studied to ensure that it can 
resist to high-temperature and solvents.  
Chapter 2 described three methods: MA-FISH, ESIMA-FISH and MA-CISH that uses the microfluidic-
assistance principle for HER2 gene assessment. These methods are the first microfluidic FISH tests for tissue 
analysis that offer an improvement of both processing time and cost. These methods are based on probe 
recirculation and reaction acceleration using back-and-forth flows, which are technically innovative. We 
performed protocol optimization for each FISH or CISH probes and applied the parameter sets obtained on 
several clinical samples for validation. We concluded that microfluidic flows help decreasing the time and 
reagent needed for FISH or CISH tests. In addition, we proved that discontinuous flows were more efficient 
for hybridization acceleration for a formamide-based probe. Briefly, we achieved faster and cheaper in-situ 
hybridization tests while keeping the same diagnostic accuracy than the standard techniques. An additional 
cost due to the microfluidic setup (the microfluidic chip and the syringe pumps) is estimated to be around 
10000$). Nevertheless, this cost can be recompensed in a long term. Another solution to decrease the 
hardware cost is to replace the micro-fabricated silicon chip by a plastic–based chip, in the condition that the 
melting temperature of the plastic chip is higher than the denaturation temperature of a FISH protocol (~ 73-
75°C). 
In chapter 3, we described a new HER2 protein quantification method, using protein a microfluidic-
microarray setup combined with IF staining. The particularity of this method compared to the literature is 
that proteins in a tissue slide are partly extracted and routed into a microfluidic chip containing Ab-
microarrays for detection of HER2 proteins. A study on a small tissue cohort shows that HER2 protein mass 
quantified by this technique correlates with the LC/MS-MS spectral counts reflecting the number of HER2 
protein present in the extraction solution. We also demonstrated that HER2 protein overexpression estimated 
by the microfluidic-microarray method agrees with the FISH scores that is an indication of HER2 
amplification. This proof-of-concept study paves the way for high-throughput tissue biomarker 
quantification that can be used in the clinics. 
The chapter 4 showed a new approach for HER2 assessment using quantitative IF combined with high-
content, automatic FISH analysis for evaluating cancer heterogeneity. This is the first method using image 
processing to analyze both IF and FISH signals cell by cell. This method successfully identified cases with 
cluster and mosaic heterogeneity in a batch of 20 tissue samples with unprecedented accuracy. In particular, 
true mosaic heterogeneity is distinguished to that due to truncation errors originating from the sample 
preparations. These achievements could pave the way to further retrospective study of heterogeneity and its 
link to clinical outcomes, guiding pathologist to identify cases having true heterogeneity.  
CHAPTER 5: CONCLUSION AND PERSPECTIVE 
133 
 
Brief, through diverse microfluidic techniques, our research provided a framework for the applications of 
microfluidics in cancer diagnosis. Faster, cheaper, simpler, and more-accurate HER2 assessment can be 
performed using a microfluidics device. In my opinion, microfluidics can become a part of clinical routine, if 
this technology gets enough support from pharmaceutical companies and governments. To realize this 
perspective, we need collaborations between research laboratories and industries to promote and 
commercialize this technology.  
5.2. Future research directions 
At the moment, MA-FISH is performed by a simple setup that requires several manual assembling-
disassembling steps. To improve the test’s user-friendliness, automatic MA-FISH can be envisaged. To 
achieve that aim, more inlets and outlets and junctions can be added in the setup holder to separate the probe 
and flanking oil solution. Moreover, sophisticate pumping system that can deliver multiple reagents can be 
integrated. Automatization of the MA-FISH protocol will be the next step to apply this technique to clinical 
diagnostics. 
The microfluidic-microarray technique is very advantageous to achieve a fast and complete tissue 
diagnostics using standard slides. Indeed, as we demonstrated the feasibility of HER2 assessment, other 
tissue biomarkers such as ER and PR can also be quantified using the same principle. The only requirement 
is that these proteins are presented and not denatured in the chosen extraction solution. We anticipate that 
this simple, quantitative cancer screening method can accurately classify tissue samples into their molecular 
subgroups. 
As our high-content analysis method is principally based on an image processing program allowing 
fluorescence scoring and signal quantification, this technique can be applied in all other fields, such as 
quantification of RNA FISH or live-imaging IF image. We can also apply the IF heterogeneity analysis to 
evaluate ITH of ER or PR biomarkers.  
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APPENDIX 
Appendix A 
Here is an example of Local’s Moran I computation. Given 5 points x1, x2, x3, x4, x5 with x1 is in the center of 
figure A.1. The point with the value x1 is placed at the center of the figure (marked in red dot), where we 
calculate the Local’s Moran I. The threshold distance marked by the large red circle. There are two point x3 
and x4 that are inside the circle and x2 and x5 are outside. 
 
Figure A.1 - Example of weight matrix calculation 
 
Thus, Local’s Moran I at unit 1 is calculated as follows 
?? ? ?? ? ????? ? ??? ? ???? ? ??? ? ???? ? ??? ? ???? ? ???? ??? ?? 
where 
? ? ? 
?? ? ????? ? ?????????  
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? ? ????? ? ??
? ? ??? ? ?? ????? ? ?? ? ? ??? ? ?? ? ? ??? ? ?? ?
?  
?? ?
?? ? ??
?  
?? ?
?? ? ??
?  
?? ?
?? ? ??
?  
?? ?
?? ? ??
?  
?? ?
?? ? ??
?  
According to the threshold distance, the points with j = 3,4 are neighbors of i = 1 
??? ? ?????? ? ?????? ? ?????? ? ? 
Thus, Local’s Moran I at unit 1 becomes 
?? ? ?? ? ??? ? ??? 
The classification of the point i=1 depends on the sign of ?? and ?? ? ??. The latter is the sum of all 
normalized value of all neighboring elements within a given distance. 
However, the local Moran’s I value would be a result of randomness. To test whether spatial association 
comes from random distribution or actual spatial autocorrelation, the significance of local Moran’s I at each I 
is computed as follow. 
??????? ? ???????????????? ? ??? ? ?? 
One generates n permutations where values of neighbors j of the unit I are assigned randomly. Then, one 
calculates ?? at each permutation. After that, the percentage of ?? over ?? (original local Moran’s I value at 
unit i) is the probability of random spatial association. This probability should be less than ?? which is the 
chosen significance or pseudo significance level. In the tumor heterogeneity analysis performed in chapter 4, 
we will not run permutations to verify local Moran’s I significance because we define high/low values using 
fixed threshold values. 
In fact, Moran’s I is a summation of individual local Moran’s I at each unit i. Thus, the relationship between 
Moran’s I and local Moran’s I are as follows. 
? ?? ????
 ??? ?? 
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where  
?= Moran’s I measure of global autocorrelation 
??= Local Moran’s I measure of local autocorrelation 
?= number of analysis units in the map 
Appendix B 
Pearson coefficient represents the linear correlation between two variables. Given two variables ??? ??, the 
Pearson correlation is defined as  
? ? ???????? ???????  
Where ??????? ??? is the covariance of ??and ??, ??and ?? are respectively the standard deviation of ??and 
??. 
If the Pearson coefficient is positive, the two variables are positively correlated. If the Pearson coefficient is 
negative, negative correlation is expected. A Pearson coefficient close having an absolute value close to 1 
means the correlation is strong and close to 0 means that there is no linear correlation between the two 
variables.  
Appendix C 
In this section, we calculate the volume of a truncated cell section, depending on the position x of the center 
of the cut. From the equation (4.2) in chapter 4, we have: 
????? ? ?? ??? ? ?????
??
??
? ?????????? ?
??
? ???
??? ? ??????? ? ??? ?
??? ? ???
? ? ??? ?? 
  
If ?? ? ?, we have ?? ? ?,??? ? ? ? ??? , we obtain: 
????? ?
? ???? ? ??? ?? ? ??? ? ?? ?
?
??
??
? ??????? ?? ?
?
? ? ?? 
(A.4) 
If ?? ? ??, we have ?? ? ??? ?? ? ? ? ???, we obtain: 
????? ?
?????? ? ??? ?? ? ??? ? ?? ?
?
??
??
? ? ??????? ?????? ?
?
?? 
 
(A.5) 
If ?? ? ?? and ?? ? ?, we have  ?? ? ? ? ??? and ?? ? ? ? ???, we have: 
????? ?
?????? ? ?
?
? ? ????
? ? ??????? ??? ?
?
? ? ? ?
?
?? 
 
(A.6) 
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???? is the probability for one HER2 locus to be placed inside the cut and it-self a random variable. ???? can 
be computed from the volume of cut ?????: 
???? ? ?????????? ?
??? ? ??? ?? ? ??? ? ?? ?
?
??
?
??? ? ??????? ?? ?
?
? ? ?? 
(A.7) 
???? ?
???? ? ??? ?? ? ??? ? ?? ?
?
??
?
??? ? ??????? ?????? ?
?
?? 
 
(A.8) 
???? ? ????
? ? ?
?
? ? ????
??? ? ??????? ??? ?
?
? ? ? ?
?
?? 
 
(A.9) 
???? ? ?? ???? ? ??????? ? ?? 
 
(A.10) 
Therefore, the locus has a probability of ???? to be placed in the domain of the cut and a probability of 
????=1–????? to be placed outside the domain. Therefore, the random variable “the locus belongs to the cut” 
follows a Bernoulli distribution. The sum of all loci in a cut follows thus a binomial distribution, i.e. a sum of 
variables following a Bernoulli distribution. The probability of a cell section having a number of dots n is 
written as 
???? ?? ????? ? ? ???? ?? ? ??? ????
??? ? ???????? (A.11) 
This is also the probability mass function of the HER2/cell number used for generating a population of cell 
section to build truncation error model. 
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